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  Huntington’s Disease (HD) is a progressive neurodegenerative disorder that is the result of 
mutant protein oligomerization in the brain. While many small molecule treatments exist that are 
used to treat the side effects associated with HD, there are currently no therapies on the market 
that target the underlying biochemical cause of the disorder. Recently, an aberrant protein-protein 
interaction between the huntingtin protein and calmodulin, a master calcium regulator in the cell, 
has been identified and validated as a potential target therapeutic target. Our goal was to synthesize 
a small molecule capable of disrupting this protein-protein interaction and validate that a small 
molecule therapy is possible for the treatment of HD. Two classes of compounds, one containing 
a bicyclic sultam and the other containing a highly aromatic pyrazoline, were synthesized and 
tested in a biochemical model of HD and demonstrated that it is indeed possible to disrupt this 
aberrant protein-protein interaction with a small molecule. There results help to validate the 
biochemical foundation for a small molecule therapy for HD and pave the way for further 
investigations into their development 
  Isocephalosporins are fully synthetic analogs of naturally occurring cephalosporins and 
possess physical and antibiotic properties worthy of further investigation.  While many oxygen-, 
carbon- and sulfur-containing isocephalosporins have been synthesized, one class of 
 iv 
isocephalosporins that is under investigated in the literature are the family of 2-
azaisocephalosporins.  To this end, it was our goal to design and execute an asymmetric synthesis 
of 2-azaisocephalosporins and synthesize both cis enantiomers to help investigate the effect of 
stereochemistry on antibiotic activity. 
  Using chiral glyceraldehydes and amino acid-derived building blocks, both cis enantiomers 
of the b-lactam core could be accessed through a Staudinger [2+2] cycloaddition. Following 
synthesis of the mono-bactam, an azide was introduced through functional group manipulation 
that was then subjected to an intramolecular reductive ring closing reaction to form the 2-
azaisocephalosporin core while also allowing for diversification at the nitrogen.  Both cis 
enantiomers of the [4,2,0] core with and without a methyl group at the 3-position (3-nor and 3-Me, 
respectively) were pursued and executed, establishing this as the first asymmetric synthesis of the 
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CHAPTER I: DEVELOPMENT AND IN VITRO VALIDATION OF SMALL 
MOLECULE THERAPY FOR THE TREATMENT OF HUNTINGTON’S DISEASE1 
 
1.1 Introduction and Background  
  Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative 
disorder whose neuropathological symptoms include perinuclear cytoplasmic protein aggregates 
and neuronal inclusion bodies while other characteristic phenotypic effects include involuntary 
movements (chorea), general neurodegenerative decline, and ultimately, death.1 HD is most 
prevalent in peoples of western European descent and affects one in every 10,000 people in the 
US, with a current estimate of 30,000 patients in the US alone.2,3 HD is characterized by an 
abnormal amount of CAG repeats in the first exon of the huntingtin gene that,1 upon expression, 
result in a polyglutamine (polyQ) expansion region near the N-terminus of the mutant huntingtin 
protein (mhtt).2 These polyQ repeats then become covalently cross-linked, leading to protein 
aggregates in the brain eventually leading to cell death. Wild type (WT) individuals carry an 
average of 6-35 CAG repeats and remain unaffected, whereas individuals with >35 repeats begin 
to show full penetrance of HD disease symptoms.3 Neuropathological symptoms of HD include 
perinuclear cytoplasmic aggregates and neuronal mhtt intranuclear inclusions while other 
                                                        
1 Some of this work previously appeared in an article in the Journal of Medicinal Chemistry 
Research. The original citation is as follows: Klus, N. J.; Kapadia, K.; McDonald, P.; Roy, A.; 
Frankowski, K. J.; Muma, N. A;. Aubé, J.; Discovery of Sultam-Containing Small-Molecule 
Disruptors of the Huntingtin-Calmodulin Protein-Protein Interaction., Med. Chem. Res., 2020, 29, 
1187-98.  
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characteristic phenotypic effects include involuntary movements (chorea), general 
neurodegenerative decline, and ultimately, death.4  
 
 
Figure 1.1. Structures of commonly used small-molecule treatments for the symptoms associated 
with HD. A) Tetrabenazine and its deuterated analog deutetrabenazine, the only FDA-approved 
drugs used to treat HD-associated chorea. B) Three common antipsychotics (quetiapine, 
haloperidol, and risperidone) used to treat the psychological effects of HD.  
 
 
  Like other progressive neurodegenerative disorders, such as Parkinson’s disease and 
Alzheimer’s, treatments for HD has remained a challenging therapeutic area for drug discovery; 
as of 2021, there are only two FDA approved mediation for the treatment of HD, tetrabenazine 
and its deuterated analog deutetrabenazine (DBZ) (Figure 1.1A).4 Like  tetrabenazine and DBZ, 
all of the therapies used to treat HD are employed to address the symptoms of the disease rather 

































treat the symptoms of HD are dopamine depleters and neuroleptics. Dopamine depleters, like DBZ, 
inhibit vesicular monoamine transporter 2 (VMAT2), which in turn depletes dopamine at the 
presynaptic striatal nerve terminals and is used to treat the chorea/hyperkinesia associated with 
HD.5 Other common “off-label” treatments are antipsychotics, such as haloperidol, risperidone, 
and quetiapine, which are used to treat the depression, anxiety, and psychological symptoms that 
accompany HD diagnosis (Figure 1.1B).6 While there have been advances in both targeting polyQ 
repeats in RNA that could be used to develop treatments for HD7-9 and in developing inhibitors of 
mHtt aggregation,10,11 these therapies are still pre-clinical and have not been validated in higher 
organisms. Other potential targets for the therapeutic development have been thoroughly 
reviewed,11-14 and one of these potential therapeutic areas is regulating transglutaminase activity 




Figure 1.2. Potential targets for therapeutics for HD. Evidence from transgenic mouse models of 
HD indicate that these processes influence the progression of the disease. Transglutaminase 
activity will be the focus of this project. 
 
 















  A current hypothesis for the cause of mhtt aggregation is the up-regulation of a family of 
enzymes called transglutaminases (TG).15 Transglutaminases catalyze the calcium-dependent 
cross-linking (transamidation) of peptide-bound glutamine residues on substrate proteins to the e-
amino-group of lysine residues on either the same or different proteins.16 These linkages can lead 
to protein aggregation and conformational changes causing detrimental effects to the proteome.16 
TG has been implicated in tau protein oligomerization in Progressive Supranuclear Palsy and 
Alzheimer’s disease models17 and there is also evidence to suggest that aberrant TG activity 
contributes to the HD phenotype.18 Transglutaminase mRNA, protein levels, and activity have all 
been shown to be up-regulated in HD cell models15,19,20 and TG proteins co-localize with mhtt in 
inclusion bodies found in HD patients.21 Furthermore, inhibiting or knocking out TG in mouse 
models increases their survival22,23 while inhibiting transglutaminase in a cellular model decreases 
cross-linking of mhtt and cytotoxicity associated with mhtt expression.20 
  Calmodulin (CaM) is a calcium (Ca2+) binding protein that, amongst its other roles in the 
cell, regulates TG activity.24,25 Studies have shown that CaM and TG proteins co-
immunoprecipitate with mhtt in transfected cell culture models as well as intranuclear inclusions 
found in HD brain samples.26 Furthermore, inhibition of CaM in cells expressing mhtt and TG 
resulted in a decrease of TG-catalyzed mhtt aggregates.26 Interestingly, WT htt does not interact 
with CaM, but mhtt has a much higher affinity for the protein.27 The increased affinity for CaM 
by mhtt alters CaM WT function and leads to aberrant biochemical processes within the cell, 
including an up-regulation of TG activity. Based on these in vitro and in vivo data, we believe that 
an underlying cause of HD is that sequestration and up-regulation of TG by the CaM-mHtt 
heterodimer leads to an increase of TG-catalyzed mhtt cross-linking contributing to the HD 
 5 
phenotype. Previous studies have provided substantial evidence that the disruption of the CaM-
mHtt protein-protein interaction (PPI) is a viable biologic target for the treatment of HD.28-30  
  Work in the Muma lab at the University of Kansas (our collaborator for the present project) 
led to a peptide consisting of amino acids 76-121 of CaM (46AA CaM peptide) that is capable of 
interrupting the interaction between mhtt and CaM.18 Expression of the 46AA CaM peptide in 
human embryonic kidney (HEK293) cells  and SH-SYS5 neuronal cells decreases TG-catalyzed 
cross-linking of mhtt and also decreases cytotoxicity associated with HD.18,19 It was also shown 
that the expression of the 46AA CaM peptide does not interfere with innate CaM processes; cells 
expressing the 46AA CaM peptide show a decreased interaction between mhtt and CaM but there 
is no effect on the binding between CaM and calcineurin, a second CaM binding partner.18,19 
Expression of the 46AA CaM peptide in HD transgenic R6/2 mice significantly reduced body 
weight loss, increased movement bouts and distance traveled, and improved rotarod performance 
compared to control mice.20 Furthermore, in vivo immunoprecipitation experiments demonstrated 
that the expression of the 46AA CaM peptide significantly reduced TG-catalyzed mhtt cross-
linking in the striatum of R6/2 mice and also reduced the percentage of htt-positive nuclei and the 
size of intranuclear htt aggregates without negatively impacting normal TG function.20 Lastly, 
expression of the 46AA CaM peptide did not disrupt innate CaM function either in vivo or in vitro; 
CaM-dependent kinase II, a second CaM dependent enzyme, retained activity in R6/2 mice and 
SH-SY5Y cells when treated with the peptide.20  
  While these data strongly imply that the disruption of this PPI is beneficial for HD 
pathology, the disruption of PPIs such as this have generally been reserved for peptides or 
peptidomimetics and viewed as difficult targets for small molecules. However, a recent study has 
shown that small molecules are capable of interrupting a similar PPI between CaM and adenylyl 
 6 
cyclase 8, supporting our hypothesis that disrupting similar PPIs with small molecules is indeed 
possible.23 Taken together, these data indicate that the disruption of the CaM-mhtt interaction is a 
viable biological target for small molecule probe development and is worthy of further 
investigation. Using this preliminary data as a guide, we sought to develop small molecule probes 
capable of disrupting this PPI and validate this interaction as a viable target for small molecules. 
Successful validation of this PPI as a target for HD treatment could lead to a novel therapeutic area 
for the treatment of HD and a paradigm shift in treatment strategies. 
 
1.2 Results and Discussion 
1.2.1 High-throughput Screening 
  To identify small-molecule disruptors of the CaM-mHtt PPI, the University of Kansas 
High-Throughput Screening Laboratory interrogated their in-house compound collection for hit 
molecules that inhibited the binding of mHtt to CaM using an AlphaScreen platform 31 The 
compound collection (ca. 225,000 compounds) comprised small molecules sourced from 
numerous vendors and collections, including the University of Kansas Chemical Methodology and 
Library Development (KU CMLD) Center. The KU CMLD center was a synthetic chemistry 
initiative whose raison d’être was to pioneer new synthetic methods for parallel synthesis and 
demonstrate their utility toward the construction of novel compound sets. The utility of such 
compound sets to identify tractable hits for various therapeutic targets has been demonstrated by 
us and others.32-35 Hit selection was prioritized based on physical properties and compound 
potency, and selected compounds were subsequently resynthesized or acquired from commercial 
sources and re-tested in the same AlphaScreen assay to confirm activity. Upon confirmation of 
activity, hit compounds were screened for assay interference, selectivity, and cytotoxicity. 
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Compounds were screened against two CaM dependent enzymes, Ca2+/CaM-dependent protein 
kinase alpha, and Ca2+/CaM dependent protein kinase2g, in the presence of CaM to analyze 
whether these compounds affected their activation. Hit compounds were also analyzed in a variety 
of cell lines to test for cytotoxicity using endogenous ATP as an index for metabolically active 
cells. While a number of compounds had confirmed activity and good selectivity and cytotoxicity 
profiles, four scaffolds were selected as candidates for further SAR studies, and three series have 




Figure 1.3. Hit sultam- and pyrazoline-containing compounds from the high-throughput screen 
chosen for SAR studies. 
 
 
1.2.2 Sultam-Containing Compounds 
The hit compound, KUC102204N (1.11a), was synthesized using the protocols developed 
by Hanson and coworkers with minor modifications (Scheme 1.1).36,37 Bromobenzylsulfonyl 
chloride 1.1 was coupled to the methyl ester of either (R)-leucine to afford a sulfonamide 1.2 which 










CaM-mHtt IC50 = 0.83 mM
KUC100769N, 1.17i-a
CaM-mHtt IC50 = 0.89 mM
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irradiation in the presence of Pd(OAc)2 effected an intramolecular Heck cyclization to produce the 
bicyclic scaffold 1.6 that was saponified with LiOH to provide carboxylic acid 1.8. To achieve the 
ketone-containing series, olefin-containing acid 1.8 was converted to the ketone 1.10 via 
ozonolysis.  HATU-promoted amide coupling afforded the target analogues for each series. (S)-




Scheme 1.1. Synthesis of sultam series. 
 
  Using the Topliss decision tree,38  a systematic approach was taken to investigate the effects 
of ring substitution on activity. A matrix was constructed by coupling eight different amines with 

































1.8, X = CH2, (S)-enantiomer 
1.9, X = CH2, (R)-enantiomer
                (70-85%)
1.10, X = O, (S)-enantiomer 




1.11 a-h, X = CH2, (S)-enantiomer
1.12 a-h, X = CH2, (R)-enantiomer
1.13 a-h, X = O, (S)-enantiomer



















and ketone 1.10) (Figure 1.4). These analogues were screened for inhibition of CaM–mHtt binding 




Figure 1.4. SAR plan for sultam series. Three sketela were coupled to eight different amines with 
electron donating and removing substituents to investigate their effect on biological activity; one 










































Table 1.1. CaM-mHtt AlphaScreen activity for compounds 1.11-1.13 a-h 
 
 Alpha Screen 
CaM–mHtt 
 (IC50, µM) 
Cytotoxicity 
(SH-SY5Y cells, 





1.12a 0.98 >300 
1.11b 12.4 >300 
1.12b 12.7 87 ± 2 
1.11c 2.8 94 ± 3 
1.12c 3 86 ± 9 
1.11d 1.38 >300 
1.12d 1.8 >300 
1.11e 15 102 ± 7 
1.12e 15.1 64 ± 2.5 
1.11f >300 >300 
1.12f >300 >300 
1.11g 16.6 101 ± 5 
1.12g 12.2 99 ± 4 
1.11h 0.55 >300 
1.12h 0.5 >300 
1.13a 2.14 39.8 
1.13b 14.59 43.8 
1.13c 11.19 41.4 
1.13d 2.03 44.2 
1.13e 24.5 43.4 
1.13f 52.56 44.6 
1.13g 31.03 40.1 
1.13h 0.97 32.3 
 
 
  The resynthesized sample of the screening hit, KUC102204N (1.11a) retained activity in 
disrupting the mHtt–CaM PPI and was found to possess no measurable toxicity to SHY5Y cells. 
We also synthesized and tested the enantiomer of KUC102204N (1.11a), which was found to have 
comparable activity and toxicity. We next investigated the effect of modifying the amine side 
chain. Replacement of the 3,4-dichlorobenzyl group with a benzyl group afforded analogues 1.10b 
 11 
and 1.11b, which were significantly less potent in disrupting the mHtt–CaM PPI; again, the 
enantiomeric sets were approximately equipotent. The 4-chlorobenzyl analogues 1.11c and 12c 
regained much of the lost potency relative to series b, though both enantiomers were slightly 
cytotoxic (ca. 90 µM ) toward SH-SY5Y cells. The 4-chloro-3-(trifluoromethyl)benzyl analogues 
1.11d and 1.12d further regained potency, though both enantiomers were still less potent than the 
hit and its enantiomer (1.11a and 1.12a, respectively). In contrast to the above-noted electron-
withdrawing group-containing congeners, analogues containing either 4-methyl or 4-methoxy 
were significantly less potent. Thus, the strongly electron-donating 4-methoxybenzyl analogues 
1.11f and 1.12f lost all mHtt–CaM disruption activity and the 4-methyl analogues 1.11e and 1.12e 
were slightly less active than the unsubstituted benzyl. Replacing the unsubstituted benzyl group 
with a methylenecyclohexyl group led to analogues of comparable potency (cf. 1.11b and 1.12b 
vs. 1.11g and 1.12g). Extending the linker length by replacing 3,4-dichlorobenzyl with 3,4-
dichlorophenylethyl led to the analogues 1.11h and 1.12h with approximately 2-fold greater 
potency than the screening hit.  
  We next synthesized a series where the methylene on the sultam ring was replaced with a 
ketone. Having established negligible potency differences due to the effect of the configuration of 
the amino acid side chain, we only synthesized the (R)-leucine derivatives. The aryl-based SAR 
trends identified above were again observed, though the keto analogues were generally 
approximately 0.5-fold as potent as the methylene-containing analogues, with two exceptions. The 
4-methoxylbenzyl keto-analogue 1.13f retained marginal activity in disrupting the mHtt–CaM PPI 
and the methylenecyclohexyl keto-analogue 1.13g was only 0.5-fold as potent as the benzyl keto-
analogue 1.13b. The keto-analogues 1.13a to 1.13h were all found to possess greater cytotoxicity 
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than any of the olefin analogues. Lastly, the compounds were tested in two assay interference 
counterscreens and were found to be inactive in these series of tests (Table 1.2).  
  The Alpha Screen uses tagged proteins that are known to interact bound to donor and 
acceptor beads that come together and, when irradiated at 680 nm, emit a photochemical readout 
in the absence of any probe or bridging component to interrupt the PPI. The His/GST assay 
counterscreen measured whether the compounds had an impact on the tagged proteins binding to 
the donor and acceptor beads and the TRU-hits assay was used to determine if any of the 
compounds act as  singlet oxygen quenchers, light scatterers (compounds that diffract light at either 
the excitation and/or emission wavelength), or color quenchers (compound that absorb light at 680 
nM (wavelength used for donor bead excitation) or between 520-620 nM (range of emission of the 
acceptor bead)) that would induce false-positive results in the assay.  
   Taken together, the SAR results demonstrate that this series of small molecules sultams is 
indeed capable of disrupting the mHtt–CaM interaction; the most potent analogue 1.12h possessed 
potency of 0.50 µM. Furthermore, several preliminary SAR trends emerged. Electron-withdrawing 
groups on the aryl group were found to be beneficial for activity, while converting the olefin to a 
ketone slightly diminished the activity. Interestingly, the configuration of the leucine side chain 
did not significantly affect activity and we found that the two-carbon linked phenethyl was more 
favorable than the one-carbon linked benzyl. The SAR trends identified here would be useful in 
guiding the design of future analogues in this series for disrupting the mHtt–CaM PPI.  
  A subset of potent analogues that also possessed minimal cytotoxicity (1.11c, 1.11d, 1.11h, 
1.12c and 1.12h) were also tested for off-target activity against other CaM-dependent kinases to 
ensure that the innate functions of CaM were not disrupted upon compound treatment (Figure 1.5). 
To determine if the test compounds affect Ca+2/CaM-dependent DAPK1 and CaMK2γ activity, an 
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in vitro kinase enzyme activity assay was performed for each kinase in the presence of CaM. 
Percent enzyme activity was calculated by normalizing the enzyme activity obtained for each 
compound to the enzyme activity obtained in the absence of any compound. Gratifyingly, the 
compounds did not inhibit DAPK1 at compound concentrations up to 100 µM and only one 
analogue (1.11h) had a statistically significant impact on CaM2Kγ activity.  
 
Table 1.2. His/GST and TRU-hits assay interference results for compounds 1.11-1.13 a-h 
 
 His/GST, IC50 
(µM) 




1.12a >300 >300 
1.11b >300 >300 
1.12b >300 >300 
1.11c >300 >300 
1.12c >300 >300 
1.11d >300 >300 
1.12d >300 >300 
1.11e >300 >300 
1.12e >300 >300 
1.11f >300 >300 
1.12f >300 >300 
1.11g >300 >300 
1.12g >300 >300 
1.11h >300 >300 
1.12h >300 >300 
1.13a >300 >300 
1.13b 200 >300 
1.13c >300 >300 
1.13d >300 >300 
1.13e 200 >300 
1.13f 300 >300 
1.13g 300 >300 
1.13h >300 >300 
 14 
 
Figure 1.5. In vitro off-target kinase testing. Compounds were tested in vitro to determine if (A) 
DAPK1 and (B) CaMK2g enzyme activity was impacted. Each compound was tested at a single 
concentration of 100 µM. Data are presented as mean ± standard error of the mean. Each 
experiment was run 3 times with at least 2 replicates per experiment. Compounds 1.11c, 1.11d, 
1.12c and 1.12h did not significantly inhibit DAPK1 or CaMK2g enzyme activity. Compound 
1.11h showed a statistically significant effect on inhibition of CaMK2g enzyme activity but not 





  Analogues 1.11d and 1.11h were further evaluated in a neuronal cell model for 
Huntington’s disease neurodegeneration (Figure 1.6). In this model, an active compound that 
reduced mHtt induced cytotoxicity in the cell would result in a RFU output comparable to that of 
the control. Unfortunately, the activity in the AlphaScreen assay did not translate to therapeutically 
relevant activity in this cellular model, with barely measurable activity even at 10 µM. Analogue 
1.11h was evaluated for preliminary pharmacokinetic properties and found to possess a kinetic 
solubility of 0.6 µM and permeability (PAMPA assay) of 7.6 × 10-7 cm/sec. Based on these data, 
the poor solubility (extracellular solubility barely above the IC50) and mediocre PAMPA 
permeability could be sufficient to prevent effective intracellular concentrations and may likely be 




Figure 1.6. In-cell HD cytotoxicity results. Compounds 1.11d and 1.11h do not show protection 
against mHtt toxicity 
 
1.2.3 Pyrazoline-Containing Compounds 
  The hit compound, KUC100769N, and its analogs was synthesized using the protocols 
developed by Sibi et al., with minor modifications (Scheme 1.2).39 The series was constructed 
through a convergent [3+2] cycloaddition using two pre-constructed building blocks: a protected 
cinnamic acid 1.15a-d and a substituted hydrazoyl halide 1.18a-g. The protected cinnamic acid 
portion was synthesized through the coupling of coupling of cinnamic acids 1.14a-d to 2-
oxazolidinone under basic conditions following conversion of the carboxylic acid to the 
corresponding acyl chloride. The hydrazoyl chlorides were constructed through the condensation 
of phenyl hydrazine and benzaldehydes 1.16a-g using a Dean-Stark trap to produce hydrazones 
1.17a-g; chlorination at benzylic position was achieved using the Corey-Kim reagent under 
previously described conditions.40,41 The two building blocks were then combined and treated with 
TEA to afford a [3+2] cycloaddition to furnish the racemic cyclized products 1.19aa-ag. The 
cycloaddition produced a mixture of constitutional isomers (N- and C- isomers) (Scheme 1.3). 
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While an enantioselective version of this reaction has been investigated,42 in this case, the absence 
of a chiral directing group allows for the addition of the nitrilium ion into either end of the olefin, 
facilitating the formation of both regioisomers. 
 
 
Scheme 1.2. Synthesis of pyrazoline series. 
 
  In most cases, the major N-isomer could be separated from minor C-isomer, but in only 




































1.16a-g 1.17a-g (94-99%) 1.18a-g (55-70%)
1.19aa-ag 1.20aa-ag 




or preparative TLC. For those structures that could be separated, the synthesis of both regioisomers 
expanded the diversity of the compound collection and allowed for investigation into the SAR of 
both series. As this was a de novo SAR campaign, the included diversity to the compound set was 
welcomed as a chance for further investigation into the biological properties of these compounds.  
  The cyclized products were subsequently reduced to provide the final target analogs 
1.20aa-ag and 1.c20aa-ag. To construct the initial SAR series, we envisioned a parallel synthesis 
wherein a series of cycloaddition partners could be reacted with each other in a matrix. To create 
the components used for the parallel synthesis, four cinnamic acid derivatives 1.14a-d and seven 
hydrazoyl chlorides 1.16a-g were synthesized, again using the Topliss tree to guide analog design 
so as to investigate the effect of substitution on two of the three rings present in the molecule; as 
previously stated, phenylhydrazine was used as the hydrazine components of the hydrazone for 
each series (Figure 1.9). To this end, 28 reactions were run in parallel using a Bohdan MiniBlock 
to produce the initial SAR series 1.20aa-dg and 1.c20aa-dg (coupling partners 1.14a and 1.17a 
produced compound 1.20aa, partners 1.14a and 1.17b produced compound 1.20ab, etc.) To isolate 
discrete compounds, the mixtures of regioisomers had to be separated after the reduction as this 
was the only step wherein any separation could be achieved using either column chromatography 
or preparative TLC. Four of the reactions resulted in inseparable mixtures of regioisomers and 
were not tested; for two of the reactions, the minor regioisomer was able to be isolated to provide 




Scheme 1.3. Mechanism and regioisomeric outcomes of [3+2] reaction and subsequent reduction 
to achieve final products. In most cases, the major product could be isolated as a discrete compound 



























































Figure 1.7. Cinnamic acid and benzaldehydes building blocks used to construct components of 
[3+2} cycloaddition. Substitution was inspired by the Topliss tree. A) Four cinnamic acids were 
used investigating different substitution at the para- position. B) Seven benzaldehydes with three 
different substitutions at the meta- and para- positions. 
 
  While the re-synthesized hit had comparable activity to that found in the initial screen and 
the other tested compounds had a wide range of activities in the CaM-mHtt AlphaScreen assay 
ranging from 900 nM to >100 µM, no tractable SAR results could be derived from the initial series 
(Table 1.3). For the cinnamic acid portion of the molecule, both p-chloro and p-methoxy 
substitution was associated positively with activity, and for the benzaldehyde portion, both meta- 
and para-substitution seemed to be positively associated with activity but no real distinctions could 























1.14a 1.14b 1.14c 1.14d
1.16a 1.16b 1.16c 1.16d
1.16e 1.16f 1.16g
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potent and least potent analogs making it hard to distinguish which substitution was better for 
overall activity. 
Table 1.3. CaM-mHtt AlphaScreen activity and SH-SY5Y toxicity data for compounds 1.20aa-
1.20dg and two C-isomers 1.c20ca and 1.c20ce. Compounds lacking data for both the CaM-mHtt 
AlphaScreen and the cytotoxicity assays were inseparable mixtures and were not tested. 
 





24h) (µM) Compound 
1.20aa 24.4 14.1 
1.20ab 25.9 - 
1.20ac 33 - 
1.20ad 30.4 - 
1.20ae 200 40.8 
1.20af 100 13.7 
1.20ag >100 14.5 
1.20ba 42.8 - 
1.20bb 22.5 - 
1.20bc 16.7 - 
1.20bd 7.8 - 
1.20be 103.6 39.0 
1.20bf 300 - 
1.20bg 61.1 - 
1.20ca 22.4 35.6 
1.c20ca 17.9 33.6 
1.20cb 0.9 9.1 
1.20cc - - 




1.c20ce 1.1 24.3 
1.20cf 16.9 25.8 
1.20cg 1.1 9.9 
1.20da 44.8 - 
1.20db 27.1 - 
1.20dc 3.2 - 
1.20dd - - 
1.20de 8.8 42.3 
1.20df - - 
1.20dg - - 
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Furthermore, although cytotoxicity data was not collected for each compound, the IC50 values were 
lower than the best compounds from the sultam-containing series indicating that even the best 
compounds would have to be optimized further to reduce problems with cytotoxicity (Table 1.3). 
Due to the non-tractable SAR of this series and the increased cytotoxicity and the relative tractable 
SAR and potency of the sultam series, these compounds were abandoned and not pursued further.  
 
1.3 Conclusion 
  In conclusion, we were able to synthesize two distinct chemotypes, one sultam-containing 
and the other pyrazoline-containing, that were capable of disrupting the CaM-mHtt PPI in a 
biochemical model. Unfortunately, the sultam-containing compound series that had the most 
promising characteristics going were unable to reduce the cytotoxicity associated with the HD 
phenotype in a cell-based model. However, what these results do show is that it is possible to 
disrupt this PPI and serve as a basis for further investigations into new chemotypes that could 
provide a compound capable of functioning in-cell. With such a disparity between the biochemical 
and the cell-based model, there may be other biochemical mechanisms that we did not investigate 
that kept the sultam-containing compounds from functioning in cell that, if identified, could 
provide further insight into synthesizing compounds that are capable of functioning in a cell-based 
model. While not the traditional method for disrupting PPI’s, small molecules are becoming more 
frequently used for this task so I am optimistic that further investigations could find a compound 




1.4: Materials and Methods 
1.4.1 Biology  
*Note: all biological testing was performed at the University of Kansas by Drs. Anuradha Roy and 
Khusboo Kapadia under the direction of Dr. Nancy Muma. 
 
1.4.1.1 Compounds: All synthesized compounds were solvated in 100% DMSO. For the 
AlphaScreen and cytotoxicity assays, compounds (final concentrations, 300, 100, 33.3, 11.1, 3.7, 
1.2, 0.4, 0.1, 0.046, 0.015, 0.005, 0.002, and 0 µM) were transferred acoustically using ECHO 555 
(Labcyte Inc.) to 384-well white Alpha assay plates (PerkinElmer) or to white polystyrene plates 
for cytotoxicity screens (Griener). All assays were performed in triplicate.  
 
1.4.1.2: CaM/mHtt Alpha-Screen Binding Assay: The compound activity was tested in triplicate 
in the His-mHtt and GST-CaM AlphaScreen assay that was optimized in the KU-HTS lab. All 
assays were performed in 384-well formats in a final volume of 30 µL/well and 0.6% DMSO. All 
proteins and beads were diluted in the interaction buffer (IB) containing 10 mM Tris-HCl, pH 8.0, 
1 mM CaCl2, 150 mM NaCl, 0.1% BSA, and 20% glycerol. Briefly, 10 nM His-mu-mHtt was 
preincubated with library compounds (15 µM) for 30 min followed by the addition of GST–CAM 
(10 nM). After 60 min at room temperature, a mixture of the acceptor Histidine (Nickel Chelate, 
10 µg/mL) and donor Glutathione beads (15 µg/mL) was added together. After 2 h at room 
temperature, Alpha counts were measured using Enspire Multilabel Plate Reader (PerkinElmer 
Inc.) using AlphaScreen default label. Percent inhibition of the AlphaScreen assay was normalized 
to DMSO positive and negative controls. 
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1.4.1.3: Counterscreen Assay 1, His-GST Protein Interaction Assay: The purified His-tagged 
GST protein (15 nM) was incubated with the compounds for 30 min at room temperature in IB 
containing 10 mM Tris-HCl, pH 8.0, 1 mM CaCl2, 150 mM NaCl, 0.1% BSA, and 20% glycerol. 
A mixture of the acceptor Histidine (Nickel Chelate, 5 µg/mL and donor Glutathione beads (5 
µg/mL)) was added together. The plates were read using an Enspire Plate reader. 
 
1.4.1.4: Counterscreen Assay 2, AlphaScreen TruHits™ assay: The AlphaScreen TruHits kit 
(PerkinElmer) was used to identify compound interference using the vendor protocol. The 
streptavidin donor beads (10 µg/mL) and the biotin acceptor beads (5 µg/mL) were diluted in the 
IB containing 10 mM Tris-HCl, pH 8.0, 1 mM CaCl2, 150 mM NaCl, 0.1% BSA, and 20% 
glycerol. The TruHits bead mix (30 µL) was incubated with the compounds for 2 h at room 
temperature. The assay plates were read using the Enspire Plate reader (PerkinElmer) using 
AlphaScreen default label. 
 
1.4.1.5: Cytotoxicity Assay: The SH-SY5Y cells (ATCC® CRL-2266) were plated in 384-well 
microplates at 6000 cells/well in 1:1 mixture of ATCC-formulated Eagle’s Minimum Essential 
Medium, Catalog No. 302003, and F12 Medium in 10% FBS. The PC12 73Q cell line was grown 
in Kaighn’s modification of Ham’s F12 media (ATCC#30-2004) supplemented with 15% horse 
serum and 2.5% FBS in the presence of G418 and Zeocin. The PC12 73Q cells were seeded at 
8000 cells/ well in poly-D-lysine coated plates (Corning). The PC12 73Q cell line can be induced 
to express full-length human huntingtin protein with 73 glutamine repeats under the control of a 
RheoSwitch (HD Community Biorepository, CHDI Foundation, and the Coriell Institute for 
Medical Research). In this assay, cells were not induced to express huntingtin protein. Media and 
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vehicle control wells were included in each assay plate. After 24 h of incubation with compounds 
at varying concentrations at 37 °C, cytotoxicity was measured on Enspire plate reader 
(PerkinElmer) using the luminescence-based CellTiter-Glo reagent (Promega Inc.). 
 
1.4.1.6: CaM-dependent Kinase Assay: To determine if the compounds inhibit the functioning 
of CaM, the activity of two CaM-dependent enzymes, calcium/CaM-dependent kinase 2γ 
(CaMK2γ, Human, recombinant; C-terminal truncation), and death-associate protein kinase 1 
(DAPK1, Human, recombinant; amino acids 1–363) were assessed. The assay was performed in 
white opaque 384-well plates (Corning, NY) using the ADP-Glo kinase activity assay kit 
(Promega, Madison, WI) and DAPK1 and CAMK2γ kinase enzyme system kit (Promega, 
Madison, WI). The assay was carried out according to the manufacturer’s protocol with slight 
modifications. The DAPK1 reaction was initiated with 25 ng DAPK1, 5 µM ATP, and 0.1 µg/µL 
myelin basic protein (native Swine) substrate in the presence of test compounds 9c, 9d, 9h, 1.10c, 
and 10h and incubated at room temperature for 60 min. The CaMK2γ reaction was initiated with 
12 ng CaMK2γ, 25 µM ATP, and 0.2 µg/µL. Autocamtide-2 substrate in the presence of test 
compounds 9c, 9d, 9h, 1.10c, and 10h and incubated at room temperature for 60 min. Each test 
compound was tested at a single concentration of 100 µM (dissolved in DMSO). Kinase enzyme 










Methyl ((2-bromophenyl)sulfonyl)-L-leucinate (1.2):  To a flame-dried flask equipped with a 
stir bar under argon was added 2-bromobenzenesulfonyl chloride 1.1 (2.00 g, 7.82 mmol), L-
methyl leucinate (1.14 g, 7.82 mmol, 1 equiv), DCM (20 mL), and TEA (2.18 mL, 15.6 mmol, 2 
equiv). The reaction was stirred at rt for 2 hours, filtered, concentrated under reduced pressure, 
and purified via flash chromatography (20% EtOAc in hexanes) to afford the sulfonamide product 
as a clear oil (1.75 g, 4.80 mmol, 61%). Rf = 0.4 (25% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 8.11 – 8.05 (m, 1H), 7.76 – 7.71 (m, 1H), 7.48 – 7.35 (m, 2H), 5.60 (d, J = 9.7 Hz, 1H), 
3.99 (ddd, J = 9.7, 8.4, 6.1 Hz, 1H), 3.42 (s, 3H), 1.77 (ddq, J = 13.1, 8.2, 6.6 Hz, 1H), 1.54 (ddd, 
J = 8.0, 5.9, 4.2 Hz, 2H), 0.88 (dd, J = 13.4, 6.6 Hz, 7H). 13C NMR (101 MHz, y3) δ 172.0, 139.1, 
135.2, 133.8, 131.3, 127.7, 120.6, 55.0, 52.4, 42.3, 24.5, 22.8, 21.6. FTIR (thin film): 3299, 2955, 
1783, 1427, 1341 cm-1. [α]D22.1 = 46.9 (c 1.0, CHCl3). HRMS (ESI, m/z): [M+H]+ calcd for 

















Methyl ((2-bromophenyl)sulfonyl)-D-leucinate (1.3): To a flame-dried flask equipped with a stir 
bar under argon was added 2-bromobenzenesulfonyl chloride 1.1 (2.00 g, 7.82 mmol,) D-methyl 
leucinate (1.14 g, 7.82 mmol, 1 equiv), DCM (20 mL), and TEA (2.18 mL, 15.6 mmol, 2 equiv). 
The reaction was stirred at rt for 2 hours, filtered, concentrated, and purified via flash 
chromatography (20% EtOAc in hexanes) to afford 1.3 as a clear, colorless oil (1.68 g, 4.60 mmol, 
59%). Rf = 0.3 (20% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 8.10 – 8.05 (m, 1H), 7.76 
– 7.71 (m, 1H), 7.47 – 7.36 (m, 2H), 5.61 (d, J = 9.7 Hz, 1H), 3.99 (ddd, J = 9.7, 8.5, 6.1 Hz, 1H), 
3.42 (s, 3H), 1.77-1.64 (m, 1H), 1.54 (ddd, J = 8.0, 5.9, 4.3 Hz, 2H), 0.90 (d, J = 6.7 Hz, 3H), 0.86 
(d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.0, 139.1, 135.2, 133.8, 131.3, 127.7, 120.6, 
55.0, 52.4, 42.3, 24.4, 22.8, 21.6. FTIR (thin film): 2955, 1738, 1340, 1165 cm-1. [α]D22.1 -48.9 (c 





















Methyl N-((2-bromophenyl)sulfonyl)-N-(but-3-en-1-yl)-L-leucinate (1.4): A flame-dried flask 
equipped with a stir bar was charged with 1.2 (1.68 g, 4.60 mmol), PPh3 (1.81 g, 6.90 mmol, 1.5 
equiv), DIAD (1.4 mL. 6.9 mmol, 1.5 equiv), and but-3-en-1-ol (0.6 mL, 6.9 mmol, 1.5 equiv), 
and DCM (30 mL) and was allowed to stir at rt for 3 hours. The reaction was then concentrated 
and the resulting oil was purified via flash chromatography (20% EtOAc in hexanes) to afford 1.4 
as a clear oil (1.54 g, 3.68 mmol, 80% yield). Rf = 0.6  (25% EtOAc in hexanes). 1H NMR (400 
MHz, CDCl3) δ 8.07 (dd, J = 7.8, 1.7 Hz, 1H), 7.66 (dd, J = 7.9, 1.3 Hz, 1H), 7.41 – 7.35 (m, 1H), 
7.34 – 7.27 (m, 1H), 5.65 (ddt, J = 17.1, 10.2, 6.8 Hz, 1H), 5.03 – 4.91 (m, 2H), 4.49 (dd, J = 8.6, 
5.8 Hz, 1H), 3.55 – 3.42 (m, 4H), 3.26 (ddd, J = 15.2, 11.2, 5.3 Hz, 1H), 2.52 – 2.40 (m, 1H), 2.29 
– 2.17 (m, 1H), 1.76 – 1.61 (m, 2H), 1.59 – 1.51 (m, 1H), 0.86 (dd, J = 12.9, 6.2 Hz, 7H). 13C NMR 
(101 MHz, CDCl3) δ 171.9, 139.5, 135.7, 134.9, 133.6, 132.6, 127.6, 120.6, 117.1, 58.4, 52.2, 
45.9, 39.7, 35.6, 24.7, 22.7, 21.9. FTIR (thin film): 2954, 1739, 1341, 1148 cm-1. [α]D22.2 -50.1 (c 






















Methyl N-((2-bromophenyl)sulfonyl)-N-(but-3-en-1-yl)-D-leucinate (1.5): A flame-dried flask 
equipped with a stir bar was charged with 1.3 (1.66 g, 4.55 mmol), PPh3 (1.19 g, 6.83 mmol, 1.5 
equiv), DIAD (1.3 mL, 6.8 mmol, 1.5 equiv), and but-3-en-1-ol (0.6 mL, 6.8 mmol, 1.5 equiv), 
and DCM (30 mL) and was allowed to stir at rt for 3 hours. The reaction was then concentrated 
and the resulting oil was purified via flash chromatography (20% EtOAc in hexanes) to afford 1.5 
as a clear oil (1.81 g, 4.55 mmol, 95% yield). Rf = 0.6 (25% EtOAc in hexanes). 1H NMR (400 
MHz, CDCl3) δ 8.14 (dd, J = 7.9, 1.7 Hz, 1H), 7.72 (dd, J = 7.8, 1.3 Hz, 1H), 7.48 – 7.33 (m, 2H), 
5.72 (ddt, J = 17.1, 10.2, 6.8 Hz, 1H), 5.09 – 5.00 (m, 2H), 4.55 (dd, J = 8.7, 5.8 Hz, 1H), 3.50-
3.60 (m, 4H), 3.33 (ddd, J = 15.3, 11.2, 5.3 Hz, 1H), 2.59 – 2.45 (m, 1H), 2.36 – 2.22 (m, 1H), 
1.82 – 1.67 (m, 2H), 1.67 – 1.54 (m, 1H), 0.94 (d, J = 6.1 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 171.9, 139.4, 135.7, 134.9, 133.6, 132.6, 127.6, 120.5, 117.1, 58.4, 
52.2, 45.9, 39.7, 35.6, 24.7, 22.7, 21.9. FTIR (thin film): 2954, 1739, 1341, 1148 cm-1. [α]D22.2 























yl)pentanoate (1.6): A flame-dried microwave vial equipped with a stir bar was charged with 1.4 
(1.44 g, 3.46 mmol), PPh3 (181 mg, 0.69 mmol, 0.2 equiv), TEA (1.4 mL, 10 mmol, 3 equiv) 
and MeCN (0.25 M). Pd(OAc)2 (78 mg, 0.35 mmol, 0.1 equiv) was then added and the reaction 
was capped and heated in the microwave at 100 °C for 1 h following a 5-minute pre-stir. The 
reaction was then cooled to rt, filtered through a pad of Celite, and thoroughly washed with DCM. 
The filtrate was then concentrated and purified via flash chromatography (20% EtOAc in hexanes) 
to afford 1.6 as a yellow oil (985 mg, 2.92 mmol, 84% yield). Rf = 0.6 (25% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 7.7, 1.4 Hz, 1H), 7.41 (td, J = 7.5, 1.4 Hz, 1H), 7.34 
– 7.26 (m, 2H), 5.22 (dd, J = 13.3, 1.2 Hz, 2H), 4.60 (dd, J = 9.2, 6.2 Hz, 1H), 3.70 (ddd, J = 14.2, 
7.9, 4.9 Hz, 1H), 3.56 (dt, J = 14.2, 5.0 Hz, 1H), 3.30 (s, 3H), 2.57 – 2.43 (m, 2H), 1.63 – 1.48 (m, 
3H), 1.42 (ddt, J = 14.7, 12.8, 6.5 Hz, 1H), 0.82 (d, J = 6.6 Hz, 7H). 13C NMR (101 MHz, CDCl3) 
δ 171.7, 147.2, 139.9, 139.9, 132.4, 130.1, 127.4, 126.3, 119.3, 57.7, 51.9, 45.2, 38.3, 35.3, 24.5, 
23.0, 21.5. FTIR (thin film): 2954, 2359, 1738, 1334, 1167 cm-1. [α]D22.7 -47.4 (c 1.0, CDCl3). 


















yl)pentanoate (1.7): A flame-dried microwave vial equipped with a stir bar was charged with 1.5 
(1.81 g, 4.33 mmol), PPh3 (227 mg, 0.87 mmol, 0.2 equiv), TEA (1.8 mL, 13 mmol, 3 equiv) 
and MeCN (0.25 M). Pd(OAc)2 (97 mg, 0.43 mmol, 0.1 equiv) was then added and the reaction 
was capped and heated in the microwave at 100 °C for 1 h following a 5-minute pre-stir. The 
reaction was then cooled to rt, filtered through a pad of Celite, and thoroughly washed with DCM. 
The filtrate was concentrated and purified via flash chromatography (20% EtOAc in hexanes) to 
afford 1.7 as a yellow oil (1.08 g, 3.21 mmol, 74% yield). Rf = 0.6 (25% EtOAc in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.93 – 7.89 (m, 1H), 7.47 (td, J = 7.5, 1.4 Hz, 1H), 7.41 – 7.33 (m, 
2H), 5.30 (d, J = 1.1 Hz, 1H), 5.27 (d, J = 1.3 Hz, 1H), 4.67 (dd, J = 9.2, 6.2 Hz, 1H), 3.76 (ddd, 
J = 14.1, 7.9, 4.9 Hz, 1H), 3.63 (ddd, J = 14.2, 6.1, 4.7 Hz, 1H), 3.36 (s, 3H), 2.61 – 2.51 (m, 2H), 
1.69 – 1.56 (m, 2H), 1.55 – 1.41 (m, 1H), 0.88 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) 
δ 171.7, 147.2, 139.9, 139.9, 132.3, 130.1, 127.4, 126.3, 119.3, 57.7, 51.9, 45.2, 38.3, 35.3, 24.5, 
23.0, 21.5. FTIR (thin film): 2954, 2359, 1738, 1333, 1151 cm-1. [α]D22.7 +46.4 (c 1.0, CHCl3). 











1.5 1.7  (74%)
Pd(OAc)2, PPh3, TEA,





yl)pentanoic acid (1.8): A flask was charged with 1.6 (973 mg, 2.88 mmol), LiOH (345 mg, 14.4 
mmol, 5 equiv), THF (7.2 mL), H2O (2.4 mL), and MeOH (2.4 mL) (0.23 M final 
concentration) and was allowed to stir at rt for 2 h or until SM was consumed (reaction monitored 
by TLC). The organic solvents were removed under reduced pressure and the remaining aqueous 
layer was washed with EtOAc and acidified with 4N HCl. The aqueous solution was then extracted 
with EtOAc, washed with brine, dried over sodium sulfate, filtered, and concentrated to afford the 
carboxylic acid 1.8 as a white solid (795 mg, 2.45 mmol, 85% yield). Rf = 0.4 (40% EtOAc in 
hexanes). 1H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 8.1, 1.3 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.34 
– 7.25 (m, 2H), 5.23 (dd, J = 12.2, 1.2 Hz, 2H), 4.67 (dd, J = 8.5, 6.8 Hz, 1H), 3.67 (ddd, J = 13.8, 
7.7, 4.0 Hz, 1H), 3.55 (ddd, J = 13.9, 7.7, 4.1 Hz, 1H), 2.71-2.45 (m, 1H), 2.52 – 2.44 (m, 1H), 
1.58 – 1.51 (m, 2H), 1.48-1.30 (m, 1H), 0.79 (d, J = 1.8 Hz, 4H), 0.77 (d, J = 1.6 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 176.8, 147.1, 139.9, 139.8, 132.5, 130.2, 127.5, 125.9, 119.4, 58.2, 
45.6, 38.5, 35.8, 24.6, 23.0, 21.3. FTIR (neat): 3197, 1740, 1314 cm-1. MP = 154–158 °C. [α]D21.2 


















yl)pentanoic acid (1.9): A flask was charged with methyl 1.7 (979 mg, 2.90 mmol), LiOH (347 
mg, 14.5 mmol, 5 equiv), THF (7.2 mL), H2O (2.4 mL), and MeOH (2.4 mL) (0.24 M final 
concentration), and was allowed to stir at rt for 2 h or until SM was consumed (reaction monitored 
by TLC). The organic solvents were then removed under reduced pressure and the remaining 
aqueous layer was washed with EtOAc and then acidified with 4N HCl. The aqueous solution was 
then extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered, and 
concentrated to give 1.9 as a white solid (656 mg, 2.02 mmol, 69% yield). Rf = 0.4 (40% EtOAc 
in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.92 – 7.85 (m, 1H), 7.51 – 7.43 (m, 1H), 7.39 – 7.30 
(m, 2H), 5.34 – 5.25 (m, 2H), 4.74 (dd, J = 8.6, 6.7 Hz, 1H), 3.73 (ddd, J = 12.4, 7.7, 4.0 Hz, 1H), 
3.61 (ddd, J = 13.8, 7.8, 4.1 Hz, 1H), 2.73 (ddd, J = 12.5, 7.7, 4.1 Hz, 1H), 2.54 (ddd, J = 13.1, 
7.7, 4.1 Hz, 1H), 1.61 (dd, J = 9.1, 5.8 Hz, 2H), 1.40 (dt, J = 13.6, 6.7 Hz, 1H), 0.87 – 0.82 (m, 
6H). 13C NMR (101 MHz, CDCl3) δ 176.9, 147.1, 139.9, 139.8, 132.5, 130.2, 127.5, 125.9, 119.4, 
58.2, 45.6, 38.5, 35.8, 24.6, 23.0, 21.3. FTIR (neat, solid): 3204, 2959, 1740, 1314 cm-1. MP = 
154–158 °C. [α]D21.2 +24.2 (c 1.0, CHCl3). HRMS (ESI, m/z): [M+H]+ calcd for C16H22NO4S+  

















(1.10): A flame-dried flask equipped with a stir bar was charged with 1.8 (1.10 g, 3.40 mmol) and 
anhydrous DCM (0.1 M) and was cooled to -78 °C. O3 was then bubbled through the solution until 
SM was consumed (reaction monitored by TLC). Dimethyl sulfide (DMS) (3.8 ml, 51 mmol, 15.0 
equiv) was then added drop wise and the reaction was concentrated and purified via flash 
chromatography (0-10% MeOH in DCM) to afford 1.10 as a white solid (1.09 g, 3.35 mmol, 94% 
yield). Rf = 0.6 (50% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.96 (ddd, J = 6.3, 3.1, 
0.8 Hz, 1H), 7.89 – 7.82 (m, 1H), 7.67 – 7.59 (m, 2H), 4.78 (t, J = 8.0 Hz, 1H), 3.62 – 3.41 
(complex, 3H), 3.27 – 3.18 (m, 1H), 1.72 – 1.67 (m, 2H), 1.59 (septet, J = 6.6 Hz, 1H), 0.95 (d, J 
= 4.1 Hz, 4H), 0.93 (d, J = 3.9 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 199.4, 176.1, 140.8, 135.5, 
132.5, 132.1, 129.5, 126.2, 58.9, 42.3, 39.9, 37.9, 24.7, 23.2, 20.9. FTIR (neat, solid): 2954, 2869, 
1710, 1693, 1324 cm-1. [α]D21.2 +15.0 (c 1.0, CHCl3). HRMS (ESI, m/z): [M+H]+ calcd for 















O3, DCM, -78 ˚C
then DMS
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General Procedure for HATU-Promoted Amide Coupling: A 1-dram vial equipped with a stir 
bar was charged with 40 mg of carboxylic acid 1.8-1.10, HATU (1.2 equiv), and MeCN (0.1 M) 
and the reaction stirred at rt for 20 min. The requisite amine component (2 equiv) was added and 
the reaction stirred for an additional 20 min. DIPEA (3 equiv) was then added and the reaction 
stirred overnight for 12–19 h. The reaction mixture was then diluted with EtOAc, transferred to a 
separatory funnel, and shaken. The layers were then separated and the organic layer washed with 
a saturated aqueous sodium bicarbonate solution and then brine. The organic layer was then dried 
over sodium sulfate, filtered, concentrated, and purified via flash chromatography (30% EtOAc in 















MeCN, rt, 12-19 h
n=1 or 2
R
X = CH2 or O






2(3H)-yl)pentanamide (1.11b): Carboxylic acid 1.8 and benzylamine were reacted according to 
the general procedure to afford the amide product 1.11b as a clear, colorless oil (45.1 mg, 0.109 
mmol, 85% yield). Rf = 0.4 (20% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 
8.0, 1.4 Hz, 1H), 7.42 (td, J = 7.5, 1.4 Hz, 1H), 7.30 (ddd, J = 7.4, 6.5, 1.5 Hz, 2H), 7.26–7.16 (m, 
3H), 7.09–7.04 (m, 2H), 6.13 (s, 1H), 5.21 (dd, J = 24.0, 1.2 Hz, 2H), 4.43 (dd, J = 8.5, 6.4 Hz, 
1H), 4.28 (dd, J = 14.8, 5.9 Hz, 1H), 4.16 (dd, J = 14.8, 5.7 Hz, 1H), 3.71 (ddd, J = 13.4, 9.2, 3.8 
Hz, 1H), 3.51 (ddd, J = 14.1, 6.3, 4.2 Hz, 1H), 2.59 (ddd, J = 13.9, 6.3, 3.8 Hz, 1H), 2.45 (ddd, J 
= 13.7, 9.2, 4.2 Hz, 1H), 1.71 (ddd, J = 14.4, 8.3, 6.4 Hz, 1H), 1.37 (ddd, J = 14.0, 8.5, 5.6 Hz, 
1H), 1.30–1.15 (m, 1H), 0.74 (d, J = 4.4 Hz, 3H), 0.72 (d, J = 4.6 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 169.9, 146.9, 140.0, 139.7, 137.7, 132.8, 130.6, 128.8, 127.7, 127.6, 127.6, 126.0, 119.8, 
59.2, 45.5, 43.8, 37.8, 35.7, 24.7, 22.8, 22.0. FTIR (thin film): 2955, 2359, 2341, 1661, 1332  










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.11c): Carboxylic acid 1.8 and 4-
chlorobenzylamine were reacted according to the general procedure to afford the amide product 
1.11c as a clear, colorless oil (51.3 mg, 0.115 mmol, 93% yield). Rf = 0.3 (20% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.2, 1.4 Hz, 1H), 7.47–7.39 (m, 1H), 7.30 (ddd, J = 
7.8, 6.3, 1.5 Hz, 2H), 7.22–7.15 (m, 2H), 7.01 (d, J = 8.4 Hz, 2H), 6.24 (s, 1H), 5.25 (d, J = 1.1 
Hz, 1H), 5.19 (d, J = 1.2 Hz, 1H), 4.43 (dd, J = 8.5, 6.4 Hz, 1H), 4.27–4.10 (m, 2H), 3.71 (ddd, J 
= 13.5, 9.4, 3.7 Hz, 1H), 3.48 (ddd, J = 14.1, 6.2, 4.2 Hz, 1H), 2.58 (ddd, J = 13.9, 6.2, 3.7 Hz, 
1H), 2.44 (ddd, J = 13.7, 9.5, 4.2 Hz, 2H), 1.70 (ddd, J = 14.4, 8.3, 6.4 Hz, 1H), 1.36 (ddd, J = 
14.0, 8.5, 5.6 Hz, 1H), 1.27–1.14 (m, 1H), 0.72 (d, J = 3.3 Hz, 3H), 0.71 (d, J = 3.4 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 170.1, 146.8, 140.0, 139.6, 136.4, 133.4, 132.8, 130.6, 129.0, 128.9, 
127.6, 126.0, 119.9, 59.2, 45.5, 43.0, 37.7, 35.7, 24.7, 22.8, 21.9. FTIR (thin film): 2955, 2359, 
2341, 1663, 1331 cm–1. [a]D22.2 –67.1 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for 










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.11d): Carboxylic acid 1.8 and 4-
chloro-3-(trifluoromethyl)benzylamine were reacted according to the general procedure to afford 
the amide product 1.11d as a clear, colorless oil (61.7 mg, 0.120 mmol, 97% yield). Rf = 0.3 (20% 
EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 8.1, 1.3 Hz, 1H), 7.46–7.40 (m, 
2H), 7.35 (d, J = 8.2 Hz, 1H), 7.32–7.26 (m, 2H), 7.25–7.20 (m, 1H), 6.41 (s, 1H), 5.26 (d, J = 1.1 
Hz, 1H), 5.20 (d, J = 1.2 Hz, 1H), 4.44 (dd, J = 8.3, 6.6 Hz, 1H), 4.26 (dd, J = 6.2, 1.7 Hz, 2H), 
3.72 (ddd, J = 13.6, 9.5, 3.6 Hz, 1H), 3.48 (ddd, J = 14.1, 6.1, 4.2 Hz, 1H), 2.59 (ddd, J = 13.9, 
6.1, 3.8 Hz, 1H), 2.44 (ddd, J = 14.1, 9.6, 3.9 Hz, 1H), 1.70 (ddd, J = 14.0, 8.1, 6.6 Hz, 1H), 1.34 
(ddd, J = 14.0, 8.3, 5.7 Hz, 1H), 1.25–1.12 (m, 1H), 0.72 (d, J = 2.2 Hz, 3H), 0.70 (d, J = 2.4 Hz, 
3H). 13C NMR (176 MHz, CDCl3) δ 170.3, 146.8, 140.0, 139.4, 137.3, 132.9, 132.0, 131.8, 131.3, 
130.6, 128.5 (q, J= 31.44 Hz), 127.6, 126.7 (q, J = 5.19 Hz), 125.9, 122.8 (q, J = 273.30), 119.9, 
59.1, 45.5, 42.6, 37.7, 35.7, 24.7, 22.6, 22.0. FTIR (thin film): 2957, 2359, 2341, 1668, 1318, 1168, 
1130 cm–1. [a]D22.4 –51.3 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for 













dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.11e): Carboxylic acid 1.8 and 4-
methylbenzylamine were reacted according to the general procedure to afford the amide product 
1.11e as a clear, colorless oil (45.8 mg, 0.107 mmol, 87% yield). Rf = 0.3 (20% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 8.2, 1.4 Hz, 1H), 7.42 (td, J = 7.4, 1.4 Hz, 1H), 7.29 
(ddd, J = 7.8, 6.4, 1.5 Hz, 2H), 7.03 (d, J = 7.7 Hz, 2H), 6.95 (d, J = 8.0 Hz, 2H), 6.07 (s, 1H), 
5.24 (d, J = 1.1 Hz, 1H), 5.18 (d, J = 1.2 Hz, 1H), 4.41 (dd, J = 8.4, 6.4 Hz, 1H), 4.23 (dd, J = 
14.6, 5.9 Hz, 1H), 4.10 (dd, J = 14.6, 5.5 Hz, 1H), 3.71 (ddd, J = 13.4, 9.2, 3.8 Hz, 1H), 3.51 (ddd, 
J = 14.1, 6.4, 4.2 Hz, 1H), 2.64–2.52 (m, 1H), 2.51–2.39 (m, 1H), 2.26 (s, 3H), 1.70 (ddd, J = 14.4, 
8.3, 6.4 Hz, 1H), 1.37 (ddd, J = 14.0, 8.5, 5.6 Hz, 1H), 1.23 (dq, J = 13.1, 6.5 Hz, 1H), 0.73 (d, J 
= 4.4 Hz, 3H), 0.71 (d, J = 4.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.8, 147.0, 140.1, 139.7, 
137.3, 134.7, 132.8, 130.5, 129.5, 127.7, 127.6, 126.0, 119.8, 59.2, 45.5, 43.5, 37.8, 35.7, 24.7, 
22.8, 22.0, 21.2. FTIR (thin film): 2955, 2359, 2341, 1661, 1332 cm–1. [α]D22.4 –71.2 (c 1.0, 










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.11f): Carboxylic acid 1.8 and 4-
methoxylbenzylamine were reacted according to the general procedure to afford the amide product 
1.11f as a clear, colorless oil (46.6 mg, 0.105 mmol, 85% yield). Rf = 0.2 (20% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 8.2, 1.4 Hz, 1H), 7.42 (td, J = 7.4, 1.4 Hz, 1H), 7.30 
(ddd, J = 6.9, 6.3, 1.4 Hz, 2H), 7.02–6.97 (m, 2H), 6.78–6.72 (m, 2H), 6.06 (s, 1H), 5.24 (d, J = 
1.1 Hz, 1H), 5.18 (d, J = 1.2 Hz, 1H), 4.41 (dd, J = 8.5, 6.4 Hz, 1H), 4.20 (dd, J = 14.5, 5.8 Hz, 
1H), 4.09 (dd, J = 14.6, 5.6 Hz, 1H), 3.73 (s, 4H), 3.51 (ddd, J = 14.1, 6.3, 4.1 Hz, 1H), 2.58 (ddd, 
J = 13.9, 6.4, 3.8 Hz, 1H), 2.45 (ddd, J = 13.6, 9.1, 4.0 Hz, 1H), 1.70 (ddd, J = 14.4, 8.3, 6.4 Hz, 
1H), 1.37 (ddd, J = 14.0, 8.4, 5.5 Hz, 1H), 1.23 (td, J = 12.9, 12.4, 6.1 Hz, 1H), 0.73 (d, J = 4.5 
Hz, 3H), 0.71 (d, J = 4.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.8, 159.1, 146.9, 140.0, 
139.7, 132.8, 130.5, 129.8, 129.0, 127.6, 126.0, 119.8, 114.2, 59.1, 55.4, 45.4, 43.2, 37.8, 35.7, 
24.7, 22.8, 21.9. FTIR (thin film): 2955, 2359, 2341, 1662, 1512 cm–1. [a]D22.1 -66.3 (c 1.0, 










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.11g): Carboxylic acid 1.8 and 4-
cyclohexylmethylamine were reacted according to the general procedure to afford the amide 
product 1.11g as a clear, colorless oil (40 mg, 0.10 mmol, 77% yield). Rf = 0.5 (20% EtOAc in 
hexanes). 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 8.2, 1.4 Hz, 1H), 7.48–7.40 (m, 1H), 7.36–
7.28 (m, 2H), 5.85 (s, 1H), 5.27 (d, J = 1.1 Hz, 1H), 5.22 (d, J = 1.3 Hz, 1H), 4.37 (dd, J = 8.5, 6.3 
Hz, 1H), 3.73 (ddd, J = 14.1, 9.2, 3.7 Hz, 1H), 3.51 (ddd, J = 14.1, 6.4, 4.1 Hz, 1H), 2.99–2.79 (m, 
2H), 2.68–2.54 (m, 1H), 2.52–2.39 (m, 1H), 1.76–1.42 (m, 7H), 1.41–0.96 (m, 5H), 0.84–0.66 (m, 
8H). 13C NMR (101 MHz, CDCl3) δ 170.0, 147.9, 140.1, 139.7, 132.8, 130.6, 127.6, 126.0, 119.8, 
59.2, 45.9, 45.5, 37.8, 35.8, 30.8, 26.4, 25.9, 25.9, 24.7, 22.8, 22.0. FTIR (thin film): 2922, 2539, 
2341, 1661, 1332 cm–1. [α]D22.4 –68.5 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for 











dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.11h): Carboxylic acid 1.8 and 3,4-
dichlorophenethylamine were reacted according to the general procedure to afford the amide 
product 1.11h as a clear, colorless oil (55 mg, 0.11 mmol, 90% yield). Rf = 0.4 (30% EtOAc in 
hexanes). 1H NMR (400 MHz, CDCl3) δ 7.88 (ddd, J = 7.7, 1.3, 0.6 Hz, 1H), 7.51 (td, J = 7.5, 1.4 
Hz, 1H), 7.41–7.32 (m, 3H), 7.24 (d, J = 2.1 Hz, 1H), 6.99 (dd, J = 8.2, 2.1 Hz, 1H), 6.06–5.99 
(m, 1H), 5.32 (d, J = 1.1 Hz, 1H), 5.27 (d, J = 1.2 Hz, 1H), 4.39 (dd, J = 8.2, 6.6 Hz, 1H), 3.70 
(ddd, J = 13.5, 9.6, 3.6 Hz, 1H), 3.47 (ddd, J = 14.1, 6.0, 4.2 Hz, 1H), 3.42–3.30 (m, 2H), 2.65 
(ddt, J = 13.3, 6.1, 3.3 Hz, 3H), 2.55–2.43 (m, 1H), 1.73 (ddd, J = 13.9, 8.1, 6.6 Hz, 1H), 1.33 
(ddd, J = 14.0, 8.3, 5.7 Hz, 1H), 1.23–1.14 (m, 1H), 0.75 (t, J = 6.8 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ 170.1, 146.9, 140.0, 139.6, 138.9, 132.9, 132.5, 130.8, 130.7, 130.6, 130.6, 128.3, 127.6, 
126.0, 119.8, 59.2, 45.5, 40.5, 37.7, 35.8, 34.8, 24.7, 22.7, 22.0. FTIR (thin film): 2955, 2868, 
1666, 1469, 1331, 1167 cm–1. [a]D22.5 –66.7 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd 










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.12a): Carboxylic acid 1.9 and 3,4-
dichlorobenzylamine were reacted according to the general procedure to afford the amide product 
1.12a as a clear, colorless oil (54.2 mg, 0.113 mmol, 91% yield). Rf = 0.4 (25% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 8.1, 1.3 Hz, 1H), 7.48–7.38 (m, 1H), 7.32–7.26 (m, 
4H), 6.93 (dd, J = 8.2, 2.1 Hz, 1H), 6.32 (d, J = 6.4 Hz, 1H), 5.26 (q, J = 1.0 Hz, 1H), 5.20 (d, J = 
1.2 Hz, 1H), 4.43 (dd, J = 8.4, 6.5 Hz, 1H), 4.18 (dd, J = 6.0, 1.5 Hz, 2H), 3.78–3.66 (m, 1H), 3.48 
(ddd, J = 14.1, 6.2, 4.2 Hz, 1H), 2.63–2.54 (m, 1H), 2.51–2.38 (m, 1H), 1.69 (ddd, J = 14.1, 8.2, 
6.5 Hz, 1H), 1.36 (ddd, J = 14.0, 8.4, 5.6 Hz, 1H), 1.28–1.13 (m, 1H), 0.72 (d, J = 2.4 Hz, 3H), 
0.71 (d, J = 2.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.2, 146.8, 140.0, 139.5, 138.2, 132.9, 
132.7, 131.6, 130.7, 130.6, 129.7, 127.6, 127.0, 125.9, 119.9, 59.1, 45.5, 42.6, 37.6, 35.7, 24.7, 
22.7, 21.9. FTIR (thin film): 2956, 2359, 2341, 1668, 1333, 1169 cm–1. [α]D21.9 +58.8 (c 1.0, 











2(3H)-yl)pentanamide (1.12b): Carboxylic acid 1.9 and benzylamine were reacted according to 
the general procedure to afford the amide product 1.12b as a clear, colorless oil (42.1 mg, 0.102 
mmol, 83% yield). Rf = 0.4 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 
8.1, 1.4 Hz, 1H), 7.46–7.38 (m, 1H), 7.32–7.26 (m, 2H), 7.26–7.16 (m, 3H), 7.09–7.03 (m, 2H), 
6.14 (s, 1H), 5.24 (d, J = 1.2 Hz, 1H), 5.18 (d, J = 1.2 Hz, 1H), 4.43 (dd, J = 8.5, 6.4 Hz, 1H), 4.28 
(dd, J = 14.8, 5.9 Hz, 1H), 4.16 (dd, J = 14.8, 5.7 Hz, 1H), 3.71 (ddd, J = 13.4, 9.2, 3.8 Hz, 1H), 
3.51 (ddd, J = 14.1, 6.4, 4.2 Hz, 1H), 2.58 (ddd, J = 13.9, 6.4, 3.7 Hz, 1H), 2.52–2.39 (m, 1H), 
1.71 (ddd, J = 14.4, 8.3, 6.4 Hz, 1H), 1.37 (ddd, J = 14.0, 8.5, 5.6 Hz, 1H), 1.31–1.16 (m, 1H), 
0.73 (d, J = 4.4 Hz, 3H), 0.72 (d, J = 4.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.9, 146.9, 
140.0, 139.7, 137.7, 132.8, 130.6, 128.8, 127.7, 127.6, 127.6, 126.0, 119.8, 59.2, 45.5, 43.8, 37.8, 
35.7, 24.7, 22.8, 22.0. FTIR (thin film): 2955, 2359, 2341, 1662, 1335, 1169 cm–1. [α]D21.6 +67.5 










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.12c): Carboxylic acid 1.9 and 4-
chlorobenzylamine were reacted according to the general procedure to afford the amide product 
1.12c as a clear, colorless oil (48.4 mg, 0.124 mmol, 88%). Rf = 0.4 (25% EtOAc in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.1, 1.4 Hz, 1H), 7.43 (td, J = 7.5, 1.3 Hz, 1H), 7.30 (ddd, 
J = 7.9, 6.2, 1.5 Hz, 2H), 7.19 (s, 1H), 7.17 (d, J = 2.0 Hz, 1H), 7.01 (d, J = 8.4 Hz, 2H), 6.25 (d, 
J = 6.9 Hz, 1H), 5.25 (d, J = 1.2 Hz, 1H), 5.19 (d, J = 1.2 Hz, 1H), 4.43 (dd, J = 8.5, 6.4 Hz, 1H), 
4.26–4.13 (m, 2H), 3.71 (ddd, J = 13.5, 9.4, 3.7 Hz, 1H), 3.48 (ddd, J = 14.0, 6.2, 4.2 Hz, 1H), 
2.58 (ddd, J = 13.9, 6.2, 3.7 Hz, 1H), 2.51–2.38 (m, 1H), 1.70 (ddd, J = 14.4, 8.3, 6.4 Hz, 1H), 
1.36 (ddd, J = 14.1, 8.5, 5.5 Hz, 1H), 1.21 (dt, J = 14.0, 6.1 Hz, 2H), 0.72 (d, J = 3.3 Hz, 3H), 0.71 
(d, J = 3.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.1, 146.8, 140.0, 139.6, 136.4, 133.4, 132.8, 
130.6, 129.0, 128.9, 127.6, 126.0, 119.9, 59.2, 45.5, 43.0, 37.7, 35.7, 24.7, 22.8, 21.9. FTIR (thin 
film): 2956, 1663, 1333, 1168 cm–1. [α]D20.9 +69.2 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ 










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.12d): Carboxylic acid 1.9 and 4-
chloro-3-(trifluoromethyl)benzylamine were reacted according to the general procedure to afford 
the amide product 1.12d as a clear, colorless oil (54.9 mg, 0.124 mmol, 86%). Rf = 0.4 (25% 
EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 8.1, 1.3 Hz, 1H), 7.46–7.40 (m, 
2H), 7.35 (d, J = 8.2 Hz, 1H), 7.32–7.26 (m, 2H), 7.22 (dd, J = 8.2, 2.2 Hz, 1H), 6.41 (s, 1H), 5.26 
(d, J = 1.1 Hz, 1H), 5.20 (d, J = 1.2 Hz, 1H), 4.44 (dd, J = 8.3, 6.6 Hz, 1H), 4.32–4.17 (m, 2H), 
3.72 (ddd, J = 13.5, 9.5, 3.6 Hz, 1H), 3.48 (ddd, J = 14.1, 6.1, 4.2 Hz, 1H), 2.59 (ddd, J = 13.9, 
6.1, 3.6 Hz, 1H), 2.52–2.39 (m, 1H), 1.70 (ddd, J = 14.4, 8.1, 6.6 Hz, 1H), 1.34 (ddd, J = 14.0, 8.3, 
5.7 Hz, 1H), 1.27–1.11 (m, 1H), 0.72 (d, J = 2.2 Hz, 3H), 0.70 (d, J = 2.3 Hz, 3H). 13C NMR (176 
MHz, CDCl3) δ 170.4, 146.8, 140.0, 139.4, 137.3, 132.9, 132.0, 131.8, 131.3, 130.6, 128.6 (q, J = 
32.08 Hz), 127.6, 126.8 (q, J = 5.25 Hz), 125.9, 122.5 (q, J = 273.35 Hz), 119.9, 59.1, 45.5, 42.6, 
37.6, 35.8, 24.7, 22.6, 22.0. FTIR (thin film): 2957, 1667, 1318, 1169, 1130 cm–1. [α]D20.9 +52.4 














dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.12e): Carboxylic acid 1.9 and 4-
methylbenzylamine were reacted according to the general procedure to afford the amide product 
1.12e as a clear, colorless oil (50.8 mg, 0.119 mmol, 96% yield). Rf = 0.4 (25% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.1, 1.6 Hz, 1H), 7.42 (ddt, J = 7.8, 7.2, 0.9 Hz, 1H), 
7.32–7.26 (m, 2H), 7.05–7.00 (m, 2H), 6.95 (d, J = 7.9 Hz, 2H), 6.08 (s, 1H), 5.24 (d, J = 1.2 Hz, 
1H), 5.18 (d, J = 1.3 Hz, 1H), 4.41 (dd, J = 8.5, 6.4 Hz, 1H), 4.23 (dd, J = 14.7, 5.9 Hz, 1H), 4.10 
(dd, J = 14.6, 5.5 Hz, 1H), 3.71 (ddd, J = 13.4, 9.2, 3.8 Hz, 1H), 3.51 (ddd, J = 14.1, 6.4, 4.2 Hz, 
1H), 2.59 (ddd, J = 13.9, 6.4, 3.8 Hz, 1H), 2.45 (ddd, J = 13.8, 9.3, 4.2 Hz, 1H), 2.26 (s, 3H), 1.70 
(ddd, J = 14.3, 8.3, 6.4 Hz, 1H), 1.37 (ddd, J = 14.0, 8.5, 5.6 Hz, 1H), 1.30–1.15 (m, 1H), 0.73 (d, 
J = 4.3 Hz, 3H), 0.71 (d, J = 4.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.8, 147.0, 140.0, 
139.7, 137.3, 134.7, 132.8, 130.5, 129.5, 127.7, 127.6, 126.0, 119.8, 59.2, 45.5, 43.5, 37.8, 35.7, 
24.7, 22.8, 22.0, 21.2. FTIR (thin film): 2923, 2359, 23412, 1668, 1334, 1168 cm–1. [α]D22.1 +68.7 











dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.12f): Carboxylic acid 1.9 and 4-
methoxylbenzylamine were reacted according to the general procedure to afford the amide product 
1.12f as a clear, colorless oil (52.3 mg, 0.124 mmol, 96%). Rf = 0.3 (25% EtOAc in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.1, 1.4 Hz, 1H), 7.45–7.39 (m, 1H), 7.33–7.26 (m, 2H), 
7.01–6.97 (m, 2H), 6.77–6.73 (m, 2H), 6.07 (s, 1H), 5.24 (d, J = 1.1 Hz, 1H), 5.18 (d, J = 1.3 Hz, 
1H), 4.40 (dd, J = 8.5, 6.4 Hz, 1H), 4.20 (dd, J = 14.6, 5.8 Hz, 1H), 4.09 (dd, J = 14.6, 5.6 Hz, 
1H), 3.74-3.66 (complex, 4H), 3.51 (ddd, J = 14.1, 6.4, 4.2 Hz, 1H), 2.58 (ddd, J = 13.5, 6.3, 3.7 
Hz, 1H), 2.50–2.39 (m, 1H), 1.69 (ddd, J = 14.3, 8.3, 6.4 Hz, 1H), 1.37 (ddd, J = 14.0, 8.5, 5.6 Hz, 
1H), 1.22 (td, J = 12.5, 11.5, 5.8 Hz, 1H), 0.73 (d, J = 4.2 Hz, 3H), 0.71 (d, J = 4.4 Hz, 4H). 13C 
NMR (101 MHz, CDCl3) δ 169.8, 159.1, 146.9, 140.0, 139.7, 132.8, 130.5, 129.8, 129.0, 127.6, 
126.0, 119.8, 114.2, 59.2, 55.4, 45.4, 43.2, 37.8, 35.7, 24.7, 22.8, 22.0. FTIR (thin film): 2966, 
1662, 1512, 1333 cm–1. [α]D21.1 +64.0 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for 










dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.12g): Carboxylic acid 1.9 and 4-
cyclohexylmethylamine were reacted according to the general procedure to afford the amide 
product 1.12g as a clear, colorless oil (43 mg, 0.103 mmol, 83% yield). Rf = 0.4 (25% EtOAc in 
hexanes). 1H NMR (400 MHz, CDCl3) δ 7.86-7.82 (m, 1H), 7.47–7.41 (m, 1H), 7.35–7.29 
(complex, 2H), 5.85 (m, 1H), 5.27 (d, J = 1.1 Hz, 1H), 5.22 (d, J = 1.3 Hz, 1H), 4.37 (dd, J = 8.5, 
6.4 Hz, 1H), 3.78-3.68 (m, 1H), 3.55-3.45 (m, 1H), 2.99–2.78 (m, 2H), 2.67–2.54 (m, 1H), 2.53–
2.38 (m, 1H), 1.76–1.45 (complex, 7H), 1.40–0.98 (complex, 5H), 0.84–0.66 (complex, 8H). 13C 
NMR (101 MHz, CDCl3) δ 170.0, 147.0, 140.1, 139.7, 132.8, 130.6, 127.6, 126.0, 119.8, 59.2, 
45.9, 45.5, 37.8, 35.8, 30.8, 26.4, 25.9, 25.9, 24.7, 22.8, 22.0. FTIR (thin film): 2922, 2851, 2359, 
2341, 1661, 1334 cm–1. [α]D22.6 +67.5 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for 











dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)pentanamide (1.12h): Carboxylic acid 1.9 and 3,4-
dichlorophenethylamine were reacted according to the general procedure to afford the amide 
product 1.12h as a clear, colorless oil (58.2 mg, 0.117 mmol, 95%). Rf = 0.4 (25% EtOAc in 
hexanes). 1H NMR (400 MHz, CDCl3) δ 7.84–7.80 (m, 1H), 7.44 (td, J = 7.6, 1.4 Hz, 1H), 7.35–
7.26 (m, 3H), 7.17 (d, J = 2.1 Hz, 1H), 6.93 (dd, J = 8.2, 2.1 Hz, 1H), 5.97 (s, 1H), 5.25 (t, J = 1.0 
Hz, 1H), 5.21 (d, J = 1.2 Hz, 1H), 4.33 (dd, J = 8.3, 6.6 Hz, 1H), 3.64 (ddd, J = 13.5, 9.5, 3.6 Hz, 
1H), 3.45–3.21 (m, 3H), 2.59 (ddt, J = 13.3, 6.0, 3.3 Hz, 3H), 2.41 (dddd, J = 13.8, 9.6, 4.2, 1.0 
Hz, 1H), 1.66 (ddd, J = 14.0, 8.1, 6.6 Hz, 1H), 1.27 (ddd, J = 14.0, 8.3, 5.7 Hz, 1H), 1.20–1.07 (m, 
1H), 0.68 (t, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 170.0, 146.7, 139.9, 139.5, 138.7, 
132.7, 132.4, 130.6, 130.5, 130.5, 130.4, 128.2, 127.4, 125.8, 119.6, 59.1, 45.3, 40.3, 37.5, 35.6, 
34.6, 24.5, 22.5, 21.8. FTIR (thin film): 2956, 1667, 1332, 1168 cm–1. [α]D20.8 +63.9 (c 1.0, CHCl3). 










yl)-4-methylpentanamide (1.13a): Carboxylic acid 1.10 and 3,4-dichlorobenzylamine were 
reacted according to the general procedure to afford the amide product 1.13a as a clear, colorless 
oil (38.5 mg, 0.080 mmol, 65% yield). Rf = 0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.87 (dd, J = 7.7, 1.2 Hz, 1H), 7.76 (dd, J = 7.6, 1.4 Hz, 1H), 7.61 (dtd, J = 22.0, 7.5, 1.4 
Hz, 2H), 7.34 (d, J = 8.2 Hz, 1H), 7.24 (d, J = 2.1 Hz, 1H), 6.99 (dd, J = 8.2, 2.1 Hz, 1H), 6.27 (t, 
J = 6.0 Hz, 1H), 4.52 (dd, J = 8.5, 6.6 Hz, 1H), 4.29–4.16 (m, 2H), 3.67–3.55 (m, 1H), 3.57–3.46 
(m, 1H), 3.39–3.27 (m, 1H), 3.28–3.16 (m, 1H), 1.77–1.65 (m, 1H), 1.58–1.46 (m, 1H), 1.44–1.32 
(m, 1H), 0.86 (d, J = 5.1 Hz, 3H), 0.84 (d, J = 5.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 199.4, 
169.3, 139.2, 137.8, 136.1, 132.9, 132.6, 131.8, 131.6, 130.6, 129.6, 129.6, 126.9, 125.5, 58.9, 
42.4, 42.4, 39.7, 37.2, 24.6, 22.6, 21.7. FTIR (thin film): 3365, 2957, 1663, 1638, 1338 cm–1. 
[α]D21.8 -41.4 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for C22H25Cl2N2O4S+ 













methylpentanamide (1.13b): Carboxylic acid 1.10 and benzylamine were reacted according to 
the general procedure to afford the amide product 1.13b as a clear, colorless oil (35.0 mg, .123 
mmol, 69%). Rf = 0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 7.5, 
1.6 Hz, 1H), 7.70 (dd, J = 7.5, 1.5 Hz, 1H), 7.54 (dtd, J = 19.5, 7.5, 1.5 Hz, 2H), 7.26–7.17 
(complex, 4H), 7.08-7.05 (m, 2H), 6.07–5.99 (m, 2H), 4.45 (dd, J = 8.6, 6.6 Hz, 1H), 4.26 (dd, J 
= 14.7, 5.9 Hz, 1H), 4.14 (dd, J = 14.7, 5.6 Hz, 1H), 3.60-4.52 (m, 1H), 3.51-3.42 (m, 1H), 3.29-
3.20 (m, 1H), 3.18-3.08 (m, 1H), 1.69-1.59 (m, 1H), 1.52-1.42 (m, 1H) 1.41–1.27 (m, 1H), 0.80 
(d, J = 2.5 Hz, 3H), 0.78 (d, J = 2.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 199.8, 169.2, 139.3, 
137.5, 136.4, 133.0, 131.9, 129.7, 128.9, 127.8, 125.8, 59.1, 43.7, 42.6, 39.8, 37.6, 24.8, 22.8, 21.8. 
FTIR (thin film): 3320, 2956, 2926, 1359, 1682 cm-1. [α]D21.4 -43.6 (c 1.0, CHCl3). HRMS (ESI, 
















methylpentanamide (1.13c): Carboxylic acid 1.10 and 4-chlorobenzylamine were reacted 
according to the general procedure to afford the amide product 1.13c as a clear, colorless oil (33.0 
mg, 0.068 mmol, 56% yield). Rf = 0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 
7.88 (dd, J = 7.8, 1.3 Hz, 1H), 7.77 (dd, J = 7.6, 1.4 Hz, 1H), 7.61 (dtd, J = 22.5, 7.5, 1.4 Hz, 2H), 
7.28–7.21 (m, 2H), 7.11–7.03 (m, 2H), 6.18 (t, J = 5.8 Hz, 1H), 4.51 (dd, J = 8.5, 6.6 Hz, 1H), 
4.32–4.16 (m, 2H), 3.67–3.56 (m, 1H), 3.57–3.46 (m, 1H), 3.37–3.28 (m, 1H), 3.27–3.15 (m, 1H), 
1.77–1.65 (m, 1H), 1.58–1.46 (m, 1H), 1.46–1.31 (m, 1H), 0.85 (d, J = 4.0 Hz, 3H), 0.84 (d, J = 
3.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 199.6, 169.4, 139.5, 136.3, 136.2, 133.6, 133.0, 131.9, 
129.8, 129.1, 129.0, 125.7, 59.1, 43.0, 42.6, 39.8, 37.5, 24.8, 22.8, 21.8. FTIR (thin film): 3366, 
2957, 1663, 1533, 1336 cm–1. [α]D21.8 -45.9 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd 












dihydrobenzo[f][1,2]thiazepin-2(3H)-yl)-4-methylpentanamide (1.13d): Carboxylic acid 1.10 
and 4-chloro-3-(trifluoromethyl)benzylamine were reacted according to the general procedure to 
afford the amide product 1.13d as a clear, colorless oil (44.0 mg, 0.085 mmol, 69% yield). Rf = 
0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.92–7.87 (m, 1H), 7.80–7.75 (m, 
1H), 7.62 (dtd, J = 19.3, 7.5, 1.4 Hz, 2H), 7.49 (d, J = 2.1 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.29 
(dd, J = 8.4, 2.2 Hz, 1H), 6.32 (t, J = 6.0 Hz, 1H), 4.53 (dd, J = 8.4, 6.8 Hz, 1H), 4.40–4.23 (m, 
2H), 3.66–3.55 (m, 1H), 3.57–3.45 (m, 1H), 3.41–3.29 (m, 1H), 3.28–3.16 (m, 1H), 1.79–1.67 (m, 
1H), 1.56–1.44 (m, 1H), 1.43–1.31 (m, 1H), 0.88–0.80 (m, 6H). 13C NMR (176 MHz, CDCl3) δ 
199.6, 169.6, 139.4, 137.1, 136.3, 133.0, 132.1, 132.0, 131.9, 131.5, 129.7, 128.7 (q, J = 31.43 
Hz), 126.8 (q, J = 5.19 Hz), 125.5, 122.7 (q, J = 273.33 Hz), 59.0, 42.6, 42.5, 39.9, 37.4, 24.8, 
22.7, 21.8. FTIR (thin film): 3398, 2959, 1664, 1532, 1319 cm–1. [α]D21.9 -46.2 (c 1.0, CHCl3). 















methylbenzyl)pentanamide (1.13e): Carboxylic acid 1.10 and 4-methylbenzylamine were 
reacted according to the general procedure to afford the amide product 1.13e as a clear, colorless 
oil (37.9 mg, 0.088 mmol, 72% yield). Rf = 0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.88 (dd, J = 7.6, 1.4 Hz, 1H), 7.77 (dd, J = 7.4, 1.6 Hz, 1H), 7.61 (dtd, J = 19.7, 7.5, 1.4 
Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 7.02 (d, J = 8.0 Hz, 2H), 6.04 (s, 1H), 4.49 (dd, J = 8.6, 6.6 Hz, 
1H), 4.29 (dd, J = 14.6, 5.8 Hz, 1H), 4.15 (dd, J = 14.6, 5.5 Hz, 1H), 3.69–3.57 (m, 1H), 3.59–
3.48 (m, 1H), 3.37–3.26 (m, 1H), 3.26–3.14 (m, 1H), 2.33 (s, 3H), 1.77–1.65 (m, 1H), 1.59–1.47 
(m, 1H), 1.47–1.35 (m, 1H), 0.86 (d, J = 2.3 Hz, 3H), 0.84 (d, J = 2.2 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 199.7, 169.0, 139.2, 137.3, 136.3, 134.3, 132.8, 131.7, 129.6, 129.4, 127.6, 125.6, 
59.0, 43.4, 42.5, 39.7, 37.4, 24.6, 22.7, 21.7, 21.0. FTIR (thin film): 3314, 2956, 2924, 2869, 1662, 
1339 cm-1. [α]D21.7 -46.8 (c 1.0, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for C23H29N2O4S+ 












4-methylpentanamide (1.13f): Carboxylic acid 1.10 and 4-methoxylbenzylamine were reacted 
according to the general procedure to afford the amide product 1.13f as a clear, colorless oil (40.7 
mg, 0.092 mmol, 75% yield). Rf = 0.2 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 
7.88 (dd, J = 7.6, 1.4 Hz, 1H), 7.77 (dd, J = 7.6, 1.5 Hz, 1H), 7.61 (dtd, J = 19.1, 7.5, 1.5 Hz, 2H), 
7.10–7.02 (m, 2H), 6.85–6.78 (m, 2H), 6.03 (t, J = 5.7 Hz, 1H), 4.49 (dd, J = 8.6, 6.6 Hz, 1H), 
4.25 (dd, J = 14.5, 5.8 Hz, 1H), 4.13 (dd, J = 14.5, 5.5 Hz, 1H), 3.79 (s, 3H), 3.68–3.57 (m, 1H), 
3.59–3.47 (m, 1H), 3.37–3.25 (m, 1H), 3.26–3.14 (m, 1H), 1.77–1.64 (m, 1H), 1.59–1.47 (m, 1H), 
1.46–1.34 (m, 1H), 0.86 (d, J = 2.4 Hz, 3H), 0.84 (d, J = 2.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 199.8, 169.1, 159.2, 139.3, 136.4, 132.9, 131.9, 129.7, 129.6, 129.2, 125.8, 114.2, 59.1, 55.4, 
43.2, 42.6, 39.8, 37.6, 24.8, 22.8, 21.8. FTIR (thin film): 3318, 2956, 1660, 1512 cm–1. [α]D21.8  













yl)-4-methylpentanamide (1.13g): Carboxylic acid 1.10 and 4-cyclohexylmethylamine were 
reacted according to the general procedure to afford the amide product 1.13g as a clear, colorless 
oil (28.0 mg, 0.123 mmol, 54% yield). Rf = 0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.90–7.86 (m, 1H), 7.74–7.70 (m, 1H), 7.62–7.53 (m, 2H), 5.76 (s, 1H), 4.40 (dd, J = 
8.5, 6.6 Hz, 1H), 3.58 (ddd, J = 12.9, 7.9, 4.8 Hz, 1H), 3.47 (ddd, J = 13.1, 8.1, 4.8 Hz, 1H), 3.28 
(ddd, J = 14.8, 8.1, 4.8 Hz, 1H), 3.14 (ddd, J = 14.8, 7.9, 4.8 Hz, 1H), 2.96–2.78 (m, 2H), 1.69–
1.39 (complex, 8H), 1.38–0.97 (complex, 6H), 0.79 (d, J = 1.4 Hz, 3H), 0.78 (d, J = 1.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 199.8, 169.3, 139.5, 136.5, 132.9, 131.9, 129.8, 125.7, 59.2, 45.8, 
42.7, 39.8, 37.7, 37.6, 30.8, 26.4, 25.8, 24.8, 22.8, 21.9. FTIR (thin film): 3382, 2923, 2851, 1660, 
1431 cm-1. [α]D21.7 -42.2 (c 0.50, CHCl3). HRMS (ESI, m/z): m/z: [M+H]+ calcd for C22H33N2O4S+ 












2(3H)-yl)-4-methylpentanamide (1.13h): Carboxylic acid 1.10 and 3,4-dichlorophenethylamine 
were reacted according to the general procedure to afford the amide product 1.13h as a clear, 
colorless oil (53.3 mg, 0.107 mmol, 87% yield). Rf = 0.2 (25% EtOAc in hexanes). 1H NMR (400 
MHz, CDCl3) δ 7.94–7.89 (m, 1H), 7.81–7.77 (m, 1H), 7.68–7.60 (m, 2H), 7.35 (d, J = 8.2 Hz, 
1H), 7.22 (d, J = 2.1 Hz, 1H), 6.98 (dd, J = 8.2, 2.1 Hz, 1H), 5.93–5.80 (m, 1H), 4.41 (dd, J = 8.3, 
6.8 Hz, 1H), 3.59–3.26 (complex, 5H), 3.18 (ddd, J = 14.6, 7.8, 4.8 Hz, 1H), 2.76–2.59 (m, 2H), 
1.68 (ddd, J = 14.0, 8.1, 6.8 Hz, 1H), 1.42 (ddd, J = 14.1, 8.3, 5.8 Hz, 1H), 1.34–1.22 (m, 1H), 
0.81 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 199.6, 169.4, 139.6, 138.7, 136.3, 133.0, 
132.6, 132.0, 130.8, 130.8, 130.7, 129.8, 128.2, 125.8, 59.2, 42.6, 40.4, 39.8, 37.4, 34.7, 24.8, 22.7, 
21.9. FTIR (thin film): 3381, 2957, 1682, 1532, 1336 cm–1. [α]D21.9 -35.7 (c 1.0, CHCl3). HRMS 


















General Procedure for the Synthesis of Protected Cinnamic Acids: To a flame-dried flask was 
added cinnamic acid 14a-d (1.0 g) and the flask was put under argon. The solid was then 
resuspended in anhydrous DCM (0.6 M) and 10 drops DMF was added. A venting needle was 
inserted into the septum and oxalyl chloride (2 equiv) was then added dropwise. The solution 
stirred at rt until SM was consumed (reaction monitored by TLC) and was then concentrated to 
provide the crude cinnamyl chloride. In a separate flame-dried flask, 2-oxazolidinone (1 equiv) 
was resuspended in THF (0.37 M) and was cooled to 0 ˚C in an ice bath. Once cooled, NaH (1.2 
equiv) was added in portions and the solution stirred at 0 ˚C for 30 min. After this time, the crude 
cinnamyl chloride was resuspended in 3 mL THF and added dropwise to the NaH solution over 
the course of 10 minutes. The solution stirred at 0 ˚C coming to rt overnight. The following day, 
the reaction was quenched with the addition of 5 mL 1N HCl and the solution was transferred to a 
separatory funnel and shaken. The layers were then separated and the aqueous layer was extracted 
2 × 30 mL EtOAc. The organic layers were then combined, dried over sodium sulfate, filtered, 
and concentrated onto Celite. The Celite was then solid-loaded and purified on via column 
chromatography (0-50% EtOAc in hexanes) to provide the protected cinnamic acid. 
1) oxalyl chloride, cat. DMF,
    DCM, rt, 2 h
2) NaH,          
    THF, 0 ˚C to 
















3-Cinnamoyloxazolidin-2-one (1.15a): Cinnamic acid 1.14a and 2-oxazolidinone were reacted 
according to the general procedure to provide 1.15a as a white solid (769 mg, 3.45 mmol, 50% 
yield). Rf = 0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.89 – 7.75 (complex, 
2H), 7.57 – 7.52 (m, 2H), 7.35 – 7.30 (m, 3H), 4.41-4.34 (m, 2H), 4.09-4.02 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 165.5, 153.7, 146.4, 134.6, 130.8, 129.0, 128.9, 116.7, 62.2, 42.9. FTIR 
(neat): 2929, 1759, 1674, 1614 cm-1. mp = 151–154 °C.  HRMS (ESI, m/z): m/z: [M+H]+ calcd 




(E)-3-(3-(p-Tolyl)acryloyl)oxazolidin-2-one (1.15b): Cinnamic acid 1.14b and 2-oxazolidinone 
were reacted according to the general procedure to provide 1.15d as a white solid (1.029 g, 4.45 
mmol, 72% yield). Rf = 0.3 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.88-7.79 
(complex, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.18 (d, J = 7.6 Hz, 2H), 4.49 – 4.39 (m, 2H), 4.15 – 4.07 












128.8, 115.6, 62.2, 42.9, 21.7. FTIR (neat): 3096, 2915, 1765, 1673, 1615 cm-1. mp = 172–175 °C. 




(E)-3-(3-(4-Chlorophenyl)acryloyl)oxazolidin-2-one (1.15c): Cinnamic acid 1.14c and 2-
oxazolidinone were reacted according to the general procedure to provide 1.15c as a white solid 
(727 mg, 2.89 mmol, 50% yield). Rf = 0.2 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) 
δ 7.81 (d, J = 15.7 Hz, 1H), 7.72 (d, J = 15.8 Hz, 1H), 7.51 – 7.44 (m, 2H), 7.33 – 7.25 (m, 2H), 
4.42-4.36 (m, 2H), 4.09-4.03 (m, 2H).13C NMR (101 MHz, CDCl3) δ 165.2, 153.7, 144.77, 136.7, 
133.1, 129.9, 129.3, 117.2, 62.2, 42.9. FTIR (neat) 3089, 2916, 1764, 1677, 1617 cm-1. mp = 171–




(E)-3-(3-(4-Methoxyphenyl)acryloyl)oxazolidin-2-one (1.15d): Cinnamic acid 1.14d and 2-
oxazolidinone were reacted according to the general procedure to provide 1.15d as a white solid 














δ 7.82 – 7.66 (complex, 2H), 7.55 – 7.47 (m, 2H), 6.87 – 6.81 (m, 2H), 4.41 – 4.34 (m, 2H), 4.10 
– 4.02 (m, 2H), 3.77 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 165.8, 161.92, 153.8, 146.3, 130.6, 
127.5, 114.5, 114.2, 62.2, 55.5, 43.0. FTIR (neat): 3097, 2911, 2359, 1774, 1665, 1590 cm-1. mp 




General Procedure for Synthesis of Hydrazones 1.17a-g: A flask was charged with 
benzaldehyde 1.16a-g (1.0 g), phenylhydrazine (1 equiv), glacial acetic acid (5 drops), and toluene 
(40 mL) and was fixed with a Dean-Stark apparatus. The solution was heated to reflux for 30 
minutes or until H2O evolution ceased. The solvent was concentrated to provide hydrazone 1.17a-




 (E)-1-Benzylidene-2-phenylhydrazine (1.17a): Benzaldehyde 1.16a and phenylhydrazine were 
















9.05 mmol, 96% yield). Rf = 0.7 (25% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.61 – 
7.54 (m, 3H), 7.51 (s, 1H), 7.32 – 7.26 (m, 2H), 7.24 – 7.17 (m, 3H), 7.07 – 7.00 (m, 2H), 6.80 (tt, 
J = 7.3, 1.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 144.8, 137.5, 135.4, 129.4, 128.7, 128.5, 
126.3, 120.2, 112.9. FTIR (neat): 3310, 3026, 2359, 1600, 1590, 1256 cm-1. HRMS (ESI, m/z): 




(E)-1-(4-Methylbenzylidene)-2-phenylhydrazine (1.17b): Benzaldehyde 1.16b and 
phenylhydrazine were reacted according to the general procedure to provide hydrazone 1.17b as a 
red solid (1.74 g, 8.25 mmol, 99% yield). Rf = 0.5 (15% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.59 (s, 1H), 7.50-7.44 (complex, 3H), 7.23 – 7.16 (m, 2H), 7.11 (d, J = 7.9 Hz, 2H), 
7.06 – 7.02 (m, 2H), 6.82 – 6.75 (m, 1H), 2.29 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 144.9, 
138.6, 137.7, 132.7, 129.5, 129.4, 126.3, 120.0, 112.8, 21.5. FTIR (neat): 3308, 2913, 2359, 1593, 













(E)-1-(4-Chlorobenzylidene)-2-phenylhydrazine (1.17c): Benzaldehyde 1.16c and 
phenylhydrazine were reacted according to the general procedure to provide hydrazone 1.17c as a 
yellow solid (1.58 g, 6.97 mmol, 98% yield). Rf = 0.4 (15% EtOAc in hexanes). 1H NMR (400 
MHz, CDCl3) δ 7.60-7.54 (complex, 2H), 7.54 – 7.47 (m, 2H), 7.30 – 7.14 (m, 4H), 7.07 – 7.00 
(m, 2H), 6.86 – 6.77 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 144.5, 135.9, 134.1, 133.9, 129.5, 
128.9, 127.4, 120.45, 112.9. FTIR (neat): 3310, 2359, 1596, 1254 cm-1. HRMS (ESI, m/z): m/z: 




(E)-1-(4-Methoxybenzylidene)-2-phenylhydrazine (1.17d): Benzaldehyde 1.16d and 
phenylhydrazine were reacted according to the general procedure to provide hydrazone 1.17d as a 
yellow solid (1.56 g, 6.89 mmol, 94% yield). Rf = 0.5 (25% EtOAc in hexanes). 1H NMR (400 
MHz, CDCl3) δ 7.66 (s, 1H), 7.62-7.57 (m, 2H), 7.49 (s, 1H), 7.31 – 7.23 (m, 2H), 7.12 – 7.06 (m, 
2H), 6.94 – 6.88 (m, 2H), 6.88 – 6.82 (m, 1H), 3.84 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 



















(E)-1-(3-Methylbenzylidene)-2-phenylhydrazine (1.17e): Benzaldehyde 1.16e and 
phenylhydrazine were reacted according to the general procedure to provide hydrazone 1.17e as a 
red solid (1.73 g, 8.83 mmol, 98% yield). Rf = 0.7 (25% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.55 (s, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.23 – 7.14 (m, 3H), 
7.07 – 7.00 (m, 2H), 6.84 – 6.75 (m, 1H), 2.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 144.8, 
138.4, 137.7, 135.3, 129.4, 129.4, 128.6, 126.8, 123.7, 120.1, 112.9, 21.5. FTIR (neat): 3317, 2914, 















(E)-1-(3-Chlorobenzylidene)-2-phenylhydrazine (1.17f): Benzaldehyde 1.16f and 
phenylhydrazine were reacted according to the general procedure to provide hydrazone 1.17e as 
an off-white solid (1.64 g, 99% yield). Rf = 0.6 (25% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.64 – 7.57 (complex, 2H), 7.53 (s, 1H), 7.41 (dt, J = 7.3, 1.6 Hz, 1H), 7.26 – 7.15 
(complex, 4H), 7.07 – 7.02 (m, 2H), 6.83 (tt, J = 7.3, 1.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
144.4, 137.3, 135.5, 134.8, 129.9, 129.5, 128.3, 125.9, 124.5, 120.6, 112.9. FTIR (neat): 3320, 
2359, 1579, 1512, 1252 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for C13H12ClN2+ 231.0684; 




(E)-1-(3-Methoxybenzylidene)-2-phenylhydrazine (1.17g): Benzaldehyde 1.16g and 
phenylhydrazine were reacted according to the general procedure to provide hydrazone 1.17g as 
an orange solid (1.62 g, 7.14 mmol, 97% yield. Rf = 0.5 (25% EtOAc in hexanes). 1H NMR (400 
MHz, CDCl3) δ 7.57 (s, 1H), 7.54 (s, 1H), 7.24 – 7.16 (complex, 4H), 7.13 – 7.08 (m, 1H), 7.06 – 












137.3, 136.9, 129.7, 129.4, 120.3, 119.4, 114.7, 112.9, 110.6, 55.4. FTIR (neat): 3313, 2964, 2360, 





General Procedure for Hydrazoyl Chloride Synthesis: To a flame-dried flask was added NCS 
(1.67 equiv) and anhydrous DCM (0.14 M) and the solution was then cooled to 0 ˚C. DMS (3 
equiv) was then added and the solution stirred at 0 ˚C for 5 minutes and was then subsequently 
cooled to -40 ˚C in an acetonitrile/dry ice bath. Once cooled, hydrazone 1.17a-g (1.25 g in 10 mL 
DCM, unless otherwise noted) was then added dropwise and the solution stirred at -40 ˚C until SM 
was consumed (reaction monitored by TLC). The solution was then warmed to rt over the course 
of 1 h and was then quenched with dH2O and transferred to a separatory funnel. The layers were 
then separated and the aqueous layer was then extracted 3 × 25 mL DCM, the organic layers were 
combined, washed sequentially with water and brine, dried over sodium sulfate, filtered, and 
concentrated to afford the crude material that was then purified via column chromatography to 






HN NCS, DMS, DCM








(Z)-N-Phenylbenzohydrazonoyl chloride (1.18a): Hydrazone 1.17a was reacted according to the 
general procedure to afford 1.18a as a red solid (813 mg, 3.52 mmol, 55% yield). Rf = 0.7 (15% 
EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.90 – 7.79 (m, 2H), 7.37 – 7.18 
(complex, 5H), 7.14 – 7.06 (m, 2H), 6.90 – 6.83 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 143.5, 
134.6, 129.5, 129.3, 128.5, 126.6, 124.8, 121.3, 113.6. FTIR (thin film): 3306, 3050, 1599, 1503, 




(Z)-N-(2-Chloro-2-(p-tolyl)vinyl)aniline (1.18b): Hydrazone 1.17b was reacted according to the 
general procedure to afford 1.18b as a red solid (899 mg, 3.67 mmol, 62% yield). Rf = 0.7 (15% 
EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.77 – 7.70 (m, 2H), 7.26 – 7.19 
(m, 2H), 7.15 – 7.06 (complex, 4H), 6.85 (tt, J = 7.3, 1.2 Hz, 1H), 2.31 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 143.6, 139.6, 131.9, 129.5, 129.3, 126.5, 125.1, 121.1, 113.5, 21.4. FTIR (thin 















(Z)-4-Chloro-N-phenylbenzohydrazonoyl chloride (1.18c): Hydrazone 1.17c  was reacted 
according to the general procedure to afford 1.18c as a red-brown solid (902 mg, 3.40 mmol, 63% 
yield). Rf = 0.7 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.92 – 7.81 
(m, 2H), 7.42 – 7.35 (m, 2H), 7.35 – 7.29 (m, 2H), 7.20 – 7.14 (m, 2H), 7.01 – 6.92 (m, 1H). 13C 
NMR (101 MHz, CDCl3) δ 143.2, 135.3, 133.1, 129.6, 128.7, 127.7, 123.6, 121.5, 113.6. FTIR 
(neat): 3307, 2390, 1600, 1501, 1150 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for C13H11Cl2N2+ 




(Z)-4-Methoxy-N-phenylbenzohydrazonoyl chloride (1.18d): Hydrazone 1.17d was reacted 
according to the general procedure to afford 1.18d as a brown solid. (0.922 g, 3.54 mmol, 64%). 
Rf = 0.6 (10% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.90 – 7.83 (m, 
2H), 7.36 – 7.27 (m, 2H), 7.21 – 7.13 (m, 2H), 6.98 – 6.88 (complex, 3H), 3.86 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 160.6, 143.6, 129.4, 127.9, 127.2, 124.8, 120.9, 113.8, 113.3, 55.4. FTIR 
(thin film): 3315, 2986, 1601, 1501, 1257 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 
















(Z)-3-Methyl-N-phenylbenzohydrazonoyl chloride (1.18e): Hydrazone 1.17e (1.0 g) was 
reacted according to the general procedure to afford 1.18e as a brown oil (712 mg, 2.91 mmol, 
61% yield). Rf = 0.8 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.67 – 
7.64 (m, 2H), 7.28 – 7.18 (complex, 3H), 7.14 – 7.08 (complex, 3H), 6.91 – 6.82 (m, 1H), 2.35 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 143.5, 138.3, 134.5, 130.2, 129.5, 128.5, 127.1, 125.1, 123.9, 
121.3, 113.6, 21.6. FTIR (neat): 3318, 2916, 1598, 1503 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ 




(Z)-3-Chloro-N-phenylbenzohydrazonoyl chloride (1.18f): Hydrazone 1.17f was reacted 
according to the general procedure to afford 1.18f as a red solid (1.012 g, 3.82 mmol, 70% yield). 
Rf = 0.7 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.86 – 7.80 (m, 
1H), 7.75 – 7.68 (m, 1H), 7.28 – 7.21 (m, 4H), 7.13 – 7.07 (m, 2H), 6.93 – 6.85 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 143.1, 136.3, 134.7, 129.7, 129.6, 129.2, 126.4, 124.6, 123.1, 121.68, 113.7. 
FTIR (thin film): 3322, 3075, 1601, 1576, 1503 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 














(Z)-3-Methoxy-N-phenylbenzohydrazonoyl chloride (1.18g): Hydrazone 1.17g was reacted 
according to the general procedure to afford 1.18g as an orange oil (868 mg, 3.33 mmol, 60% 
yield). Rf = 0.6 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.57 – 7.50 
(m, 1H), 7.51 – 7.45 (m, 1H), 7.36-7.27 (complex, 3H), 7.22 – 7.14 (m, 2H), 6.99 – 6.90 (m, 2H), 
3.88 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 159.6, 143.3, 135.8, 129.4, 129.4, 124.4, 121.2, 119.0, 
114.9, 113.4, 111.8, 55.4. FTIR (neat): 3322, 2936, 2832, 2359, 1598, 1503, 1251 cm-1. HRMS 





















1.4.2.4: General Procedure for Parallel Synthesis of Pyrazoline Library: Stock solutions of 
1.18a-g and 1.15a-d were prepared and 1.15a-d (82-110 mg in 2 ml anhydrous DCM, 0.57-0.65 
mmol, 1.0 equiv) to a Bohdan MiniBlock fitted with 17 × 110 mm reaction vials in the respective 
positions. To this was then added  1.18a-g (150 mg on 2 mL anhydrous DCM) at the appropriate 
positions to create a matrix of reactions wherein each hydrazoyl chloride was reacted with each 
protected cinnamic acid. Once combined, the reaction vessels were cooled to -78 ˚C using a dry 
ice/isopropanol bath and, once cooled, TEA (1.5 equiv) was added and the reactions warmed to rt 
overnight. The following day, the solvent was removed under a stream of nitrogen and the crude 
products were then resuspended in 8 mL THF. A 2M stock solution of NaBH4 in H2O was prepared 









































(6% each for 2
 compounds isolated)
NaBH4 in H2O,




cooled to 0 °C, and quenched with 2 mL 4N HCl. The layers were then separated and the aqueous 
layer was extracted 3 x 10mL EtOAc. The organic layers were then combined, washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product 
was then purified via column chromatography (0-100% DCM in hexanes) or preparative TLC to 
obtain a mixture of regioisomers. Fractions containing single regioisomers were combined to 




(Trans)-1,3,4-triphenyl-4,5-dihydro-1H-pyrazol-5-yl)methanol (1.20aa) and ((trans)-1,3,5-
triphenyl-4,5-dihydro-1H-pyrazol-4-yl)methanol (1.c20aa): Protected cinnamic acid 1.15a 
(0.095 g, 0.44 mmol, 1.0 equiv) and hydrazoyl chloride 1.18a (150 mg, 0.57 mmol, 1.5 equiv) 
were reacted according to the general procedure to afford 1.20aa and 1.c20aa as a mixture of 
regioisomers (95 mg, 0.29 mmol, 41% yield). Fractions containing a single regioisomer were 
combined to provide 1.20aa as a yellow amorphous solid (63 mg, 0.19 mmol, 27% yield). 1.c20aa 
not isolated. 1.20aa: Rf = 0.4 (75% DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.65 – 7.56 
(m, 2H), 7.27 – 7.07 (complex, 12H), 6.85 – 6.75 (m, 1H), 4.71 – 4.50 (m, 2H), 4.35 – 4.07 (m, 
2H), 3.95 – 3.63 (m, 2H), 1.69 – 1.60 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 150.4, 144.7, 140.9, 








film): 3389, 3026, 2929, 1595, 1492 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for C22H21N20+ 




((Trans)-1,4-diphenyl-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-5-yl)methanol (1.20ab) and 
((trans)-1,5-diphenyl-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-4-yl)methanol (1.c20ab): Protected 
cinnamic acid 1.15a (89 mg, 0.41 mmol, 1.0 equiv) and hydrazoyl chloride 1.18b (150 mg, 0.61 
mmol, 1.5 equiv) were reacted according to the general procedure to afford 1.20ab and 1.c20ab 
as a mixture of regioisomers (0.115 g, 0.34 mmol, 49% yield). Fractions containing a single 
regioisomers were combined to afford 1.20ab as a yellow amorphous solid (94.0 mg, 0.28 mmol, 
40% yield). 1.c20ab not isolated. 1.20ab: Rf = 0.4 (75% DCM in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.49 (d, J = 8.3 Hz, 2H), 7.24 – 7.08 (m, 9H), 6.98 (d, J = 8.0 Hz, 2H), 6.83 – 6.74 (m, 
1H), 4.58 (d, J = 4.3 Hz, 1H), 4.17 (X of ABX system, J = 8.8, 4.6 Hz, 1H), 3.89 – 3.73 (AB of 
ABX system, m, 2H), 2.21 (s, 3H), 1.68 – 1.60 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 150.6, 
144.9, 141.0, 138.7, 129.4, 129.3, 129.3, 129.2, 127.6, 127.4, 126.6, 119.6, 113.6, 71.5, 62.2, 55.1, 
21.5. FTIR (neat): 3365, 3026, 2918, 1594, 1494 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 













(1.c20ac): Protected cinnamic acid 1.15a (82 mg, 0.38 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18c (150 mg, 0.57 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20ac and 1.c20ac as a mixture of regioisomers (118 mg, 0.33 mmol, 50% yield). Fractions 
containing a single regioisomer were combined to afford 1.20ac as a yellow amorphous solid (89 
mg, 0.24 mmol, 38% yield). 1.c20ac not isolated. 1.20ac: Rf = 0.4 (75% DCM in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.5 Hz, 1H), 7.26 – 7.07 (m, 10H), 6.85 – 6.77 (m, 1H), 
4.58 (d, J = 4.4 Hz, 1H), 4.21 (q, J = 4.6 Hz, 1H), 3.93 – 3.70 (m, 2H), 1.63 (dd, J = 7.5, 4.8 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ 149.3, 144.4, 140.7, 134.3, 130.6, 129.5, 129.5, 128.8, 127.7 
127.7, 127.5, 119.9, 113.6, 71.6, 62.1, 54.8. FTIR (thin film): 3395, 3027, 2929, 1595, 1489 cm-1. 















(1.c20ad): Protected cinnamic acid 1.15a (84 mg, 0.39 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18d (150 mg, 0.58 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20ad and 1.c20ad as a mixture of regioisomers (118 mg, 0.33 mmol, 50% yield). Fractions 
containing a single regioisomer were combined to afford 1.20ad as a yellow amorphous solid (101 
mg, 0.28 mmol, 43% yield). 1.c20ad not isolated. 1.20ad: Rf = 0.3 (75% DCM in hexanes). 1H 
NMR (400 MHz, CDCl3δ 7.58 – 7.47 (m, 2H), 7.24 – 7.06 (complex, 10H), 6.82 – 6.73 (m, 1H), 
6.73 – 6.66 (m, 2H), 4.57 (d, J = 4.3 Hz, 1H), 4.15 (app. q, J = 4.4 Hz, 2H), 3.90 – 3.73 (m, 2H), 
3.68 (s, 3H), 1.68 (app. t, J = 5.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 160.1, 150.5, 145.1, 
141.1, 129.4, 129.4, 128.2, 127.6, 127.5, 124.7, 119.5, 114.0, 113.5, 71.5, 62.3, 55.4, 55.2. FTIR 
(neat): 3384, 2930, 1594, 1494 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for C23H23N202+  












((Trans)-1,4-diphenyl-3-(m-tolyl)-4,5-dihydro-1H-pyrazol-5-yl)methanol (1.20ae) and 
((trans)-5-(4-chlorophenyl)-1-phenyl-3-(m-tolyl)-4,5-dihydro-1H-pyrazol-4-yl)methanol 
(1.c20ae): Protected cinnamic acid 1.15a (89 mg, 0.41 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18e (150 mg, 0.61 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20ae and 1.c20ae as a mixture of regioisomers (154 mg, 0.45 mmol, 73%). Fractions containing 
a single regioisomer were combined to afford 1.20ae as a yellow amorphous solid. (112 mg, 0.33 
mmol, 53%) 1.c20ae not isolated. 1.20ae: Rf = 0.4 (75% DCM in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.55 – 7.49 (m, 1H), 7.34 – 7.26 (m, 1H), 7.25 – 7.09 (complex, 9H), 7.05 (t, J = 7.6 Hz, 
1H), 7.00 – 6.92 (m, 1H), 6.79 (tt, J = 7.2, 1.3 Hz, 1H), 4.59 (d, J = 4.1 Hz, 1H), 4.18 (X of ABX, 
J= 8.88, 3.88 Hz, 1H), 3.84 (A of ABX system, JAB= 11.48Hz, JAX= 5.38 Hz, 1H), 3.79 (B of ABX 
system, JAB= 11.48 Hz, JBX = 2.90 Hz, 1H) 2.22 (s, 3H), 1.63 (s, 1H). 13C NMR (101 MHz, CDCl3) 
δ 150.6, 144.7, 141.0, 138.1, 131.9, 129.5, 129.4, 129.3, 128.4, 127.6, 127.5, 127.1, 123.9, 119.7, 
113.6, 71.5, 62.2, 54.9, 21.6. FTIR (thin film): 3354, 1594, 1554, 1496. HRMS (ESI, m/z): m/z: 












(1.c20af): Protected cinnamic acid 1.15a (82 mg, 0.38 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18f (150 mg, 0.57 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20af and 1.c20af as a mixture of regioisomers (107 mg, 0.29 mmol, 45% yield). Fractions 
containing single regioisomers were combined to afford 1.20af as a yellow amorphous solid (65 
mg, 0.14 mmol, 18% yield). 1.c20af not isolated. 1.20af: Rf = 0.4 (75% DCM in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 7.39 – 7.31 (m, 1H), 7.29 – 7.02 (complex, 11H), 6.88 – 
6.74 (m, 1H), 4.58 (d, J = 4.2 Hz, 1H), 4.27 – 4.18 (X of ABX system, m, 1H), 3.92 – 3.74 (AB 
of ABX system, m, 2H), 1.68 – 1.50 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 148.9, 144.2, 140.5, 
134.5, 133.9, 129.8, 129.5, 129.5, 128.4, 127.7, 127.5, 126.3, 124.6, 120.1, 113.7, 71.6, 62.1, 54.7. 
FTIR (thin film): 3398, 1592, 1497 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ Calcd for C22H20Cl N20+ 













(1.c20ag): Protected cinnamic acid 1.15a (84 mg, 0.38 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18g (150 mg, 0.58 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20ag and 1.c20ag as a mixture of regioisomers (109 mg, 0.31 mmol, 46% yield). Fractions 
containing a single regioisomer were combined to afford 1.20ag as a yellow amorphous solid (90 
mg, 0.14 mmol, 38% yield). 1.c20ag not isolated. 1.20ag: Rf = 0.3 (75% DCM in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.26 – 7.04 (m, 12H), 6.85 – 6.76 (m, 1H), 6.74 – 6.66 (m, 1H), 4.59 
(d, J = 4.2 Hz, 1H), 4.20 (X of ABX system, J =8.4, 4.12 Hz, 1H), 3.90 – 3.75 (AB of ABX system, 
m, 2H), 3.68 (s, 3H), 1.71 – 1.56 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 159.6, 150.3, 144.6, 
141.0, 133.4, 129.5, 129.4, 129.4, 127.6, 127.5, 119.8, 119.4, 114.8, 113.6, 111.4, 71.6, 62.2, 55.3, 
55.0. FTIR (neat): 3392, 2933, 1593, 1489 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 











((Trans)-1,3-diphenyl-4-(p-tolyl)-4,5-dihydro-1H-pyrazol-5-yl)methanol (1.20ba) and 
((trans)-1,3-diphenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-4-yl)methanol (1.c20ba): Protected 
cinnamic acid 1.15b (100 mg, 0.38 mmol, 1.0 equiv) and hydrazoyl chloride 1.18a (150 mg, 0.65 
mmol, 1.5 equiv) were reacted according to the general procedure to afford 1.20ba and 1.c20ba 
as a mixture of regioisomers (122 mg, 0.36 mmol, 52% yield). Fractions containing a single 
regioisomer were combined to afford 1.20ba as a yellow amorphous solid (95 mg, 0.28 mmol, 
41% yield). 1.c20ba not isolated. 1.20ba: Rf = 0.4 (75% DCM in hexanes) 1H NMR (400 MHz, 
CDCl3) δ 7.62 – 7.57 (m, 2H), 7.24 – 7.09 (m, 7H), 7.00 (s, 4H), 6.82 – 6.76 (m, 1H), 4.57 (d, J = 
4.3 Hz, 1H), 4.17 (q, J = 4.3 Hz, 1H), 3.93 – 3.70 (m, 2H), 2.20 (s, 3H), 1.65 – 1.58 (m, 1H). 13C 
NMR (101 MHz, CDCl3) δ 150.6, 144.8, 138.0, 137.2, 132.1, 130.0, 129.4, 128.6, 128.5, 127.5, 
126.6, 119.7, 113.6, 71.6, 62.2, 54.6, 21.2. FTIR (thin film): 3398, 2921, 1594, 1492 cm-1. HRMS 











((Trans)-1-phenyl-3,4-di-p-tolyl-4,5-dihydro-1H-pyrazol-5-yl)methanol (1.20bb) and 
((trans)-1-phenyl-3,5-di-p-tolyl-4,5-dihydro-1H-pyrazol-4-yl)methanol (1.c20bb): Protected 
cinnamic acid 1.15b (95 mg, 0.41 mmol, 1.0 equiv) and hydrazoyl chloride 1.18b (150 mg, 0.61 
mmol, 1.5 equiv) were reacted according to the general procedure to afford 1.20bb and 1.c20bb 
as a mixture of regioisomers (128 mg, 0.36 mmol, 54% yield). Fractions containing a single 
regioisomer were combined to afford 1.20bb as a yellow amorphous solid (107 mg, 0.30 mmol, 
46% yield). 1.20bb not isolated. 1.20bb: Rf = 0.4 (75% DCM in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.49 (d, J = 8.2 Hz, 2H), 7.24 – 7.15 (m, 2H), 7.15 – 7.09 (m, 2H), 7.02 – 6.95 (m, 6H), 
6.82 – 6.74 (m, 1H), 4.55 (d, J = 4.3 Hz, 1H), 4.14 (q, J = 4.3 Hz, 1H), 3.93 – 3.70 (m, 2H), 2.21 
(s, 3H), 2.19 (s, 3H), 1.67 – 1.61 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 150.8, 144.9, 138.6, 
138.1, 137.1, 129.9, 129.4, 129.3, 129.2, 127.5, 126.6, 119.5, 113.5, 71.6, 62.3, 54.7, 21.5, 21.2. 
FTIR (thin film): 3392, 3026, 2919, 1595, 1496 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ Calcd for 












yl)methanol (1.c20bc): Protected cinnamic acid 1.15b (88 mg, 0.38 mmol, 1.0 equiv) and 
hydrazoyl chloride 1.18c (150 mg, 0.57 mmol, 1.5 equiv) were reacted according to the general 
procedure to afford 1.20bc and 1.c20bc as a mixture of regioisomers (77 mg, 0.21 mmol, 33% 
yield). Fractions containing a single regioisomer were combined to afford 1.20dc as a yellow 
amorphous solid (34 mg, 0.12 mmol, 14% yield). 1.c20bc not isolated. 1.20bc: Rf = 0.5 (75% 
DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.55 – 7.47 (m, 2H), 7.26 – 7.09 (m, 6H), 7.04 
– 6.94 (m, 4H), 6.85 – 6.77 (m, 1H), 4.54 (d, J = 4.4 Hz, 1H), 4.18 (q, J = 4.7 Hz, 2H), 3.96 – 3.70 
(m, 2H), 2.21 (s, 3H), 1.61 (dd, J = 7.6, 4.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 149.4, 144.5, 
137.7, 137.4, 134.2, 130.7, 130.1, 129.5, 128.7, 127.8, 127.4, 119.9, 113.7, 71.7, 62.1, 54.5, 21.2. 
FTIR (thin film): 3378, 2922, 1595, 1499 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 














yl)methanol (1.c20bd): Protected cinnamic acid 1.15b (89 mg, 0.39 mmol, 1.0 equiv) and 
hydrazoyl chloride 1.18d (150 mg, 0.58 mmol, 1.5 equiv) were reacted according to the general 
procedure to afford 1.20bd and 1.c20bd as a mixture of regioisomers (127 mg, 0.34 mmol, 53% 
yield). To obtain pure regioisomers, the crude was first run on a 24 g flash column using 100% 
DCM as eluent followed by 50% EtOAc in hexanes. The material was then again purified on a 12  
g flash column using a gradient of 0-25% EtOAc in hexanes. Fractions containing a single 
regioisomer were combined to afford 1.20bd as a yellow amorphous solid (84 mg, 0.23 mmol, 
35% yield). 1.c20bd not isolated. 1.20bd: Rf =0.2 (75% DCM in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 7.58 – 7.49 (m, 2H), 7.24 – 7.16 (m, 2H), 7.11 (d, J = 8.1 Hz, 2H), 6.99 (complex, app. 
s, 4H), 6.77 (t, J = 7.3 Hz, 1H), 6.73 – 6.68 (m, 2H), 4.53 (d, J = 4.3 Hz, 1H), 4.16 – 4.09 (m, 1H), 
3.87 – 3.73 (m, 2H), 3.68 (s, 3H), 2.20 (s, 3H), 1.70 – 1.61 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 160.0, 150.7, 145.1, 138.1, 137.1, 130.0, 129.4, 128.1, 127.5, 124.8, 119.4, 113.9, 113.5, 71.7, 
62.2, 55.4, 54.8, 21.2. FTIR (thin film): 3409, 2931, 1594, 1495 cm-1. HRMS (ESI, m/z): m/z: 














(1.c20be): Protected cinnamic acid 1.15b (93 mg, 0.411 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18e (150 mg, 0.61 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20be and 1.c20be as a mixture of regioisomers (156 mg, 0.42 mmol, 66%). Fractions containing 
a single regioisomer were combined to afford only 1.20be as a yellow amorphous solid (81 mg, 
0.22 mmol, 34% yield). 1.c20be not isolated. 1.20be: Rf = 0.4 (75% DCM in hexanes). 1H NMR 
(400 MHz, CDCl3) δ 7.53 (s, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.26 – 7.17 (m, 2H), 7.18 – 7.12 (m, 
2H), 7.08 – 6.94 (m, 6H), 6.83 – 6.76 (m, 1H), 4.56 (d, J = 4.1 Hz, 1H), 4.21 – 4.13 (m, 1H), 3.89 
– 3.73 (m, 2H), 2.23 (s, 3H), 2.20 (s, 3H), 1.59 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 150.8, 
144.8, 138.1, 137.1, 131.9, 130.0, 129.5, 129.4, 128.4, 127.4, 127.1, 123.9, 119.6, 113.6, 71.6, 
62.2, 54.6, 21.6, 21.20 FTIR (thin film): 3385, 3024, 2920, 1556, 1497 cm-1. HRMS (ESI, m/z): 












yl)methanol (1.c20bf): Protected cinnamic acid 1.15b (88 mg, 0.38 mmol, 1.0 equiv) and 
hydrazoyl chloride 1.18f (150 mg, 0.57 mmol, 1.5 equiv) were reacted according to the general 
procedure to afford 1.20bf and 1.c20bf as a mixture of regioisomers (108 mg, 0.29 mmol, 45% 
yield). Fractions containing single regioisomers were combined to afford 1.20bf as a yellow 
amorphous solid (37 mg, 0.10 mmol, 16% yield). 1.c20bf not isolated. 1.20bf: Rf =0.5 (75% DCM 
in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.63 (m, 1H), 7.38 – 7.33 (m, 1H), 7.27 – 6.96 
(m, 10H), 6.84 – 6.78 (m, 1H), 4.54 (d, J = 4.2 Hz, 1H), 4.20 (q, J = 4.2 Hz, 1H), 3.91 – 3.72 (m, 
2H), 2.21 (s, 3H), 1.66 – 1.52 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 149.1, 144.3, 137.6, 137.4, 
134.5, 134.0, 130.2, 129.8, 129.5, 128.4, 127.4, 126.4, 124.7, 120.0, 113.7, 71.7, 62.1, 54.3, 21.2. 
FTIR (thin film): 3384, 2922, 1593, 1497 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 













yl)methanol (1.c20bg): Protected cinnamic acid 1.15b (89 mg, 0.39 mmol, 1.0 equiv) and 
hydrazoyl chloride 1.18g (150 mg, 0.58 mmol, 1.5 equiv) were reacted according to the general 
procedure to afford 1.20bg and 1.c20bg as a mixture of regioisomers (126 mg, 0.34 mmol, 53% 
yield). To obtain pure regioisomer, the crude material was purified on a 12 g flash column using a 
gradient of 75-100% in DCM then 50% EtOAc in hexanes. Fractions containing major regioisomer 
were then purified on a 12 g flash column using 0-30% EtOAc in hexanes. Fractions containing a 
single regioisomer were combined to afford 1.20bg as a yellow amorphous solid (44 mg, 0.12 
mmol, 19% yield). 1.c20bg not isolated. 1.20bg: Rf =0.2 (75% DCM in hexanes). 1H NMR (400 
MHz, CDCl3) δ 7.25 – 7.03 (complex, 7H), 7.00 (complex, app. s, 4H), 6.84 – 6.76 (m, 1H), 6.74 
– 6.66 (m, 1H), 4.55 (d, J = 4.2 Hz, 1H), 4.18 (q, J = 4.2 Hz, 1H), 3.89 – 3.74 (m, 1H), 3.69 (s, 
1H), 2.20 (s, 3H), 1.63 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 159.5, 150.4, 144.6, 137.95, 137.1, 
133.3, 129.9, 129.4, 129.3, 127.3, 119.6, 119.3, 114.7, 113.5, 111.2, 71.5, 62.0, 55.2, 54.5, 21.1. 
FTIR (thin film): 3402, 2923, 1593, 1498 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 














(1.c20ca): Protected cinnamic acid 1.15c (110 ,g, 0.44 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18a (150 mg, 0.65 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20ca and 1.c20ca as a mixture of regioisomers (101 mg, 0.28 mmol, 43% yield). Fractions 
containing a single regioisomer were combined to afford the major regioisomer 1.20ca (71 mg, 
0.21 mmol, 30% yield) and minor regioisomer 1.c20ca (13.6 mg, 0.037 mmol, 6% yield) as yellow 
amorphous solids. 1.20ca: Rf = 0.3 (75% DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.61 – 
7.53 (m, 2H), 7.27 – 7.09 (complex, 9H), 7.09 – 7.02 (m, 2H), 6.84 – 6.77 (m, 1H), 4.60 (d, J = 
3.4 Hz, 1H), 4.21 – 4.10 (m, 1H), 3.88 – 3.75 (m, 1H), 1.63 (t, J = 6.1 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ 149.9, 144.5, 139.4, 133.4, 131.8, 129.6, 129.5, 128.9, 128.8, 128.6, 126.5, 119.9, 
113.6, 71.3, 61.9, 54.2. FTIR (neat): 3362, 3056, 2924, 1594, 1489 cm-1. HRMS (ESI, m/z): m/z: 
[M+H]+ calcd for C22H20ClN20+ 363.1259; found 363.1253. 1.c20ba: Rf = 0.4 (75% DCM in 
hexanes). 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.56 (m, 2H), 7.33 – 7.08 (m, 9H), 7.01 – 6.94 (m, 
2H), 6.72 (t, J = 7.3 Hz, 1H), 5.28 (d, J = 3.9 Hz, 1H), 3.96 – 3.88 (m, 1H), 3.76 – 3.68 (m, 1H), 
3.59 – 3.50 (m, 1H), 1.54 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 145.9, 143.8, 139.9, 133.5, 132.1, 










3058, 2924, 1595, 1491 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for C22H20ClN20+ 363.1259; 






yl)methanol (1.c20cb): Protected cinnamic acid 1.15c (100 mg, 0.41 mmol, 1.0 equiv) and 
hydrazoyl chloride 1.18b (150 mg, 0.61 mmol, 1.5 equiv) were reacted according to the general 
procedure to afford 1.20cb and 1.c20cb as a mixture of regioisomers (124 mg, 0.33 mmol, 52% 
yield). Fractions containing a single regioisomers were combined to afford 1.20cb as a yellow 
amorphous solid (95 mg, 0.26 mmol, 40% yield). 1.c20cb not isolated. 1.20cb: Rf = 0.3 (75% 
DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.1 Hz, 2H), 7.25 – 7.08 (complex, 
6H), 7.08 – 6.96 (complex, 4H), 6.84 – 6.75 (m, 1H), 4.57 (d, J = 4.0 Hz, 1H), 4.13 (app. q, J = 
4.4 Hz, 1H), 3.85 – 3.76 (m, 2H), 2.22 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 150.2, 144.7, 139.5, 
138.9, 133.3, 129.5, 129.5, 129.3, 128.9, 128.9, 126.5, 119.7, 113.7, 71.3, 61.9, 54.3, 21.5. FTIR 
(thin film): 3391, 3028, 2920, 1595, 1496 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 














(1.c20cc): Protected cinnamic acid 1.15c (95 mg, 0.38 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18c (150 mg, 0.57 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20cc and 1.c20cc as a mixture of regioisomers (112 mg, 0.28 mmol, 47% yield). Fractions 
containing single a regioisomer were combined to afford 1.20cc as a yellow amorphous solid (56 
mg, 0.14 mmol, 23% yield). 1.c20cc not isolated. 1.20cc: Rf = 0.4 (75% DCM in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.60 – 7.52 (m, 2H), 7.35 – 7.17 (complex, 8H), 7.14 – 7.08 (m, 2H), 
6.95 – 6.86 (m, 1H), 4.65 (d, J = 4.2 Hz, 1H), 4.30 – 4.22 (X of ABX system, m, 1H), 3.95 – 3.83 
(AB of ABX system, m, 2H), 1.73 – 1.66 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 148.6, 144.0, 
138.9, 134.3, 133.5, 130.2, 129.5, 129.4, 128.8, 128.7, 127.5, 120.0, 113.5, 71.3, 61.7, 53.9. FTIR 
(thin film): 3402, 3058, 2930, 1596, 1499 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for 
















yl)methanol (1.20cd) and ((trans)-5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl)methanol (1.c20cd): Protected cinnamic acid 1.15c (97 mg, 0.39 
mmol, 1.0 equiv) and hydrazoyl chloride 1.18d (150 mg, 0.58 mmol, 1.5 equiv) were reacted 
according to the general procedure to afford 1.20cd and 1.c20cd as a mixture of regioisomers (116 
mg, 0.30 mmol, 49% yield). Fractions containing a single regioisomer were combined to afford 
1.20cd as a yellow amorphous solid (106 mg, 0.27 mmol, 44% yield). 1.c20cd not isolated. 1.20cd: 
Rf = 0.2 (75% DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.8 Hz, 2H), 7.25 – 
7.13 (complex, 4H), 7.13 – 7.08 (m, 2H), 7.07 – 7.01 (m, 2H), 6.79 (t, J = 7.3 Hz, 1H), 6.75– 6.69 
(m, 2H), 4.56 (d, J = 4.1 Hz, 1H), 4.11 (X of ABX system, J = 8.64, 4.08 Hz, 1H), 3.85 – 3.74 
(AB of ABX system, m, 2H), 3.69 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.2, 150.0, 144.8, 
139.5, 133.3, 129.5, 129.5, 128.9, 128.1, 124.4, 119.6, 114.1, 113.5, 71.3, 62.0, 55.4, 54.5. FTIR 
(thin film): 3395, 2933, 1595, 1495 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ calcd for C23H22ClN202+ 
















yl)methanol (1.c20ce): Protected cinnamic acid 1.15c (103 mg, 0.411 mmol, 1.0 equiv) and 
hydrazoyl chloride 18e (150 mg, 0.613 mmol, 1.5 equiv) were reacted according to the general 
procedure to afford 1.20ce and 1.c20ce as a mixture of regioisomers (114 mg, .30 mmol, 49%) 
Fractions containing a single regioisomer were combined to afford 1.20ce (99 mg, 0.26 mmol, 
43%) and 1.c20ce (14 mg, 0.039 mmol, 6% yield) as yellow amorphous solids. 1.20ce: Rf = 0.3 
(75% DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 7.31 – 6.95 (m, 11H), 6.81 
(tt, J = 7.2, 1.2 Hz, 1H), 4.59 (d, J = 3.9 Hz, 1H), 4.20-4.10 (X of ABX system, m, 1H), 3.83 – 
3.78 (AB of ABX system, m, 2H), 2.24 (s, 3H), 1.64 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 150.2, 
144.5, 139.5, 138.3, 133.4, 131.7, 129.7, 129.5, 129.5, 128.9, 128.5, 127.0, 123.8, 119.9, 113.6, 
71.2, 61.9, 54.2, 21.5. FTIR (thin film): 3376, 3039, 2922, 1595, 1498 cm-1. HRMS (ESI, m/z): 
m/z: [M+H]+ calcd for C23H22ClN20+ 377.1415; found 377.1409. 1.c20ce: Rf = 0.4 (75% DCM in 
hexanes). 1H NMR (400 MHz, CDCl3) δ 7.51 (s, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.23 – 7.09 (m, 
7H), 7.06 (d, J = 7.7 Hz, 1H), 7.01 – 6.96 (m, 2H), 6.72 (t, J = 7.3 Hz, 1H), 5.27 (d, J = 3.9 Hz, 
1H), 3.92 (dd, J = 10.8, 4.0 Hz, 1H), 3.72 (dd, J = 10.9, 7.8 Hz, 1H), 3.58 – 3.49 (m, 1H), 2.31 (s, 










129.7, 129.4, 129.2, 128.8, 127.4, 126.6, 123.2, 119.4, 113.2, 66.8, 62.5, 58.9, 21.6. FTIR (thin 
film): 3408, 3041, 2923, 1596, 1499 cm-1. HRMS (ESI, m/z): m/z: [M+H]+ Calcd for 





yl)methanol (1.20cf) and ((trans)-3-(3-chlorophenyl)-5-(4-chlorophenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl)methanol (1.c20cf): Protected cinnamic acid 1.15c (95 mg, 0.38 mmol, 
1.0 equiv) and hydrazoyl chloride 1.18f (150 mg, 0.57 mmol, 1.5 equiv) were reacted according 
to the general procedure to afford 1.20cf and 1.c20cf as a mixture of regioisomers (120 mg, 0.30 
mmol, 50% yield). Fractions containing a single regioisomer were combined to afford 1.20cf (94 
mg, 0.24 mmol, 39% yield) as a yellow amorphous solid. 1.c20cf not isolated. 1.20cf: Rf = 0.4 
(75% DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 2.0 Hz, 1H), 7.32 (dt, J = 6.9, 
1.7 Hz, 1H), 7.27 – 7.01 (complex, 10H), 6.83 (tt, J = 7.2, 1.2 Hz, 1H), 4.57 (d, J = 4.0 Hz, 1H), 
4.23 – 4.15 (X of ABX system, m, 1H), 3.87 – 3.76 (AB of ABX system, m, 2H), 1.63 – 1.55 (m, 
1H). 13C NMR (101 MHz, CDCl3) δ 148.4, 143.9, 138.9, 134.7, 133.7, 133.6, 129.9, 129.7, 129.6, 


















yl)methanol (1.20cg) and ((trans)-5-(4-chlorophenyl)-3-(3-methoxyphenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl)methanol (1.c20cg): Protected cinnamic acid 1.15c (97 mg, 0.39 
mmol, 1.0 equiv) and hydrazoyl chloride 1.18g (150 mg, 0.58 mmol, 1.5 equiv) were reacted 
according to the general procedure to afford 1.20cg and 1.c20cg as a mixture of regioisomers (130 
mg, 0.33 mmol, 54% yield). Fractions containing a single regioisomer were combined to afford 
1.20cg as a yellow amorphous solid (86 mg, 0.22 mmol, 36% yield). 1.c20cg not isolated. 1.20cg: 
Rf = 0.2 (75% DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.02 (m, 11H), 6.86 – 6.77 
(m, 1H), 6.76 – 6.68 (m, 1H), 4.57 (d, J = 4.0 Hz, 1H), 4.17 (X of ABX system, J = 8.60, 4.24 Hz, 
1H), 3.87 – 3.77 (AB of ABX system, m, 2H), 3.70 (s, 3H), 1.64 (t, J = 5.9 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 159.5, 149.7, 144.2, 139.3, 133.3, 132.9, 129.5, 129.4, 129.4, 128.8, 119.8, 
119.1, 114.7, 113.5, 111.3, 71.2, 61.8, 55.2, 54.1. FTIR (thin film): 3407, 2934, 1593, 1498 cm-1. 
















(1.c20da): Protected cinnamic acid 1.15d (110 mg, 0.44 mmol, 1.0 equiv) and hydrazoyl chloride 
1.18a (150 mg, 0.65 mmol, 1.5 equiv) were reacted according to the general procedure to afford 
1.20da and 1.c20da as a mixture of regioisomers (68 mg, 0.19 mmol, 29% yield). To obtain pure 
regioisomers, the crude product was initially purified  on a 24 g flash column (100% DCM) and 
then again on a 24 g column flash column (100% DCM followed by 100% EtOAc). Fractions 
containing a single regioisomer were combined to afford 1.20da as a yellow amorphous solid (35 
mg, 0.10 mmol, 15% yield). 1.c20da not isolated. 1.20da: Rf = 0.3 (75% DCM in hexanes). 1H 
NMR (400 MHz, CDC3) δ 7.63 – 7.55 (m, 2H), 7.24 – 7.10 (m, 7H), 7.05 – 7.00 (m, 2H), 6.79 (tt, 
J = 7.2, 1.2 Hz, 1H), 6.75 – 6.67 (m, 2H), 4.55 (d, J = 4.2 Hz, 1H), 4.19 – 4.10 (m, 1H), 3.80 (qd, 
J = 11.5, 4.3 Hz, 2H), 3.65 (s, 3H).FTIR (neat): 3397, 2929, 1594, 1491 cm-1. HRMS (ESI, m/z): 















yl)methanol (1.c20db): Protected cinnamic acid 1.15d (100 mg, 0.41 mmol, 1.0 equiv) and 
hydrazoyl chloride 1.18b (150 mg, 0.61 mmol, 1.5 equiv) were reacted according to the general 
procedure to afford 1.20db and 1.c20db as a mixture of regioisomers (97 mg, 0.26 mmol, 41% 
yield). To obtain pure regioisomers, the crude material was first purified on a 12 g flash column 
(100% DCM) then purified again on a 12 g flash column (80%-100% DCM in hexanes then 100% 
EtOAc). Fractions containing a single regioisomer were combined to afford 1.20db as a yellow 
amorphous solid (42 mg, 0.11 mmol, 18% yield). 1.c20db not isolated. 1.20db: Rf = 0.2 (75% 
DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.52 – 7.46 (m, 2H), 7.24 – 7.10 (complex, 4H), 
7.05 – 6.95 (complex, 4H), 6.82 – 6.75 (m, 1H), 6.74 – 6.67 (m, 2H), 4.53 (d, J = 4.2 Hz, 1H), 
4.13 (q, J = 4.1 Hz, 1H), 3.87 – 3.72 (m, 2H), 3.65 (s, 3H), 2.21 (s, 3H), 1.70 – 1.59 (m, 3H). 13C 
NMR (101 MHz, CDCl3) δ 158.9, 150.9, 144.9, 138.6, 133.2, 129.4, 129.3, 129.2, 128.7, 126.6, 
119.5, 114.7, 113.5, 71.5, 62.2, 55.3, 54.2, 21.5. FTIR (thin film): 3398, 2929, 1594, 1495 cm-1. 













yl)methanol (1.20dc) and ((trans)-3-(4-chlorophenyl)-5-(4-methoxyphenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl)methanol (1.c20dc): Protected cinnamic acid 1.15d (94 mg, 0.38 
mmol, 1.0 equiv) and hydrazoyl chloride 1.18c (150 mg, 0.57 mmol, 1.5 equiv) were reacted 
according to the general procedure to afford 1.20dc and 1.c20dc as a mixture of regioisomers (80 
mg, 0.21 mmol, 34% yield). Fractions containing a single regioisomer were combined to afford 
1.20dc as a yellow amorphous solid (30 mg, 0.076 mmol, 12% yield). 1.c20dc not isolated. 1.20dc: 
Rf = 0.2 (75% DCM in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.47 (m, 1H), 7.26 – 7.17 
(m, 1H), 7.17 – 7.08 (complex, 3H), 7.05 – 6.98 (m, 2H), 6.85 – 6.76 (m, 1H), 6.76 – 6.70 (m, 
2H), 4.53 (d, J = 3.2 Hz, 1H), 4.16 (q, J = 4.1 Hz, 2H), 3.96 – 3.73 (m, 2H), 3.67 (s, 1H), 1.63 (s, 
1H). 13C NMR (101 MHz, CDCl3) δ 159.1, 149.5, 144.5, 134.2, 132.7, 130.6, 129.5, 128.7, 128.61, 
127.8, 119.9, 114.8, 113.6, 71.7, 62.1, 55.4, 54.1. FTIR (thin film): 3398, 2928, 1595, 1499 cm-1. 
















yl)methanol (1.c20dd): Products could not be separated via column chromatography or 






yl)methanol (1.c20de): Protected cinnamic acid 1.15d (102 mg, 0.41 mmol, 1.0 equiv) and 
hydrazoyl chloride 1.18e (150 mg, 0.61 mmol, 1.5 equiv) were reacted according to the general 




















Fractions containing a single regioisomer were combined to afford 1.20de as a yellow amorphous 
solid (23 mg, 0.061 mmol, 9%). 1.c20de not isolated. 1.20de: Rf = 0.4 (75% DCM in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.55 – 7.49 (m, 1H), 7.34 – 7.28 (m, 1H), 7.25 – 7.00 (complex, 7H), 
6.99 – 6.94 (m, 1H), 6.84 – 6.75 (m, 1H), 6.75 – 6.69 (m, 2H), 4.55 (d, J = 4.1 Hz, 1H), 4.19 – 
4.11 (X of ABX system, m, 1H), 3.83 (A of ABX system, JAB = 11.48 Hz, JAX = 5.37 Hz, 1H), 3.79 
(B of ABX system, JAB = 11.48 Hz, JBX = 3.47 Hz, 1H) 3.66 (s, 3H), 2.23 (s, 3H), 1.57 (s, 1H). 13C 
NMR (101 MHz, CDCl3) δ 158.9, 150.9, 144.8, 138.1, 133.2, 131.9, 129.5, 129.4, 128.6, 128.4, 
127.1, 123.9, 119.6, 114.7, 113.6, 71.5, 62.2, 55.4, 54.2, 21.6. FTIR (thin film): 3398, 3029, 2924, 






yl)methanol (1.20df) and ((trans)-3-(3-chlorophenyl)-5-(4-methoxyphenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl)methanol (1.c20df): Products could not be separated via column 














yl)methanol (1.20dg) and ((trans)-3-(3-methoxyphenyl)-5-(4-methoxyphenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl)methanol (1.20dg): Products could not be separated via column 















CHAPTER II: ASYMMETRIC SYNTHESIS OF 2-AZAISOCEPHALOSPORINS 
 
2.1 Isocephalosporin Review    
Cephalosporins (Figure 2.1) are a class of natural products first isolated from the fungus 
Acremonium chrysoenum that have been utilized extensively in the clinic as narrow- and broad-
spectrum antibiotics.43-45 Cephalosporins constitute a class of β-lactam antibiotics that, like other  
β-lactams, exert their antibacterial activity through inhibition of bacterial cell wall synthesis and 
have been found to be active against a range of Gram-negative and Gram-positive bacteria. 
Naturally occurring cephalosporins are  produced by a range of fungi and bacteria and various  
substitution at the 3- and 7-positions. Those containing a 7-β-MeO functionality constitutes a 
subclass of cephalosporins called cephamycins, which are also clinically relevant drugs. While 
these are an important subclass of cephalosporin antibiotics, this chapter will focus only on 

















  While the basis of the cephalosporin core structure is defined as a [4.2.0] bicyclic structure 
with a sulfur atom at the 1-position, early work on the derivatization of this scaffold established a 
series of requirements to achieve optimal biological activity. These include a degree of 
unsaturation between the 3 and 4 positions, a free carboxylic acid at the 4 position, an acylamino 
substituent at the 7 position, and a requirement that the protons attached to the bridgehead position 
and the 7 position be cis to one another.46 
  Many semi-synthetic analogs of cephalosporin C have been synthesized that keep the same 
core structure intact while diversifying the 7-acylamino and 3-position functionalities. In addition, 
many wholly synthetic unnatural cephalosporins analogs have since  been synthesized wherein the 
sulfur atom has been replaced with an oxygen, nitrogen, or carbon atom or wherein the heteroatom 
has been moved to the 2 position of the non-b-lactam ring. The first unnatural cephalosporins to 
be synthesized were oxacephatholin and carbacephatholin by Christensen et al. in the early 1970’s 
and, since then, a wide range of unnatural scaffolds have been synthesized in an attempt to unlock 
hitherto unknown antibiotic activity and/or improved pharmacokinetic and pharmacodynamic 
profiles.  First,  I will review the syntheses of these wholly synthetic and unnatural scaffolds and 
their antibacterial activities when available. Racemic and asymmetric syntheses will be separated 
where applicable, however, many of the racemic synthesis are used to produce optically active 
compounds, but require some sort of resolution to separate the isomers and achieve 
enantiomerically pure final products.  I will then discuss my work on the synthesis of novel 2-
azaisocephalosporins in the following sections. 
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2.2: 1-Isocephalosporin Derivatives  
2.2.1: 1-Azaisocephaloporins 
One of the earliest syntheses of a the 1-azecepham core was accomplished by Wolfe., et 
al. in 1972 who used a ring-opening/ring-closing strategy that eventually formed the bicyclic 
structure as a mixture of cis and trans isomers (Figure 2.2).47 Synthesis began with a previously 
described48 chlorinolysis of anhydropenicillin 2.1, methylation of the resulting carboxylic acid, 
and treatment of this compound with one molar equivalent of NBS to provide di-halogenated 2.2. 
An azide was then selectively installed at the bromine-bearing carbon to provide 2.3. Following 
PtO2--promoted azide reduction and base-promoted Cl-displacement, 2.3 underwent an 
intramolecular SN2 ring-closing to create the 1-aza-cephalosporin core 2.4. The group stopped here 




Figure 2.2. Synthesis of 1-azacephalosporin skeleton. (a) Cl2 then H2O; (b) Ph2CN;2 (c) NBS; (d) 





































A series of triazolocephems (wherein the nitrogen at the 1-position and the carbon at the 
2-position are part of an attached triazole) was published in 1981 by Pearson while at Beecham 
Pharmaceuticals (Figure 2.3).49 The syntheses of the 3-nor and 3-Me analogs followed similar 
routes. To access the 3-nor scaffold, the monobactam 2.5 was subjected to the “usual chlorinolysis, 
sodium azide sequence” (Cl2 then NaN3) to convert the 2-thiomethyl functionality to an azide as a 
mixture of cis  and trans diastereomers that could be readily separated by column chromatography. 
This compound was then alkylated with propargyl bromide to provide alkyne-containing 
compound 2.6, which was subsequently refluxed in toluene to produce tricyclic trazoloazetidinone 
core. The ∆3 degree of unsaturation was then installed using a modified Grieco elimination via 
addition and oxidative elimination of a phenylselenyl group at the 4-position to provide 2.7; 
deprotection of the amine and amidation with phenoxyacetyl chloride followed by acidic tBu ester 




Figure 2.3. Synthesis of 3-nor- and 3-Me-triazoloazetidinone scaffolds by Pearce. (a) Cl2 then 
NaN3; (b) LiHMDS, propargyl bromide; (c) but-3-yn-2-one; (d) toluene, reflux; (e) LiHMDS, 









































To place a methyl substituent at the 3-position, but-3-yn-2-one was used in the alkylation 
to provide alcohol 2.8. Refluxing this compound in toluene followed by elimination of the 
hydroxyl and isomerization of the resulting exo olefin with DBU provided 2.9. As before, acidic 
deprotection of the amine and amidation with phenoxyacetyl chloride followed by acidic tBu ester 
cleavage afforded the target 3-methyl-triazoloazeitidinone. Both compounds had antibiotic activity 
against S. pneumoniae, S. aureus, and B. subtilis with the 3-Me compound having approximately 
10-fold activity over the 3-nor compound against the targets (5 µg/mL MIC vs. 50 µg/mL MIC). 
 
2.2.2: Carbacephalosporins 
1-Carba-desthioephems (carbacephems) are a class of compounds wherein the sulfur atom 
found in the cephalosporin core has been replaced with a carbon. This group of compounds 
represents arguably the most successful class of cephalosporin analogs and have demonstrated 
clinical success as antibiotics. For example, loracarbef  [marketed as Lorabid] is a third-generation 
cephalosporin that was FDA approved and released in 1991 by Eli Lilly. Furthermore, while 
carbacephems have been found to be equipotent to their 1-thio congeners, they can demonstrate 
increased stability in vivo.50-52  
 
2.2.2.1: Racemic Syntheses and Those Involving Resolutions 
  In 1974, Christensen and coworkers reported the first racemic synthesis of a carbacephem 
wherein they synthesized 1-carbacephatholin, a direct S®C replacement of the cephalosporin 
cephatholin (Figure 2.4A). The same group later published a synthesis of the des-thio congener of 
cefamandole, carbacefamandole, following a similar synthetic sequence (Figure 2.4B).53,54 These 
compounds share the common cephalosporin core with different substitution at the 3- and 7-
 104 
positions. To synthesize 1-carbocephatholin, Schiff-base 2.10 and azidoacetyl chloride were used 
as components for a Staudinger [2+2] cycloaddition to form  (±)-azetidinone 2.11 that was treated 





Figure 2.4. 1-carbacephatholin and 1-carbacefamandole synthesis by Cama and Christensen. A) 
Racemic synthesis of 1-carbacephatholin and 1-carbacefamandole. (a) TEA, azidoacetyl chloride; 
(b) 10% H2SO4 in AcOH; (c) AcCl, pyridine; (d) NaH; (e) Pd/C, H2; (f) thienylacetyl chloride; (g) 
aq. sodium bicarbonate. B) Representative synthesis of 1-carbacefamandole following an 
analogous synthetic route. C) Minimum Inhibitory Concentration (µg/mL) of (±)-carbacephatholin 


















































(±)-2.16 1.56 3.12 1.56 1.56





































  The hydroxy group was then re-acylated with acetyl chloride to access 2.12, which was 
subjected to an intramolecular Wittig cyclization to afford the 1-carbacephalosporin skeleton 2.13.  
Hydrogenation of this compound afforded both azide reduction to reveal the free amine as well as 
benzyl ester cleavage to provide the carboxylic acid. The free amine was subsequently acylated 
with 2-thienylacetyl chloride to afford (±)-1-carbacephatholin 2.14.  
  The synthesis of (±)-1-carbacefamandole began with 2.15, a very close analog of building 
block 2.11 (PMB ester vs. benzyl ester), undergoing an annulation with azidoacetyl chloride to 
provide azetidinone 2.15. The rest of the synthesis followed a similar route to complete (±)-1-
carbacefamandole 2.16.54 Both of the desthiocephalosporin analogs were tested for antibacterial 
activity against a range of biological targets and exhibited similar activity to the parent 
cephalosporins even as racemates vs. enantiopure cephalosporins (Figure 2.4C).  
Researchers at Shionogi Pharmaceuticals used a diversity-oriented, linear synthesis to 
access four different carbacephem cores that had a variety of substitutions at the 3-position, 
including 3-tetrazolylthiomehtyl-, 3-methyl-, 3-methoxy-, and 3-H-1-desthiocarbacephalosporins 
(Figure 2.5).55 Synthesis began with a previously described56 deconstruction of 6-APA to form a 
chiral amine building block that was used to form a Schiff base with pent-4-enal, which underwent 
a Staudinger [2+2] cycloaddition to afford the racemic cis-azetidinone core 2.17. Base-mediated 
double bond isomerization, 7’-azide reduction/acylation, and olefin epoxidation provided late-
state intermediate 2.18.  The 3-tetrazolylthiomehtyl side chain was introduced through 
nucleophilic epoxide opening upon treatment of 2.18 with 5-thiomethyltetrazole. Oxidation of the 
resulting alcohol provided ketone 2.19 that, following conversion of the 1,4-butadiene sidechain 
to an ylide under Nagata conditions,57 was subjected to an intramolecular Wittig cyclization to 
form 3-tetrazolylthiomehtyl-1-carbacephalosporin 2.20, similar to that seen in Figure 2.4. 
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Compound 2.20 was then reduced with magnesium and acetic acid to cleave the 3-
tetrazolylthiomehtyl side-chain, providing exomethylene compound 2.21, which was then 
converted to both the 3-methyl and 3-methoxy scaffolds under the different conditions given in 
Figure 2.5.  
 
 
Figure 2.5. Shionogi Pharmaceuticals synthesis of 3-thiotetrazole-, 3-Me-, 3-methoxy-, and 3-H-
carbacephem skeleta. (a) pent-4-enal; (b) azidoacetyl chloride, TEA; (c) TEA; (d) Zn–AcOH; (e) 
phenylacetyl chloride; (f) m-CPBA; (g) N-methyl-5-thiotetrazole, n-BuLi; (h) CrO3; (i) O3; (j) Zn–
AcOH; (k) SOCl2; (l) PPh3; (m) heat; (n) Mg–AcOH; (o) TEA; (p) O3; (q) Zn–AcOH; (r) 
diazomethane; (s) HClO4–H2O then acetone; (t) O3 then Zn–AcOH; (u) SOCl2; (v) PPh3; (w) H+; 
























































































  Isomerization of the olefin under basic conditions afforded the 3-methyl core 2.22, whereas 
ozonation of the double bond and sequential reduction and methylation of the resulting ketone 
provided the 3-methoxy core 2.23. Finally, the 3-H scaffold was synthesized by converting 
epoxide 2.19 to a protected 1,2-diol and again converting the 1,4-butadiene into a phosphorane 
under previously described conditions. Acetonide deprotection, oxidative diol cleavage and 
intramolecular Wittig cyclization of the resulting aldehyde provided 3-H compound 2.24.  
 
Table 2.1. Antibiotic activity of the 3-functionalized carbacephems with a variety of 7-acylamino 











































Minimum Inhibitory Concentration (µg/mL)
6.3 0.8 1.6 1.6
50 25 50 50
25 3.1 25 12.5
12.5 0.8 0.8 0.8
25 25 6.3 1.6
12.5 1.6 3.1 0.8
12.5 0.4 0.05 0.05
>100 3.1 6.3 6.3
25 0.05 0.05 0.01
6.3 3.1 >100 100
 109 
With each skeleton in hand, the 7’-amino group was functionalized with a variety of side 
chains and deprotected to reveal the free carboxylic acids. The compounds were analyzed for 
biological activity against a range of Gram-positive and Gram-negative bacterial species 
organisms (selected data, Table 2.1). Of these molecules, compound 2.20 exhibited the greatest 
antibacterial activity, but none of the compounds were overall more efficacious than the 
corresponding cephalosporin (data not shown).  
Building on this route to access carbacephalosporins, researchers as Kyowa Hakko Kogyo 
developed an enzymatic resolution that would be used to synthesize and test a series of 
enantiomerically pure 3-H-1-desthiocarbacephems.58,59   To access the racemic 3-H-1-
desthiocarbacephalosporin core 2.24 (see Figure 2.5)55 the team then employed two different 
enzymatic resolutions to achieve only the correct (6R,7S)-stereoisomer with a variety of different 
7-acylamino substituents (Figure 2.6). To install a phenylglycine substituent at the 7-position, 
racemic free amine 2.25 was incubated with D-phenylglycine methyl ester and intact cells of 
Pseudomonas melanogenum KY-8541, a penicillin acylase-producing β-lactamase deficient 
mutant, that acylated only the correct (6R,7S)-stereoisomer to obtain (6R,7S)- 2.24. To install other 
side-chains, instead of beginning with the free amine, racemic 2.24 was incubated with Kluyvera 
citrophila KY-7844, a strain of bacteria that expresses penicillin acylase at high levels and cleaves 
the 7-aminioacyl substituent, to selectively obtain (6R,7S)-2.25 as the sole product. The free amine 
was then acylated with either p-hydroxyphenyl glycine or an ATM side chain to achieve the target 




Figure 2.6. Enzymatic resolution of racemic 3-H-carbocephalosporins to achieve enantiopure 
(6R,7S) final products. 
 
The racemic and enantiopure compounds were then tested against a range of bacterial 
targets (Table 2.2); cefotoxime, the parent sulfur-containing cephalosporin was also tested as a 
control. The enantiomerically pure compounds were generally more active than the corresponding 
racemic mixtures. Ceftizoxime and both (±)- and (6R,7S)-2.27 exhibited similar activity against E. 
coli and K. pneumoniae and were more active against the same targets compared to (±)- and 
(6R,7S)-2.26. However, both (±)- and (6R,7S)-2.26 exhibited similar activity against S. aureus and 

































































































































In the same year, the group published a paper outlining the synthesis of a novel set of 3-
Cl-1-desthiocephalosporins mimicking the substitution found in the cephalosporin cefaclor.50 One 
compound in the series, loracarbef (2.33) (Figure 2.7, Table 2.3), turned out to be immensely 
successful and was marketed by Eli Lilly as Lorabid.  
Synthesis of these compounds began with the 3-H-1-desthiocephalosporin skeleton 2.28; 
treatment of this compound with thiophenol and base gave the sulfated product 2.29 almost 
quantitatively. Treatment of this compound with m-CPBA gave the phenylsulfinyl compound, 
which was then chlorinated in a Pummerer-type reaction to afford the α-chloro sulfoxide and, upon 
heating, liberated sulfinic acid to give the 3-Cl-1-desthio bicyclic structure 2.30. Treatment of 2.30 
with TFA and hydrazine hydrate produced amino acid 2.31 that was carried forward to make both 
a racemic and enantiopure compounds. To make the racemic compound, 2.31 was coupled with 
ATM-chloride to provide (±) 2.32 (not shown). To access the optically pure compounds, 2.31 was 
then enzymatically resolved in the same manner as previously described (see Figure 2.6) to obtain 
(6R, 7S)-2.31. The free amine was then coupled to the ATM side-chain to afford (6R, 7S)-2.32 and 
phenylglycine or PMB-glycine to produce final the final compounds (6R,7S)-2.33-2.34, 
respectively, that were used for testing. Of these compounds, (6R,7S)-2.32 had the best overall 
















Figure 2.7. Synthesis of 3-chloro-carbocephalosporins. A) synthesis of (±)-2.32. B) Enzymatic 
resolution and synthesis of (6R,7S)-2.33 and -2.34. (a) thiophenol; (b) m-CPBA; (c) SOCl2; (d) 
toluene, reflux; (e) TFA; (f) N2H4 • H2O; (g) ATM-Cl; (h) phenylacetyl chloride; (i) K. citrophila; 




































































Y = H 2.33  (Lorabid)


















2.2.2.2: Asymmetric Syntheses 
  An early enantioselective synthesis of carbacephalosporin nucleus was accomplished by 
Evans60 through the use of (4S)-phenyloxazolidylacetyl chloride as a chiral auxiliary in the 
Staudinger [2+2] cyclization to create the β-lactam core 2.35 in 80% yield and 92:8 er (Figure 
2.8). Hydrogenation 2.35 reduced the olefin and a dissolving metal reduction effected concomitant 
removal of the chiral auxiliary and reduction of the aromatic group; the free amine was then 
protected with Boc2O to provide 2.36. Ozonation of this material accessed malonate ester 2.37 that 


































previous carbacephalosporin syntheses that close the ring through an intramolecular Wittig 
cyclization, 2.38 was instead treated with Rh2(OAc)4 to effect an intramolecular N-H insertion to 
afford the 3-OH-carbacephalosporin nucleus, which was trapped in situ with 
trifluoromethanesulfonic to provide the carbacephalosporin core 2.39. Side chain modifications 





Figure 2.8. First enantioselective synthesis of the carbacephalosporin core by Evans. (a) Pd/C, H2; 
(b) Li-NH3; (c) Boc2O; (d) O3; (e) tosyl azide, DIPEA; (f) titanium tetrabenzyloxide, BnOH; (g) 
Rh2(OAc)4; (h) Tf2O; (i) TFA, anisole; (j) phenoxyacetic anhydride; (k) cysteamine-PNB 
















































Inspired by this synthesis, an enantioselective synthesis of (6R,7S)-2.33 (Lorabid) was 
published by Eli Lilly wherein the azetidinone core was synthesized through a [2+2] cycloaddition 
using an acyl chloride bearing a chiral auxiliary to form β-lactam core again in 92:8 dr.61 A 
rhodium-catalyzed N-H insertion was again used to form the bicyclic structure and functional 
group manipulation provided the first enantioselective synthesis of (6R,7S)-2.33.  
 
2.2.3: 1-Oxocephalosporins 
2.2.3.1: Racemic Syntheses and Those Requiring Resolutions 
  The first true cephalosporin analog to be synthesized wherein the sulfur atom was 
exchanged for an oxygen atom was with the total synthesis of (±) oxacephatholin by Cama and 
Christensen while at Merck (Figure 2.9).62 Synthesis of (±) oxacephatholin began with the 
treatment of α-aminodiehtylphosphonoacetate 2.41 with ethyl thioformate and MeI to provide 
imine 2.42, which, when treated with azidoacetyl chloride in TEA, underwent a [2+2] Staudinger 
cycloaddition to afford trans-azetidinone 2.43. Treatment of compound 2.43 with Cl2 and 1-
hydroxy-3-acetoxy-2-propanone provided β-lactam 2.44 as a 1:1 mixture of cis:trans isomers due 
to the reaction proceeding through an acyl-iminium transition state followed by nucleophilic attack 
at either face of the β-lactam core. An intramolecular Wittig-reaction provided bicyclic compound 
2.45 and the cis- and trans-isomers were separated on chromatography to provide the desired 
diastereomer in 28% yield from 2.44. The bicyclic structure was then doubly deprotected under 
reducing conditions to provide the corresponding amino acid; functionalization of the 7-amine 
with thienylacetyl chloride and treatment with NaHCO3 to form the sodium salt provided the target 
compound (±) oxacephatholin 2.46. When tested against a variety of biological targets, (±) 
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oxacephatholin exhibited equivalent antibacterial activity as the single, naturally occurring (6S, 




Figure 2.9. Total synthesis of (±)-l-oxacephatholin. (a) ethyl thionoformate, CCl4; (b) K2CO3, 
MeI; (c) azidoacetyl chloride, TEA; (d) Cl2; (e) 1-hydroxy-3-acetoxy-2-propanone, AgBF4, Ag2O; 





































































  In 1977, Nagata and co-workers from the Shionogi Pharmaceutical Company published a 
synthesis of enantiomerically pure 3-methyl 1-oxacephalosporin 2.58 and its 7-acylamino 
derivatives (Figure 2.10).57 Instead of building their β-lactam core, the researchers began their 
synthesis with a previously reported cleavage of 6-APA63 to produce azetidinone 2.47, which was 
deprotected with p-TsOH to provide the free amine salt 2.48. Following a similar series of 
reactions as Cama et al., compound 2.48 was treated with Cl2 to access 2-chloro-monobactam 2.49 
followed by nucleophilic substitution using propargyl alcohol to provide compound 2.50 as a 
mixture of 2:1 cis:trans isomers that were separated by chromatography. Amidation of the 7-amine 
and hydration of the alkyne provided compound 2.51, which was then converted to 2.52 using a 
series of reactions that will be cited many times in later isocephalosporin syntheses.  To provide 
the ylide 2.52, isopropylideneacetate was ozonized and the resulting ketone was reduced to the 
primary alcohol with zinc/acetic-acid. Reaction of the primary alcohol with thionyl chloride 
followed by displacement of the halide with triphenylphosphine provided the target ylide 2.52. 
Ring-closure was achieved through an intramolecular Wittig reaction to access the 1-
oxocephalosporin core 2.53. This material was then treated with phosphorous pentachloride to 



















Minimum Inhibitory Concentration (µg/mL)
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followed by acidic diphenylmethyl ester deprotection to provide final compounds 2.55-2.57; 
compound 2.58 is produced from simply deprotecting the carboxylic acid in compound 2.53. The 
authors reported that the final compounds 2.56-2.58 “all showed antibacterial activity against 
Gram-positive and -negative bacteria as much as 4-8x higher than that of their cephalosporin 
analogs,” although no quantitative data was provided. Interestingly, 2.55, the oxocephalosporin 
analog of cephalexin, was inactive, demonstrating that atom switches can influence the biological 
activities into the cephalosporin scaffold; the researchers suggested that this is due to the relative 
instability of 2.56 vs cephalexin. 
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Figure 2.10. Synthesis of (±)-3-Me-1-oxocephalosporins by Nagata. (a) p-TsOH, acetone; (b) Cl2 
then NaHCO3; (c) ZnCl2, propargyl alcohol; (d) phenylacetyl chloride, pyridine; (e) H2SO4–
HgSO4; (f) O3; (g) Zn–HOAc; (h) SOCl2–pyridine; (i) PPh3; (j) heat, dioxane; (k) PCl5; (l) 


































































































H H H H H
H H F






  In 1979, two years after this work, Pearson and Branch at Beecham Pharmaceuticals 
published a similar paper wherein they also synthesized enantiopure 3’-methyl- and 3-desmethyl-
1-oxocephalosporins.64 The team followed a similar synthetic strategy to produce analogous 
compounds that, when tested, replicated the data published by Nagata. Interestingly, compounds 
from both groups that contained a free amine on the on the 7’-acylamino side chain are completely 
inactive; it is hypothesized that this is due to intramolecular β-lactam ring opening by the 
nucleophilic amine.  
  The same year, Christensen and coworkers accomplished the first total synthesis of (±) 
oxacefamandole and again demonstrated that oxocephalosporins may be just as, if not more, active 
then their cephalosporin counterparts (Figure 2.11A). Christensen began the synthesis of (±) 
oxacefamandole in a similar manner to the synthesis of oxacephatholin (see Figure 2.9) with the 
construction of azetidinone 2.59 that was treated with Cl2 to convert the thiomethyl group into a 
chloride. Silver-mediated condensation of hydroxyacetone 2.60 with the 2-chloro-monobactam 
provided 2.61 as a mixture of isomers. Interestingly, this transformation was successful whereas 
analogous attempts using 1,3-dihydroxyacetone by Nagata failed.57 Refluxing this material in 
dioxane facilitated an intramolecular Wittig cyclization to access the 1-oxocepholosporin core; 
cis- and trans-isomers were then separated by chromatography to provide 2.62. Reduction of the 
7’-azide provided a free amine that was coupled to L-O-formylmandeloyl chloride and 
concomitant deprotection of the 7-acylamino group and carboxylic acid under acid/base conditions 
provided (±) oxacefamandole 2.63. The target compound was then tested as a racemic mixture 
against a range of bacterial targets and exhibited equivalent or better activity than its cefamandole 




Figure 2.11. Synthesis and antibiotic activity of (±) 1-oxocefamandole by Christensen. A) 
synthetic route to (±) 1-oxocefamandole. (a) Cl2; (b) AgBF4, hydroxyketone 2.60; (c) dioxane, 
reflux; (d) Pd/C, EtOAc; (e) L-O-formylmandeloyl chloride; (f) TFA-anisole then NaHCO3. B) 
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2.2.3.2: Asymmetric Syntheses 
  Up to this point, one problem with all of the syntheses of 1-oxacephams was that they were 
not completely diastereoselective. In each synthesis, treatment of the chlorinated azetidinone with 
a Lewis acid causes the formation of an acyliminium ion that can be attacked at either the 
diastereotopic face by the oxygen nucleophile, leading to  both the cis and trans isomer product. 
To overcome this, Nagata et. al. came up with a completely stereocontrolled synthesis of 7α 1-
oxacephems from penicillins via a series of intramolecular ring-forming and -breaking steps 
(Figure 2.12).65  
  The synthesis began with the acylation of 6-aminopenicillate 2.64 to afford 2.65. Treatment 
of this compound with Cl2 followed by treatment with ZnCl caused an intramolecular nucleophilic 
addition of the carbonyl on the 7’-aminoacyl side chain into the acyl iminium ion intermediate to 
provide oxazoline 2.66 as the sole diastereomer. From there, selective reduction using aluminum 
amalgam provided oxazolidine 2.67, which was subsequently reacted with phenylacetyl chloride 
to provide acetyloxazolidine 2.68. Reductive ring cleavage provided the cis acetonyl ether 2.69 in 
40-51% yield as the sole diastereomer. Completely regioselective bromination of the ketone at the 
terminal methyl group was achieved by reaction with CuBr2 and triethyl orthoformate in ethanol 
provided α-bromo ketal 2.70. The ketal was then hydrolyzed to give the brominated ketone 2.71, 
which underwent facile nucleophilic substitution to provide thiotetrazole compound 2.72 and the 
equivalent acetate 2.73. These compounds were then easily converted to 1-oxacephem compounds 
2.74 and 2.75 using their previously developed synthetic sequence devised in their laboratory (see 






Figure 2.12. First completely stereocontrolled synthesis of 1-oxocephalosporins accomplished 
through an intramolecular ring-opening and ring-closing strategy by Nagata. (a) CH3O2CCOCl, 
TEA; (b) Cl2, DCM; (c) ZnCl2, TEA; (d) Al-amalgam, 5-10% THF in H2O; (e) phenylacetyl 
chloride; (f) ethereal HCl, Zn, t-BuOH; (g) CuBr2, HC(OET)3; (h) HClO4, acetone; (i) AcONa; (j) 
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2.3: 2-Isocephalosporin Derivatives  
2.3.1: 2-Thioisocephalosporins 
  The first published synthesis of a thioisocephalosporin comes from Gleason et al. and 
provides a generalized racemic synthesis to both C-3 functionalized and C-3 desmethyl isocephem 
systems (Figure 2.13).66 The cis-azetidinone core 2.76 is formed via a Staudinger [2+2] 
cycloaddition through the annulation of azidoacetyl chloride and the imine formed from 2,4-
dimethoxybenzylamine and methyl glyoxylate. Subsequent oxidative deprotection of the amide 
nitrogen afforded free amine 2.77 and reduction of the methyl ester and tosylation of the resulting 
alcohol afforded protected intermediate 2.78 (Figure 2.13a). Reduction of the C-7 azide with Zn–
HOAc afforded the primary amine which was then reacted with 2-thienylacetyl acid chloride to 
afford 2.79. The tosyl group was converted to the primary halide by treatment with KI and 
subsequently displaced with triphenylmethanethiol; deprotection upon treatment with silver nitrate 
in methanol provided thiol 2.80. Treatment the thiol with benzhydryl β-bromopyruvate provided 
bicyclic compound 2.81 and subsequent dehydration using thionyl chloride-pyridine provides the 
C-3 desmethyl skeleton which is then deprotected using TFA to provide the free carboxylic acid 
2.82. Using a different 7-acylamino side-chain, the C-3 functionalized analogs were prepared by 
alkylating the free thiol 2.83 with tert-butyl 3-bromo-2-oxobutyrate followed by dehydration with 
trifluoromethanesulfonic anhydride to afford intermediate 2.84 (Figure 2.13B). Subsequent radical 
bromination of the primary carbon was then achieved using NBS and AIBN and the resulting 
halide was displaced using potassium acetate and the carboxylic acid then deprotected using TFA 






Figure 2.13. Synthesis of (±) 3-nor- and (±) 3-Me-2-thioisocephalosporins. A) synthesis of 
desmethyl skeleton. a) K2S2O8, pH 5-6.5; (b) NaBH4; (c) Tos-Cl; (d) Zn/AcOH; (e) 2-thienylacetic 
acid; (f) KI, acetone; (g) NaSC(Ph)3; (h) AgNO3, MeOH; (i) benzhydryl b-bromopyruvate; (j) 
SOCl2, pyridine; (k) TFA; (l) tert-butyl 3-bromo-2-oxobutyrate; (m) TFAA, pyridine; (n) NBS, 
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Table 2.5. Antibiotic activity of racemic 3-nor-2-thioisocephalosporin and its enantiopure 3-nor-






  When the racemic 3-nor-2-thioisocephalorporin 2.82 was tested against its enantiopure 1-
thio-cephalosporin congener, the unnatural cephalosporin exhibited almost equivalent, and 
sometimes better, activity against a range of targets that, when normalized for being racemic, 
would be analogous to its enantiopure counterpart (Table 2.5).   
  During their 1977 campaign investigating new a range of new isocephems, Doyle et al. 
also successfully synthesized the 3-nor- and 3-Me-2-thioisocepham (Figure 2.14).67  This synthesis 
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formed between protected α-amino-β-ketobutyric or α-amino-β-acetobutyric acid (for the 3-Me or 
3-nor skeletal, respectively) and cinnamaldehyde to form the cis-azetidinone 2.86. Ozonolysis of 
the olefin and reduction and protection of the resulting ketone with tosyl chloride provided 2.87. 
Treatment with trifluoroacetic acid deprotected the ketal to produce the enol which was again 
protected with a tosyl group to afford di-protected alcohol 2.88. Treatment of the protected diol 
with hydrogen sulfide and TEA facilitated ring closure and 7-azide reduction in one step to afford 
compound 2.89. This compound was then reacted with phenoxyacetyl chloride to install the side 
chain and treated with palladium on carbon to reveal the carboxylic acid 2.90. While no data was 
provided, the authors stated that  both the 3-nor- and 3-Me-2-thiosisocephalosporins were active 




Figure 2.14. Synthesis of (±) 3-nor- and 3-Me-2-thioisocephalosporins by Doyle. (a) O3; (b) 








































R = H, Me
2.86 2.87 2.88
2.89 2.90





In 1998, Hwu et. al. developed a series of potent mechanism-based 2-azaisocephems that 
took advantage electron-withdrawing C-3 substitution on the cephalosporin ring to help promote 
reactivity (Figure 2.15).68 The researchers hypothesized that the ease with which the C-3 
substituent could function as a leaving group would correlate to antibacterial activity. The 
researchers made their starting (±) cis-azetidinone core 2.91 using a previously described69 
Staudinger reaction between the Schiff base formed between α-amino-dibenzyl malonate and 
cinnamaldehyde, and azidoacetyl chloride. Ozonolysis of the olefin followed by reduction of the 
aldehyde and protection of the resulting alcohol with methanesulfonyl chloride provided 
azetidinone 2.92. Displacement of the mesyl group with sodium azide followed by Pd/C azide 
reduction facilitated an intramolecular amidation that, after tautomerization to the enol, gave 2-
azaisocepham 2.92 in 94% yield. The C-3 hydroxyl group was then functionalized with either a 
mesyl or triflate group to produce compounds 2.93 and 2.94, respectively. These compounds, 
along with cefotaxime, a known cephalosporin, were tested against a range of bacterial targets and 
just hypothesized, compound 2.94 containing the trifluoromethanesulfonyl substituent at C-3 
performed better against all biological targets than the corresponding mesyl-containing compound 




Figure 2.15. Synthesis of (±) 3-Ms- and 3-Tf-2-azaisocephalosporins. A) synthetic scheme. (a) 
NaN3, DMF; (b) Pd/C H2, EtOH; (c) MsCl, pyridine; (e) TfCl, pyridine; (d) PdCl2, H2. B) antibiotic 
activity of the target compounds compared to cefotaxime. Minimal Inhibitory Concentrations 
(µg/mL) reported.  
 
2.3.3: 2-Oxoisocephalosporins 
2.3.3.1: Racemic Syntheses and Those Involving Resolutions 
  In the 1970’s, as part of their thorough investigation into unnatural cephalosporin analogs, 
Doyle and coworkers published a series of papers wherein they synthesized a range of 2-
oxoisocephalosporins and investigated the effect of different substituents around the morpholine-
like ring. Each of the syntheses involved a Staudinger cycloaddition followed by ozonolysis to 
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compounds had rather esoteric functionalization on the 6-membered ring, but in their final paper 
on 2-oxacepham synthesis, Doyle synthesized an analog containing a 3-acetoxymethyl group as 




 Figure 2.16. Synthesis of (±) 3-acetoxymethyl-2-isocephalosporin by Doyle. (a) Tf2O; (b) TEA; 
(c) Br2 or I2; (d) KOAc; (e) H2S, TEA; (f) phenoxyacetic acid; (g) Pd/C, H2. 
 
  This synthesis began with their previous intermediate tosylated enol 2.95. Triflation of the 
enol provided compound 2.96 which upon treatment with TEA formed allene 2.97. This 
intermediate was then dihalogenated upon treatment with either bromine or iodine to form 
compound 2.98a or b and was then reacted with excess potassium acetate to give the targeted 2-
oxacepham system 2.99. Reduction of the azide, side chain coupling, and debenzylation revealed 
the target carboxylic acid 2.100.  
  Hakimelahi et al. published a racemic synthesis of a 3-hydroxy-2-oxoisocephem71 


























































aminomalonate and cinnamaldehyde and azidoacetyl chloride to form cis-azetidinone 2.101. 
(Figure 2.17). Azide reduction and coupling at the 3-position, ozonolysis of the olefin and its 
subsequent reduction produced alcohol 2.102 that, when incubated in acidic conditions, produced 
the 3-hydroxy-2-oxocephem core; Reduction of the benzyl ester under hydrogenation conditions 




Figure 2.17. Racemic synthesis of 3-OH-2-oxoisocephalosporin. (a) H2S, TEA; (b) phenoxyacetic 
acid; (c) O3; (d) NaBH4/Al2O3; (e) 1:1 TFA:DCM; (g) PdCl2, H2. 
 
  In 1980, Tenneson and Belleau published an early diastereoselective synthesis of 3-methyl 
2-oxocephem72 beginning with a Staudinger cycloaddition formed between the Schiff base of 
protected D-threonine and cinnamaldehyde and azidoacetyl chloride to form azetidinone 2.104 
(Figure 2.18). Using D-threonine as a chiral director, they were able to achieve a 9:1 ratio of the 
intended (3S, 4S)-cis-azetidinone 2.104 to its opposite cis-conformation; the diastereomers were 
then separated via HPLC and the productive intermediate was carried forward. Ozonolysis of the 
olefin produced a primary alcohol that following was mesylated to obtain a di-protected compound 
that, following de-silylation and oxidation of the resulting alcohol with Jones reagent, provided 




























structure; side-chain manipulation and benzoyl ester cleavage provided final compound 2.106. 
This diastereomer was then tested against a range of biological targets and proved more efficacious 





Figure 2.18. Racemic synthesis of 3-methyl-2-oxoisocephalosporins by Tenneson and Belleau. 
(a) O3; (b) NaBH4; (c) MsCl; (d) CrO3 • H2SO4; (e) TEA, reflux; (f) PtO2, H2;(g) phenylacetic acid, 
EEDQ; (h) Pd/C, H2. 
 
  In a subsequent series of papers, a group at Otsuka Pharmaceutical company in Japan 
followed a similar synthesis to produce a series of optically active 3-functinoalized 2-oxacephems 
that contained structural elements found in other third generation cephalosporins in an attempt to 
produce novel broad spectrum antibiotics like previously mentioned flomoxef;73,74 this was 
achieved through bromination and nucleophilic substitution at the 3-methyl functionality to 
introduce a variety of functional groups at the 3-position. 104 
 
2.3.3.2: Asymmetric Syntheses 
  A stereo-controlled synthesis of 3-nor-2-oxocephems was achieved through a different 
synthetic strategy (Figure 2.19).75 Synthesis began with aspartic acid derivative anhydride 2.107 





























Cleavage of the lactone ring under acidic aqueous conditions achieved amine 2.109 that was 
converted to azetidinone 2.110 upon treatment of 2,2-diethoxyacealdehye and p-nitrobenzyl 
isocyanide as a single diastereomer. The free alcohol was then mesylated and the p-
nitrobenzylamide group was converted into the PNB ester to afford compound 2.111, a compound 
similar as that described previously by Doyle (see Figure 2.16). Deprotection of the acetal afforded 
enol 2.112 and cyclization under basic conditions afforded the protected 3-nor-2-oxocephem 2.113 
whereas treatment of the mesylate with hydrogen sulfide provided 3-nor-isocephem 2.114. While 
they do not complete the synthesis in the paper, azide reduction and side chain coupling followed 




Figure 2.19. Stereocontrolled synthesis of 3-nor-2-oxo- and 2-thioisocephalosporins. (a) NaBH4; 
(b) LDA, p-toluenesulfonyl azide; (c) TFA then Amberlite IRA-45; (d) 2,2-diethoxyacetaldehyde, 
















































2.4: Review Conclusion  
  As we have seen, isocephalosporins of all types have demonstrated success as antibiotics 
in the laboratory and some in clinical settings. Unnatural cephalosporin derivatives have 
demonstrated antibiotic activity against both Gram-positive and Gram-positive bacteria and, in 
some cases, have demonstrated superior physical properties and antibiotic activity to their naturally 
occurring sulfur-containing congener. While 1-isocephalosporins remain the most widely 
investigated family of fully synthetic cephalosporin analogs, 2-isocephalosporins have been shown 
to be equipotent to their 1-isocephalosporin and 1-thio congeners against a variety of bacterial 
targets. It has also been demonstrated that changing the heteroatom in the secondary ring can 
influence the antibiotic activity of the compound, for better or worse.  
  In terms of their synthesis, a wide range of synthetic strategies have been employed to 
create the [4,2,0] core. Although the antibiotic activity of the cephalosporin is associated with a 
single cis diastereomer, the vast majority of isocephalosporin syntheses produce a mixture of cis-
enantiomers as the final product. However, asymmetric syntheses have been devised that employ 
either the resolution of the productive diastereomer or a completely stereocontrolled synthesis. 
However, they are executed, these asymmetric methods can produce the productive enantiomer as 
the final product which can help provide a clearer picture of the antibiotic activity of the compound 
without having to extrapolate the data from a racemic mixture to the discrete compound. For both 
racemic and asymmetric syntheses, the Staudinger [2+2] cycloaddition has been the preferred 
method for synthesizing the azetidinone core due to the relative ease of forming the b-lactam core 
decorated with all of the functionality needed to form the rest of the bicyclic structure and the high 
level of diastereoselectivity that can be achieved. Another common strategy for synthesizing 
isocephalosporins is through the de- and re-construction of existing b-lactam compounds to make 
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the target of interest. This strategy is beneficial in that the medicinal chemist can take advantage 
of the existing stereochemistry in the molecule to impart the correct stereochemistry on the 
product.  
  However they are synthesized, unnatural cephalosporins are a worthy target for the 
medicinal chemist and with antibiotic resistance on the rise, synthesizing completely novel 
cephalosporin derivatives that bacterial targets have not seen while still employing the privileged 
b-lactam core could help to produce new antibiotics with new and unusual antibiotic activity.  
 
2.5: Project Introduction 
  Of the isocephalosporins, 2-azaisocephalosporins are relatively under-investigated 
compared to other families of isocephems. While the synthesis of 2-thio- and 2-oxo-
isocephalosporins have been reported by a number of different groups, only two groups have 
reported the syntheses of 2-aza-cephalosporins,68,76 both in a racemic manner. However, the few 
examples that do exist have been shown to have good activity against a number of bacterial targets 
and are suggest the class is worthy of more attention (see Figure 2.15). To this end, the first goal 
of this project was to develop an asymmetric synthesis of 2-azisocephalosporins to investigate 
their antibiotic activity against bacterial targets. The second goal, as a larger initiative in our lab 
to investigate the role of stereochemistry on the biological activity of b-lactam antibiotics, was to 
synthesize both possible cis diastereomers of the target compounds as discrete stereoisomers to 
investigate whether or not the stereochemistry of the molecule had an effect on antibiotic activity. 
I first focused on the fully saturated, piperidine-like core of the [4.2.0] system lacking the ∆3 




Figure 2.20. Target 3-Me- and 3-nor-2-azaisocephalosporin compounds in both the naturally 
occurring (6S,7R) and opposite (6R,7S) stereochemistry.  
 
2.6: Proof of Concept Synthesis 
  As summarized in the previous section, the Staudinger [2+2] cycloaddition is one of the 
most direct ways to synthesize the b-lactam core. Furthermore, it has been demonstrated that the 
both cis enantiomers can be obtained in the product depending upon the stereochemistry of the 
building blocks used in the reaction; D-(R)-glyceraldehyde 2.115 produces the opposite cis 
conformation than naturally occurring cephalosporins whereas L-(S)-glyceraldehyde 2.116 will 
produce the naturally occurring cis stereochemistry that is usually associated with b-lactam 
antibiotic activity (Figure 2.21).77 For our initial synthesis, D-(R)-glyceraldehyde 2.115 was 
chosen as the aldehyde component of the Schiff base used in the cycloaddition to form the 
azetidinone core.  The use of this chiral directing group in the Staudinger cycloaddition has been 
shown to impart cis stereochemistry with high levels of diastereoselectivity.78,79  This was mostly 















































glyceraldehyde is either unavailable commercially or very costly (~$100/g) so it must be 




Figure 2.21. Effect of aldehyde stereochemistry on the stereochemical outcome of the target 
molecules. 
 
  A protected serine amino-acid derivative 2.117 was chosen for the amine portion of the 
Schiff base.  The protected alcohol would provide a functional handle that could be used form the 
piperidine-like secondary ring and the carboxylic acid would eventually provide the carboxylic 
acid at the 4-position of bicyclic system required for antibiotic activity. Furthermore, amines 
derived from chiral amino acids have been shown to help impart the cis-stereochemistry in the 
Staudinger reaction with high levels of diastereoselectivity.72,74,80 By coupling the protected chiral 
amino acid with the chiral glyceraldehyde, we hoped to impart a high level of diastereoseletivity 






































was used as the ketene precursor as it had already been used in analogous reactions for the 
asymmetric synthesis of b-lactams and was readily commercially available.78   
  Thus, for the initial synthesis, we envisioned forming the b-lactam core through a 
Staudinger cycloaddition between the Schiff base formed between 2.115 and the free amine of 
TIPS-protected 2.117, and subsequently installing an amine at 2-position of the monobactam via 
diol deprotection and cleavage and subsequent reductive amination at the resulting aldehyde. From 
there, an intramolecular ring-closing reaction could bring the two pendant functionalities together 




Figure 2.22. Initial retrosynthesis for 7-benzoxy proof of concept synthesis. 
 
  The protected alcohol was formed in a straightforward manner beginning with the 
silylation of N-Boc-serine benzyl ester 2.117 with TIPS-OTf in the presence of pyridine to afford 
































provided an amine salt that was used without further purification; this salt was not bench stable so 
it had to be used immediately upon synthesis. Treatment of the amine salt with TEA and D-(R)-
glyceraldehyde 2.115 sequentially in the presence of anhydrous magnesium sulfate (MgSO4) 
formed the imine quantitatively as determined by 1H NMR. Subsequent filtration of the imine and 
annulation with the ketene formed by 2-benzoxyacetyl chloride in the presence of TEA provided 
the cis-b lactam 2.119 with high diastereoseletivity (20:1 vs the unwanted cis-product) in modest 
yields (38-52% over 2 steps). Relative diastereoselectivity was determined using UPLC through 




Scheme 2.1. Serine silylation, amine deprotection, and Staudinger [2+2] to form 2.119. 
 
  Unfortunately, all acidic conditions that were attempted to afford acetonide deprotection 
also caused elimination of protected alcohol to form the dehydroalanine product as the major 








































circumnavigate this problem, the O-silyl group was exchanged for a halogen as it is a worse leaving 
group and is expected to be less prone to elimination.  
  To this end, TIPS deprotection provided free alcohol 2.120 that was then converted to a 
halide. Deprotection using TBAF was attempted, however, due to the basicity of the reagent, 
treatment of 2.119 with TBAF again resulted in elimination of the alcohol to form the a,b-
unsaturated product instead of desilylation. Thus, the use of triethylamine trihydrofluoride as an 
acidic fluoride source resulted in clean deprotection of the alcohol without any formation of the 
eliminated product.  With alcohol 2.120 in hand, an Appel reaction was used to convert the primary 
alcohol to a halide that could be displaced later in the synthesis to form the bicyclic system (Figure 
2.23A). Carbon tetrachloride was selected as the halogen source to form chlorine-containing 2.121 
as both Appel reactions using CBr4 and molecular iodide resulted in decomposition of the starting 
material. Unfortunately, the subsequent acetonide deprotection was unsuccessful once again.  
  Acetonide deprotection was attempted with a range of Brønsted acids, but each led to the 
formation of the eliminated product as the major product (Figure 2.23B). As alcohol 2.120 was 
already in hand, converting the alcohol to an amine via intermolecular displacement was briefly 
attempted, but all attempts resulted in a complex mixture wherein the major product was the 
eliminated dehydroalanine product. At this point, the lability of the a-carbonyl proton had foiled 




Figure 2.23. Initial unsuccessful nitrogen installation using benzyl ester-containing scaffold. A) 
Synthetic scheme. B) Brønsted acid conditions attempted to effect acetonide deprotection that led 





































































  The benzyl ester was reduced to an alcohol with the intent of oxidizing the alcohol back up 
to a carboxylic acid later in the synthesis (Scheme 2.2). Treatment of 2.118 with LAH cleanly 
reduced the benzyl ester to primary alcohol 2.122. However, the benzyl alcohol side-product co-
eluted with the product regardless of the mobile phase used during column chromatography so a 
different purification method had to be used to obtain the clean product. Eventually, purification 
of the alcohol was accomplished through a steam distillation using 50 mL dH2O per gram of 
starting material to provide pure 2.122 in roughly 80% yield. The alcohol was then acylated using 
a 2:2:1 mixture of DCM, pyridine, and Ac2O to provide the bis-protected amino alcohol 2.123 that 
would subsequently be used to form the b-lactam core. Boc deprotection, condensation with D-
(R)-glyceraldehyde, and treatment of the Schiff base with 2-benzoxyacetyl and TEA formed the 
azetidinone core 2.124. Desilylation was then accomplished using a buffered TBAF solution (2:1 
AcOH:TBAF) to prevent acyl migration, which provided alcohol 2.125 with no formation of the 
eliminated product. At this point, instead of trying to install a pre-functionalized amine, an azide 
was introduced instead so as to facilitate late-stage diversification at the nitrogen atom instead of 
building the nitrogen functionality as a part of the synthesis. The azide was introduced via triflation 
of the alcohol with trifluoromethanesulfonic anhydride (Tf2O) and subsequent displacement of the 
triflate with tetrabutylammonium azide (TBAA), affording 2.126. This reaction had one benefit to 
the traditional mesylation/NaN3 displacement sequence in that tetrabutylammonium azide is 
soluble in DCM so the reaction could be accomplished without an intermediate aqueous workup 
and solvent swap that is required when performing the mesylation/NaN3 displacement sequence.  
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Scheme 2.2. Proof-of-concept b-lactam synthesis wherein the benzyl ester was reduced and 
exchanged for an acylated alcohol. 
 
  With the azidated material in hand, the next step was to find selective acetonide 
deprotection conditions that would leave the acyl group intact. Every Brønsted acid that was tried 
either led to the concomitant deprotection of the acyl group in some degree or proceeded at such a 
slow rate as to be unusable (Table 2.6). Eventually, the type of acid was changed from a Brønsted 
acid to a Lewis acid, and after a bit of optimization, treatment of 2.126 with lanthanum nitrate 
heptahydrate (La(NO3)3•7H2O) could selectively deprotect the acetonide in the presence of the 
acyl group to afford diol 2.127; 4 equivalents of La(NO3)3•7H2O at 100 ˚C for 1.5-3.0 hours led to 





























BnO HH1) 25% TFA in DCM
2) 2.115, TEA






















Table 2.6. Acetonide deprotection optimization table. 
 
 
Reaction # Conditions Ratio A:B Notes 
1 p-TsOH (2 equiv), THF 40 ˚C N/A incomplete conversion 
2 p-TsOH (2 equiv), 3:1 THF:Water, 40 ˚C N/A incomplete conversion 
3 p-TsOH (2 equiv), THF, 80 ˚C 2:1 incomplete conversion 
4 Amberlyst (1 equiv), MeOH, 80 ˚C 3:1  
5 Amberlyst (1 equiv), acetone, 80 ˚C 1:4 slow conversion 
6 Amberlyst (1 equiv) THF, 80 ˚C 4:1 slow conversion 
7 Amberlyst (10 equiv) MeOH, 80 ˚C 10:1  
8 Amberlyst (25 equiv) MeOH, 80 ˚C 10:1 new side products 
9 Amberlyst (50 equiv) MeOH, 80 ˚C 10:1 new side products 
10 1:1 4N HCl:THF 5:2  
11 1:1 2N HCl:THF N/A incomplete conversion 
12 1:3 4N HCl:THF N/A incomplete conversion 
13 PPTS (0.1 equiv) 3:1 THF:H2O N/A incomplete conversion 
14 PPTS (1 equiv), 3:1 THF:H2O 1:1  
15 PPTS (0.1 equiv), THF only 1:1  
16 La(NO3)3 (0.5 equiv), MeCN, 100 ˚C 1:0 43% conv. After 2 h 
17 La(NO3)3 (0.5 equiv), MeCN, 120 ˚C 1:0 38% conv. After 1.5 h 
18 La(NO3)3 (1 equiv), MeCN, 120 ˚C 1:0 33% conv. After 1.5 h 
19 La(NO3)3 (1 equiv), MeCN, 120 ˚C,18 h N/A decomposed 
20 La(NO3)3 (2 equiv), MeCN, 100 ˚C 1:0 100% conv., 8hr 
21 La(NO3)3 (3 equiv), MeCN, 100 ˚C 1:0 100% conv., 4hr 

















  Diol cleavage of 2.127 using silica-supported NaIO4 in DCM provided aldehyde 2.128 and, 
with the aldehyde in hand, the scaffold was then primed for ring closure. Initially, 2.128 was treated 
with PPh3 to promote an intramolecular aza-Wittig reaction to form an imine that could 
subsequently be reduced to produce the target scaffold, but this sequence was highly 
irreproducible. Hydrogenation of 2.128 with Pd/C accomplished azide reduction, imine formation, 
and imine reduction in one step to provide the target bicyclic compound 2.129. While this reaction 
was relatively clean, purification of free amine proved difficult so a ring-closing/N-
functionalization step was devised to form the piperidine-like ring and functionalize the free amine 





Scheme 2.3. Oxidative diol cleavage and reductive ring closing to form 2-azaisocephalosporin 
bicyclic structure.  
 
 
  For each of the series, 2.128 was hydrogenated with Pd/C and H2, filtered over Celite, and 
concentrated to afford the intermediate amine 2.129, which was then resuspended and derivatized. 
A range of functional groups were attached to the nitrogen, including alkyl, acyl, and Boc groups,  




















NaIO4 on SiO2 Pd/C, H2
2.127 2.128 (90%) 2.129
(not isolated)
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Ac2O in the presence of pyridine to afford acylated product 2.130. Alkylation was accomplished 
through reductive amination with formaldehyde and sodium cyanoborohydride (NaCNBH4) in 
MeOH to provide methylated product 2.131. Normal Boc-protection conditions using DMAP were 
not possible with this scaffold as even catalytic amounts of DMAP resulted in decomposition of 
2.129, however treatment of the free amine with Boc2O and hexaflouroisopropanol (HFIP) at room 
temperature for 30-45 minutes to provided protected amine 2.132. Based on our interest in the role 
of nitrogen basicity on antibiotic activity and due to the instability of the free amine in compound 

































2.130 (31% over 2 steps)
2.131 (41% over 2 steps)
2.132 (28% over 2 steps)
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  For the two scaffolds, acyl deprotection using standard K2CO3 in MeOH deprotection 
conditions at 0 ˚C provided free alcohols 2.133 and 2.134 that could then be oxidized with Jones 
reagent (CrO3 and H2SO4) to provide the requisite carboxylic acid necessary for antibiotic activity. 
Both 2.133 and 2.134 could be oxidized with Jones reagent to obtain carboxylic acids 2.135 and 
2.136, respectively, but only 2.135 could be purified with an acid–base extraction. As 2.136 is 
zwitterionic, instead of using an acid-base workup, the final reaction mixture was basified to afford 
the carboxylate salt, filtered, and purified via reverse phase chromatography to afford 2.136. With 
the 7-benzoxy test synthesis accomplished, the next goal was to synthesize 7-aminoacyl analogs 




Scheme 2.5. Acyl-deprotection and alcohol oxidation to access target proof-of-concept N-Ac- and 
N-Me-2-azaisocephalosporins compounds 
 
2.7 Target Compound Synthesis  
2.7.1 Unnatural (6S,7R)-series 
  As previously stated, the overall goal of the project was to synthesize both cis (6R, 7S) and 


























R = Ac 2.133 (87%)
= Me 2.134 (80%)
R = Ac 2.135 (72%)
= Me 2.136
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of stereochemistry on antibiotic activity of b-lactam antibiotics (Figure 2.20). The 3-nor (6S,7R) 
series was the first series attempted.  
  The series possessing the (6S,7R) unnatural stereochemistry was synthesized in the same 
way as the 7-benzoxy test series, although some unforeseen challenges cropped up along the way. 
The first challenge was to figure out a way to install the requisite 7-amino group that could 
amidated later in the synthesis. To accomplish this, azidoacetyl chloride 2.137 was chosen as the 
ketene component of the Staudinger cycloaddition instead of 2-benzoxyacetyl chloride (Figure 
2.24). By using azidoacetyl chloride as our ketene component, an azide is installed at the eventual 
7-position of the b-lactam which can later be easily converted to a secondary amine and 
functionalized to introduce the acylamino functionality found in b-lactam antibiotics. While 
azidoacetyl chloride has been used previously in b-lactam syntheses,54,62,66 it is not commercially 
available and requires an involved fractional distillation to achieve its purification. Furthermore, 
as a low-boiling point azide, it is also potentially explosive. Despite these challenges, azidoacetyl 
chloride was successfully synthesized by first introducing an azide onto bromoacetyl chloride 
using NaN3 and then converting the carboxylic acid to the corresponding acyl-chloride via oxalyl 
chloride and catalytic DMF; fractional distillation then provided the low-molecular weight 
building-block as a clear, colorless oil. While I did not encounter any problems during the 
synthesis, oxalyl chloride was added via syringe pump and was run behind a blast shield as was 







Figure 2.24. Synthesis of azidoacetyl chloride 2.137. 
 
  Reacting the Schiff base formed between deprotected 2.123 and D-(R)-glyceraldehyde 
2.115 with azidoacetyl chloride 2.137 formed (6R,7S) azetidinone 2.138 24:1 dr of the intended 
diastereomer to the opposite (6S,7R) (Figure 2.25A). Next, the azide was then reduced with either 
PtO2 or Pd/C to provide free amine 2.139. The azide was reduced at this point as opposed to later 
in the synthesis, as is common in isocephalosporin syntheses, to avoid chemoselectivity issues that 
could arise from having two nucleophilic nitrogen atoms in the same molecule. PtO2 was used 
initially as it is historically the metal of choice used for azide reduction on b-lactam scaffolds; 
however due to the scale on which these reactions needed to be done and the cost of PtO2, an 
alternate set of hydrogenation conditions had to be devised using Pd/C. This switch of reductants 
actually turned out to be beneficial as the reaction could be completed in a matter of hours using 
Pd/C whereas it took approx. 48 hours for the hydrogenation to be competed using PtO2. Initially, 
the free amine was then coupled to phenylacetyl chloride to provide 2.140 and the TIPS group was 
again deprotected using 2:1 AcOH:TBAF at 30˚ for 48 hours to provide 2.141. When attempting 
to convert the alcohol to the azide, treatment of the 2.141 with Tf2O and TBAA led to product 
decomposition so a new method for introducing the azide was investigated. Instead of using the 
one-pot reaction that was successful on the previous scaffold, a two-step mesylation/displacement 
sequence was found more reliable. Thus, the alcohol was mesylated with MsCl and then treated 










containing compound 2.142. Unfortunately, treatment of 2.142 with La(NO3)3 resulted in a 
previously described intramolecular ring-opening of the b-lactam core along with concomitant 




Figure 2.25. Initial attempted synthesis or 7-acylamino scaffold. A) synthesis of intermediates 
until acetonide deprotection step. B) Intramolecular ring-opening reaction effected by treatment of 


















































































  As this problem was documented to happen penicillin G that has the same phenylacetyl 
side-chain,81 instead of coupling the 2.139 to phenylacetyl chloride, phenoxyacetyl chloride was 
used to afford phenoxyamide 2.143 (Scheme 2.6). Treatment of this compound with a 2:1 mixture 
of AcOH and TBAF afforded alcohol 2.144 which was then converted to the azide-containing 
compound 2.145 using the same MsCl/NaN3 conditions as previously described.  Compound 2.145 
was then treated with La(NO3)3 to afford 2.146 with no formation of the unwanted by-product. 
Oxidative diol cleavage using silica-bound NaIO4 provided 2.147. Hydrogenation of this 
compound provided intermediate amine 2.148 (not isolated), which has , to this point, only been 
then treated to previously described acylation conditions to provide 2.149. 2.150 is in process, and 
once obtained, treatment of the compounds with K2CO3 in MeOH will provide alcohols 2.151 and 





Scheme 2.6. Synthesis of ent-7-acylamino-3-nor-2-azaisocephalosporin. Dashed lines indicate 
































































































K2CO3, MeOH CrO3, H2SO4
2.143 (69%)
2.144 (73%) 2.145 (74%)
2.146 (70%) 2.147 (64%)
2.148
(not isolated)
R = Ac 2.149
= Me 2.150
R = Ac 2.151
= Me 2.152




  The 3-Me scaffolds were synthesized in a similar manner, this time using N-Boc-threonine-
benzyl ester 2.155 as a starting material (Scheme 2.7). O-Silylation (2.156), ester reduction 
(2.157), and acetylation of the alcohol provided 2.158. The protected amine was then treated with 
25% TFA in DCM and condensed with D-(R)-glyceraldehyde 2.115 to form a Schiff base that, 
when reacted with azidoacetyl chloride 2.137 and TEA, formed monobactam 2.159 in 48-57% 




Scheme 2.7. Synthesis of threonine-derived protected amine and formation of ent-3-Me 
































2.157 (82%) 2.158 (58%)
1) 25% TFA in DCM
2) 2.115, TEA










  Azide reduction provided free amine 2.160 that was reacted with phenoxyacetyl chloride 
to access amide 2.161 (Scheme 2.8). Unlike the 3-nor scaffold, treatment of 2.161 with 2:1 
AcOH:TBAF did not unsuccessfully deprotect the TIPS group regardless of how many equivalents 
of the reagents were used. Instead, TEA trihydrofluoride provided de-silylated material 2.162 after 
48 hours at 45 ̊ C in 70% yield. Mesylating the alcohol and subsequently treating this material with 
3.5 equivalents of NaN3 and 6 equivalents of 15-crown-5 in the microwave at 100 ˚C for 4 hours 
provided clean conversion of the alcohol to azide 2.163 in consistent yields around 60%. 
La(NO3)3-mediated acetonide deprotection provided compound 2.164 and oxidative diol cleavage 
provided aldehyde 2.165. At this time, reductive cyclization with Pd/C provided bicyclic 
compound 2.166 and acetylation or methylation provided 2.167 and 2.168, respectively, but the 
compounds have not been carried further in the synthesis. Acyl-deprotection and oxidation will 




Scheme 2.8. Synthesis of ent-7-acylamino-3-Me-2-azaisocephalosporins. Dashed arrows indicate 

































































































K2CO3, MeOH CrO3, H2SO4
X = N3, 2.159 (57%)
2.161 (90%)
2.162 (70%) 2.163 (61%)
2.164 (87%) 2.165 (81%)
2.166
(not isolated)
R = Ac 2.167 (35%)
= Me 2.168 (28%)
R = Ac 2.169
= Me 2.170
R = Ac 2.171
= Me 2.172
Pd/C
H2= NH2, 2.160 (88%)
(yields over 2 steps)
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2.7.2: Natural (6R, 7S) Series 
  The (6R,7S) series was synthesized in the same manner except for the use of L-(S)-
glyceraldehyde instead of the D-(R)-glyceraldehyde that was previously used. The aldehyde was 
synthesized according to literature precedent82 and bulb-to-bulb distillation yielded the aldehyde 
2.116 as a clear, colorless oil as a 61% weight-percent solution in DCM (Scheme 2.9). Previous 
reports indicate that the aldehyde needed to be freshly distilled before each use, but in our hands,  
this did not seem to be the case.   
 
 
Scheme 2.9. Synthesis of L-(S)-glyceraldehyde 
 
 
  When using the “matched” L-(S)-glyceraldehyde 2.116 and L-amino acid 2.123 and 2.154, 
monobactams 2.173 (Scheme 2.10) and 2.187 (Scheme 2.11) were formed in roughly the same 
yield but diastereoselectivity was increased to 24:1 dr and 23:1 dr, respectively. The rest of the 
syntheses followed the same synthetic sequence as previously described for the two scaffolds, 
except that for both the 3-nor and 3-Me series, the mesylation and NaN3 displacement sequence 
was used to install the azide instead of the Tf2O-tetrabutylammonium azide sequence used 
previously (Schemes 2.10 and 2.11). At this time, I have reached compound 2.181 for the 3-nor 





















Scheme 2.10. Synthesis of (6R,7S)-3-nor-2-azaisocephalosporins. Dashed arrows indicate  
































































































K2CO3, MeOH CrO3, H2SO4
X = N3, 2.173 (60%)
2.175 (57%)




R = Ac 2.181
= Me 2.182
R = Ac 2.183
= Me 2.184
R = Ac 2.185
= Me 2.186
Pd/C




Scheme 2.11. Synthesis of (6R,7S)-3-Me-2-azaisocephalosporins. Dashed arrows indicate 

































































































K2CO3, MeOH CrO3, H2SO4






R = Ac 2.195
= Me 2.196
R = Ac 2.197
= Me 2.198
R = Ac 2.199
= Me 2.200
Pd/C
H2= NH2, 2.188 (93%)
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2.8: Conclusion  
  Through the use of an asymmetric Staudinger [2+2] cycloaddition, I was able to 
successfully asymmetrically synthesize both cis enantiomers of the b-lactam using enantiomeric 
glyceraldehydes 2.115 and 2.116 in both a “matched” and “mis-matched” form with amino acid-
derived building blocks.  Two different acyl chlorides have been shown to be supported in the 
cycloaddition, as well  as two different amino acid-derived amines that enable the installation of 
both the 3-nor and 3-methyl groups on the isocephalosporin core. Unlike previous syntheses that 
either used pre-functionalized amines to build the scaffold or did not try to, I was able to devise a 
route that allowed for a variety of functional groups to be installed at the nitrogen.  This route is 
adaptable and customizable and can facilitate the asymmetric synthesis of a broad range of 2-
azaisocephalosporins through the installation of different amide side chains, functionalization at 
the 3 position, and derivatization at the nitrogen.  To this end, this work has provided the first 
asymmetric synthesis of the 2-azaisocephalosporin core that will can be used to further 
investigations into this previously under investigated scaffold and  access new chemical space to 
ultimately facilitate the discovery of novel antibiotics.   
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2.9.2.1: General Procedure for Amino Ester Alcohol Silylation:83 A flask was charged 2.117 
or 2.155, DCM (0.20 M) and 2,6-lutidene (2.0 equiv) and the solution was cooled to –78 ˚C in a 
dry ice/acetone bath.  To this was then added TIPS-OTf  (1.10 equiv) dropwise and the reaction 
stirred at –78 ˚C for 4 h or until  complete (reaction monitored by TLC.  Once complete, the 
reaction was warmed to rt, poured into a separatory funnel, diluted with H2O, and shaken. The 
layers were then separated and the aqueous layer was extracted 3–4× DCM.  The organic layers 
were then combined, washed with brine, dried over sodium sulfate, filtered, and concentrated.  The 
crude material was then purified  via column chromatography (0-10% EtOAc in hexanes) to afford 
the product as a clear, colorless oil.  For large scale reactions where column chromatography was 
impractical, the crude material was instead immobilized on a silica plug and eluted with 5-10% 




























Benzyl N-(tert-butoxycarbonyl)-O-(triisopropylsilyl)-L-serinate (2.118): 2.117 (62.1 g, 210 
mmol) was reacted according to the general procedure to afford 2.118 as a clear, colorless oil (93.3 
g, 202.1 mmol, 96%).  Rf = 0.8 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.93-7.19 
(complex, 4H), 5.41 (M of ABXM system, d, J = 8.7 Hz, 1H), 5.17 (s, 2H), 4.44-4.36 (X of ABXM 
system, m, 1H), 4.17 (A part of ABXM system, JAB = 9.9, JAX= 2.06 Hz, 1H), 3.94 (B part of 
ABXM system, JAB = 9.8, JBX= 3.14 Hz, 1H), 1.44 (s, 9H), 1.11 – 0.95 (complex, 21H). 13C NMR 
(101 MHz, CDCl3) δ 170.82, 155.52, 135.50, 128.64, 128.45, 79.91, 67.25, 64.32, 55.97, 28.44, 




Benzyl N-(tert-butoxycarbonyl)-O-(triisopropylsilyl)-L-threoninate (2.156).  2.155 (18.86 g, 
60.98 mmol) was reacted according to the general procedure to afford 2.156 as a clear, colorless 
oil (25.3 g, 54.3 mmol, 89%). Rf = 0.7 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 
7.34 (d, J = 3.4 Hz, 5H), 5.22 (d, J = 9.8 Hz, 1H), 5.18 – 5.07 (ABq, J = 12.3 Hz, 2H,), 4.65 – 4.57 


















21H). 13C NMR (101 MHz, CDCl3) δ 171.3, 156.4, 135.4, 128.6, 128.6, 128.5, 79.9, 69.3, 67.3, 




2.9.2.2: General Procedure for Benzyl Ester Reduction: A flame-dried flask was charged with 
2118 or 2.156 and was equipped with a flame-dried addition funnel and the unit was put under 
argon.  To this was then added anhydrous THF (0.15 M) and the solution was cooled to 0 ˚C in an 
ice bath. Once cooled, LAH (1.10 equiv, 1.0 or 2.4 M in THF) was added dropwise via addition 
funnel and the reaction stirred at 0 ˚C for 30 minutes or until SM was consumed (reaction 
monitored by TLC).  Once SM was consumed, the temperature of the reaction was maintained at 
0 ˚C and a saturated aqueous sodium potassium tartrate solution was slowly added until gas 
evolution ceased.  The reaction was then decanted into a separatory funnel and the residual material 
in the flask was resuspended in a H2O/EtOAc mixture and 2N HCl was added while stirring until 
the amalgam turned into a fine white precipitate.  The solution was then transferred to the original 
separatory funnel containing the decanted material and was diluted with EtOAc and shaken.  The 
layers were then separated and the aqueous layer was then extracted 3× EtOAc. The organic layers 
were then combined, washed 2× with saturated aqueous sodium potassium tartrate, washed with 
brine, dried over sodium sulfate, filtered, and concentrated.  The crude material was then 
transferred to a new flask and was resuspended in dH2O.  The flask was then equipped with a 










R = H or Me








2.122 or 2.157 
(81-85%)
 164 
under house vacuum (~150 torr). To fully remove the benzyl alcohol, 50 mL dH2O per gram of 
SM was used in the steam distillation and the temperature was kept at or below 95 ˚C to avoid 
side-product formation. Once complete, the material was resuspended in saturated aqueous sodium 
potassium tartrate and transferred to a separatory funnel, diluted with EtOAc and shaken.  The aq. 
layer was then extracted 3× EtOAc and the organic layers were combined, washed with brine, 
dried over sodium sulfate, filtered and concentrated to afford the pure alcohol as a clear, slightly 
yellow oil.  If needed, the material was then purified via column chromatography 0–20% EtOAc 




Tert-butyl (R)-(1-hydroxy-3-((triisopropylsilyl)oxy)propan-2-yl)carbamate (2.122):  2.118 
was reacted according to the general procedure to afford 2.122 as a clear, slightly orange oil (34.52 
g, 99.32 mmol, 82%).  Rf = 0.5 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 5.20 (br. 
s, 1H), 3.95-3.80 (complex, 3H), 3.76 – 3.60 (complex, 1H), 1.44 (s, 9H), 1.19 – 0.95 (complex, 
21H). 13C NMR (101 MHz, CDCl3) δ 156.14, 79.67, 64.95, 64.47, 52.76, 28.50, 18.03, 18.03, 













Tert-butyl ((2R,3R)-1-hydroxy-3-((triisopropylsilyl)oxy)butan-2-yl)carbamate (2.157): 2.156 
(24.05 g, 51.63 mmol) was reacted according to the general procedure and purified via column 
chromatography (0-35% EtOAc in hexanes) to afford 2.157 as a clear, colorless oil (13.4 g, 37.1 
mmol, 72%). Rf = 0.4 (15% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 4.95 (s, 1H), 4.23 
(qd, J = 6.3, 2.4 Hz, 1H), 3.75 – 3.65 (m, 3H), 3.62 – 3.51 (m, 1H), 1.46 (s, 12H), 1.23 (d, J = 6.3 
Hz, 4H), 1.08 (s, 24H). 13C NMR (101 MHz, CDCl3) δ 156.9, 79.6, 68.3, 64.2, 57.6, 28.3, 20.9, 




2.9.2.3: General Procedure for Amino Alcohol Acylation:84 A flask was charged with 2.123 or 
2.158 and to this was added DCM, pyridine, and Ac2O sequentially (2:2:1 ratio by volume, 0.15 
M overall)  and the reaction stirred at rt overnight.  The following day, the reaction was quenched 
with a saturated aqueous sodium bicarbonate solution followed by solid sodium bicarbonate until 
the pH of the solution was ~7-8.  The material was then transferred to a separatory funnel and was 
diluted with EtOAc and shaken.  The layers were then separated and the aqueous layer was then 
















R = H or Me
2:2:1 DCM:pyridine:Ac2O,










with brine, dried over sodium sulfate, filtered, and concentrated to afford the acylated material as 




(R)-2-((Tert-butoxycarbonyl)amino)-3-((triisopropylsilyl)oxy)propyl acetate (2.123): 2.122 
(33.55 g,  96.53 mmol) was reacted according to the general procedure to afford 2.123 as a clear, 
orange oil (36.0 g, 92.4 mmol, 96%). Rf = 0.7 (15% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3)  δ 4.90-4.76 (m, 1H), 4.19 (A part of ABMXY system, JAB = 8, JAM = 6.0 Hz, 1H), 4.12 (B 
part of ABMXY system, JAB= 12, JBM = 6.69 Hz, 1H), 3.92 (M part of ABMXY system, m, app. 
br. s., 1H), 3.81 (X part of ABMXY system, JXY = 12.0, JXM = 4.00, 2H), 3.72 (Y part of ABMXY 
system, JXY = 8.0, JYM = 4.0 Hz, 1H), 2.05 (s, 3H), 1.44 (s, 9H), 1.15-0.99 (complex, 21H). 13C 
NMR (101 MHz, CDCl3) δ 170.90, 155.48, 79.61, 63.32, 62.40, 50.69, 28.44, 20.91, 18.00, 11.95. 




(2R,3R)-2-((Tert-butoxycarbonyl)amino)-3-((triisopropylsilyl)oxy)butyl acetate (2.158):  
















clear, slightly orange oil (13.6 g, 33.7 mmol, 91%).  Rf = 0.6 (15% EtOAc in hexanes). 1H NMR 
(400 MHz, CDCl3)  δ 4.75 (d, J = 9.5 Hz, 1H), 4.24 – 4.15 (m, 1H), 4.14 – 4.02 (m, 32), 3.77 (q, 
J = 7.3 Hz, 1H), 2.03 (s, 3H), 1.44 (s, 9H), 1.21 (d, J = 6.3 Hz, 3H), 1.06 (s, 21H). 13C NMR (101 
MHz, CDCl3) δ 170.9, 156.1, 79.5, 67.2, 64.0, 54.6, 21.0, 20.8, 18.3, 18.2, 12.8. FTIR (thin film): 




2.9.2.4: General Procedure for (6S,7R) Azetidinone Synthesis:  A flask was charged with 2.123 
or 2.158 and the material was resuspended in  DCM. To this was then added TFA (25% by volume, 
0.15 M overall concentration) and the reaction stirred at rt for 30 minutes.  After this time, the 
material was concentrated, resuspended in EtOAc, transferred to a separatory funnel, and shaken.  
The layers were then separated and the organic layer was then washed 4-6× dH2O.  The combined 
aqueous layer was then extracted 2× EtOAc and the organic layers were then combined, dried over 
sodium sulfate, filtered into a new flask, and concentrated.  The crude amine salt was then 
resuspended in DCM (0.15 M) and to this was added TEA (5 equiv), MgSO4 (5 equiv), and 2.115 
(1 equiv, 50% solution in DCM) and the solution stirred at rt for 30 minutes or until complete 









R = H or Me
1) 25% TFA in DCM,
   rt, 30 min
2) 1.115, MgSO4, TEA,
   DCM, rt, 30-45 min
3) 2-benzocyacetyl 
   chloride or  2.137, TEA,

















funnel) and the filtrate was transferred to a flame-dried 3-neck flask and was concentrated.  Once 
concentrated, the flask was equipped with a flame-dried addition funnel and the unit was put under 
argon.  The crude imine was then resuspended in anhydrous DCM (0.10 M) and was cooled to 0 
˚C in an ice bath.  Once cooled, TEA (3 equiv) was then added through a side-neck on the flask 
followed by the dropwise addition of 2-benzoxyacetyl chloride (1.5 equiv) or 2.137 (1.5 equiv) 
dissolved in anhydrous DCM ( final concentration to 0.075 M).  The reaction then stirred overnight 
coming to rt.  The following day, the reaction was concentrated and the crude material was then 
resuspended in Et2O and transferred to a separatory funnel.  The material was then diluted with 
water and brine and was shaken. The layers were then separated and the aqueous layer was again 
extracted with a mixture of water and brine.  The combined aqueous layers were then extracted 5× 
with Et2O and the organic layers were then combined, washed with brine, dried over sodium 
sulfate, filtered, and concentrated to afford the crude material as black oil.  The material was then 





((triisopropylsilyl)oxy)propyl acetate (2.124): 2.123 (11.95 g, 30.67 mmol)  and 2-
benzoxyacetyl chloride were reacted according to the general procedure to afford the 2.124 as a 










MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 4.91 (d, J = 11.7 Hz, 1H), 4.63 (d, J = 11.7 Hz, 1H), 4.58 (d, 
J = 5.3 Hz, 1H), 4.48 – 4.34 (m, 2H), 4.30 – 4.20 (m, 1H), 4.17 (dd, J = 8.7, 6.7 Hz, 1H), 4.08 – 
3.99 (m, 1H), 3.89 (d, J = 7.3 Hz, 2H), 3.74 (dd, J = 9.0, 5.3 Hz, 1H), 3.62 (dd, J = 8.7, 6.2 Hz, 
1H), 2.05 (s, 3H), 1.42 (s, 3H), 1.32 (s, 3H), 1.15 – 0.99 (complex, 21H). 13C NMR (101 MHz, 
CDCl3) δ 170.8, 168.0, 137.0, 128.6, 128.2, 127.9, 109.7, 80.0, 77.0, 73.0, 67.0, 61.6, 61.4, 61.0, 





((triisopropylsilyl)oxy)propyl acetate (2.138): 2.123 (12.1 g, 31.06 mmol) was reacted with 
2.115 according to the general procedure to afford 2.138 as a clear, colorless oil (7.02 g, 31.1 
mmol, 47%). Rf = 0.8 (35% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 4.63 (d, J = 5.4 
Hz, 1H), 4.46 – 4.32 (m, 2H), 4.25 – 4.13 (complex, 2H), 4.03 – 3.96 (m, 1H), 3.95 – 3.83 (m, 
2H), 3.75 (dd, J = 8.8, 5.3 Hz, 1H), 3.66 – 3.60 (m, 1H), 2.07 (s, 3H), 1.43 (s, 3H), 1.34 (s, 3H), 
1.16 – 0.96 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 170.7, 164.3, 110.1, 76.7, 66.6, 63.7, 61.4, 














((triisopropylsilyl)oxy)butyl acetate (2.159): 2.158 (7.15 g , 17.7 mmol) was reacted with 2.115 
according to the general procedure to afford 2.159 as a clear, colorless oil (5.01 g, 10.0 mmol, 
57%). Rf = 0.8 (35% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 4.61 – 4.53 (m, 3H), 4.30 
– 4.19 (m, 3H), 3.79 – 3.67 (m, 2H), 3.66 – 3.57 (m, 1H), 2.07 (s, 3H), 1.40 (s, 3H), 1.36 – 1.31 
(m, 3H), 1.25 (d, J = 6.3 Hz, 3H), 1.06 (s, 21H). 13C NMR (101 MHz, CDCl3) δ 170.7, 163.9, 
110.2, 77.0, 68.0, 66.7, 63.5, 61.2, 60.6, 60.4, 26.8, 25.1, 21.1, 20.4, 18.2, 12.7. FTIR (thin film): 

















2.9.2.5: General Procedure for (6R,7S) Azetidinone Synthesis: This procedure is the same as 
the procedure for the synthesis of the (6S,7R) azetidinone core (see section 2.10.2.4) except that 





((triisopropylsilyl)oxy)propyl acetate (2.173):  2.123 (2.00 g, 5.13 mmol)  was reacted with 
2.116 according to the general procedure to afford 2.173 as a clear, colorless oil (1.50 g, 3.09 
mmol, 60%).  Rf = 0.8 (30% EtOAc in hexanes).  1H NMR (400 MHz, CDCl3) δ 4.61 (d, J = 5.4 
Hz, 1H), 4.27 (d, J = 6.3 Hz, 2H), 4.25 – 4.15 (m, 2H), 4.08 – 3.98 (m, 1H), 3.94 (d, J = 6.7 Hz, 









R = H or Me
1) 25% TFA in DCM,
   rt, 30 min
2) 1.116, MgSO4, TEA,
   DCM, rt, 30-45 min
3) 2.137, TEA,





















(m, 21H). 13C NMR (101 MHz, CDCl3) δ 170.9, 164.7, 110.1, 76.6, 66.7, 63.8, 62.1, 60.2, 59.8, 





((triisopropylsilyl)oxy)butyl acetate (2.187):  2.158 (5.76 g, 14.3 mmol) was reacted  with 2.116 
according to the general procedure to afford 2.187 as a clear, colorless oil (4.01 g, 8.04 mmol, 
56%).  Rf = 0.8 (35% EtOAc in hexanes). 1H NMR (400 CDCl3) δ 4.67 (d, J = 5.4 Hz, 1H), 4.60 
– 4.50 (m, 1H), 4.40 (dd, J = 11.4, 4.1 Hz, 1H), 4.33 – 4.19 (m, 2H), 4.18 – 4.10 (m, 1H), 3.85 – 
3.75 (m, 2H), 3.56 (dd, J = 8.5, 6.5 Hz, 1H), 2.06 (s, 3H), 1.41 (s, 3H), 1.33 (s, 3H), 1.29 (d, J = 
6.3 Hz, 3H), 1.06 (s, 21H).  13C NMR (101 MHz, CDCl3) δ 170.8, 164.6, 110.1, 76.7, 68.2, 66.6, 
63.7, 61.5, 61.2, 59.7, 26.6, 24.9, 21.0, 20.6, 18.3, 18.2, 12.6. FTIR (thin film): 2941, 2865, 2104, 














2.9.2.6: General Synthesis for 7-Azide Reduction: A flame-dried flask was charged with 2.138, 
2.159, 2.173, or 2.187 and Pd/C (0.20 equiv, 10 wt %) and was put under argon. To this was then 
added anhydrous THF (0.10 M) and the solution was sparged with a balloon of H2 for 20 minutes. 
The balloon was then removed from solution and the flask was left to stir under an atmosphere of 
hydrogen for 2–6 h until SM was consumed (reaction monitored by UPLC).  Once complete, the 
reaction was sparged with an argon balloon and was then filtered over Celite to afford the amine 





((triisopropylsilyl)oxy)propyl acetate (2.139): 2.138 (2.73 g, 5.63 mmol) was reacted according 
to the general procedure to afford 2.139 as a clear, colorless oil (2.49 g, 5.34 mmol, 95%).  Rf = 








R = H or Me








R = H or Me
2.139, 2.160, 2.174, or 2.188
(88-95%)
R










1H), 4.24 – 4.14 (m, 2H), 3.99 – 3.89 (m, 1H), 3.87 (d, J = 7.7 Hz, 2H), 3.76 – 3.66 (m, 2H), 2.04 
(s, 3H), 1.42 (s, 3H), 1.33 (s, 3H), 1.15-0.96 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 170.8, 
170.1, 109.6, 76.9, 66.9, 61.7, 61.6, 61.5, 59.6, 55.2, 26.8, 25.2, 21.0, 12.0. FTIR (thin film): 2941, 





((triisopropylsilyl)oxy)butyl acetate(2.159): 2.160 (3.50 g, 7.02 mmol) was reacted according to 
the general procedure to afford 2.160 as a clear, colorless oil (3.15 g, 6.66 mmol, 95%). Rf = 0.2 
(35% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 4.67 – 4.53 (m, 2H), 4.35 – 4.20 (m, 3H), 
4.17 (d, J = 5.3 Hz, 1H), 3.80 – 3.61 (m, 3H), 2.07 (s, 3H), 1.41 (s, 3H), 1.35 (s, 3H), 1.24 (d, J = 
6.3 Hz, 3H), 1.06 (s, 21H). 13C NMR (101 MHz, CDCl3) δ 170.9, 170.4, 109.5, 77.6, 68.1, 67.0, 
















((triisopropylsilyl)oxy)propyl acetate (2.174): 2.173 (1.66 g, 3.43 mmol) was reacted according 
to the general procedure to afford 2.174 as a clear, colorless oil (1.52 g, 3.31 mmol, 97%). Rf =  
0.2 (50% EtOAc). 1H NMR (400 MHz, CDCl3) δ 4.35 – 4.23 (m, 3H), 4.20 – 4.12 (m, 2H), 4.06 
– 3.91 (m, 3H), 3.76 – 3.64 (m, 2H), 2.06 (s, 3H), 1.43 (s, 3H), 1.35 (s, 3H), 1.17 – 0.92 (m, 21H). 
13C NMR (101 MHz, CDCl3) δ 171.3, 171.0, 109.5, 77.1, 67.0, 62.6, 61.7, 60.5, 60.0, 54.6, 26.8, 





((triisopropylsilyl)oxy)butyl acetate (2.188): 2.187 (3.98 g, 7.98 mmol) was reacted according 
to the general procedure to afford 2.188 as a clear, colorless oil (3.52 g, 7.45 mmol, 93%). Rf = 


















4.39 (dd, J = 11.3, 4.2 Hz, 1H), 4.35 – 4.26 (m, 2H), 4.22 (d, J = 5.5 Hz, 1H), 4.17 – 4.07 (m, 1H), 
3.83 – 3.71 (m, 2H), 3.62 (dd, J = 8.7, 7.1 Hz, 1H), 2.04 (s, 3H), 1.41 (s, 3H), 1.32 (s, 3H), 1.28 
(d, J = 6.4 Hz, 3H), 1.10 – 1.02 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 171.1, 170.8, 109.3, 
77.4, 68.6, 67.0, 63.8, 61.6, 59.8, 59.1, 26.6, 25.0, 21.1, 20.6, 18.3, 18.2, 12.6. FTIR (thin film): 




2.9.2.7: General Procedure for 7-Amide Coupling: A flask was charged with 2.139, 2.160, 
2.174, or 2.188 and the material was resuspended in DCM (0.15 M).  To this was then added 
pyridine (1.2 equiv) and phenoxyacetyl chloride (1.2 equiv) and the reaction stirred at rt for 10 
minutes. After this time, the reaction was quenched with the addition of a saturated aqueous 
sodium bicarbonate solution, transferred to a separatory funnel, and shaken.  The layers were then 
separated and the aq. layer was extracted 3x with EtOAc. The organic layers were then combined 
and washed 3× 2N HCl, washed with brine, dried over sodium sulfate, filtered, and concentrated.  
The crude material was then purified via column chromatography (0-50% EtOAc in hexanes) to 









R = H or Me
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phenoxyacetamido)azetidin-1-yl)-3-((triisopropylsilyl)oxy)propyl acetate (2.143): 2.139 (2.41 
g, 5.25 mmol) was reacted with phenoxyacetyl chloride according to the general procedure to 
afford 2.143 as a clear, colorless oil (2.14 g, 3.61 mmol, 69%). Rf = 0.7 (50% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.33 (app. t, J = 7.99 Hz, 2H), 7.20 (d, J = 8.7 Hz, 1H), 7.05 (app. 
t, J = 7.99 Hz, 1H) 6.89 (app d, J = 8.39 Hz, 2H), 5.28 (dd, J = 8.6, 5.2 Hz, 1H), 4.55 – 4.47 
(complex, 3H), 4.43 – 4.35 (m, 1H), 4.07 – 3.97 (m, 1H), 3.97 – 3.81 (complex, 5H), 3.67 (dd, J 
= 8.9, 5.9 Hz, 1H), 2.06 (s, 3H), 1.43 (s, 3H), 1.27 (s, 3H), 1.15 – 0.98 (m, 21H). 13C NMR (101 
MHz, CDCl3) δ 170.8, 168.8, 166.2, 157.0, 130.0, 122.5, 114.8, 110.0, 75.9, 67.1, 66.3, 61.7, 61.4, 




















phenoxyacetamido)azetidin-1-yl)-3-((triisopropylsilyl)oxy)butyl acetate (2.160): 2.159 (3.40 
g, 7.18 mmol) was reacted with phenoxyacetyl chloride according to the general procedure to 
afford 2.160 as a clear, colorless oil (3.12 g, 5.14 mmol, 72%). Rf = 0.6 (35% EtOAc in hexanes).  
1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 8.7, 7.4 Hz, 2H), 7.15 (d, J = 8.1 Hz, 1H), 7.05 (app. 
t, J = 7.4 Hz, 1H), 6.94 (app. d, J = 7.8 Hz, 2H), 5.22 (dd, J = 8.2, 5.1 Hz, 1H), 4.62 (dd, J = 11.5, 
3.9 Hz, 1H), 4.57 – 4.47 (complex, 3H), 4.32 (p, J = 6.3 Hz, 1H), 4.11 – 4.01 (m, 1H), 3.87 – 3.78 
(m, 2H), 3.77 – 3.68 (m, 1H), 3.63 (dd, J = 8.9, 6.2 Hz, 1H), 2.06 (s, 3H), 1.40 (s, 3H), 1.29 – 1.26 
(complex, 6H), 1.07 (s, 21H). 13C NMR (101 MHz, CDCl3) δ 170.9, 168.9, 165.8, 157.0, 130.0, 
122.6, 114.8, 110.0, 76.5, 68.0, 67.1, 66.4, 61.5, 61.4, 61.0, 55.6, 26.6, 25.1, 21.1, 20.6, 18.2, 12.7. 


















phenoxyacetamido)azetidin-1-yl)-3-((triisopropylsilyl)oxy)propyl acetate (2.175):  2.174 
(1.51 g, 3.30 mmol) was reacted with phenoxyacetyl chloride according to the general procedure 
to afford 2.175 as a clear, colorless oil (1.11 g, 3.30 mmol, 57%). Rf = 0.6 (50% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3) δ 7.33 (app. t, J = 8.0 Hz, 2H), 7.19 (d, J = 8.7 Hz, 1H), 7.05 (t, J = 
7.4 Hz, 1H), 6.92 (d, J = 7.7 Hz, 2H), 5.27 (dd, J = 8.7, 5.2 Hz, 1H), 4.53 (s, 2H), 4.37 – 4.25 (m, 
2H), 4.09 – 3.95 (m, 4H), 3.93 – 3.83 (m, 2H), 3.64 (dd, J = 8.9, 6.1 Hz, 1H), 2.08 (s, 3H), 1.42 
(s, 3H), 1.28 (s, 3H), 1.16 – 0.98 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 171.0, 168.8, 166.5, 
157.0, 130.0, 122.6, 114.8, 110.0, 75.8, 67.1, 66.4, 62.4, 60.9, 60.4, 55.8, 55.6, 26.6, 25.0, 21.0, 























phenoxyacetamido)azetidin-1-yl)-3-((triisopropylsilyl)oxy)butyl acetate (2.189): 2.188 (3.83 
g, 8.10 mmol) was reacted with phenoxyacetyl chloride according to the general procedure to 
afford 2.189 as a clear, colorless oil (3.27 g, 5.39 mmol, 67%). Rf = 0.7 (50% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.34 (dd, J = 8.8, 7.4 Hz, 2H), 7.23 (d, J = 8.6 Hz, 1H), 7.05 (app. 
t, J = 7.4 Hz, 1H), 6.92 (app. d, J = 7.8 Hz, 2H), 5.35 (dd, J = 8.7, 5.3 Hz, 1H), 4.63 – 4.50 
(complex, 3H), 4.42 (dd, J = 11.4, 4.5 Hz, 1H), 4.38 – 4.30 (m, 1H), 4.02 (dd, J = 7.4, 6.5 Hz, 1H), 
3.95 (dd, J = 7.6, 5.3 Hz, 1H), 3.87 (dd, J = 8.7, 6.8 Hz, 1H), 3.84 – 3.75 (m, 1H), 3.63 (dd, J = 
8.7, 6.6 Hz, 1H), 2.07 (s, 3H), 1.41 (s, 3H), 1.32 (d, J = 6.4 Hz, 3H), 1.26 (s, 3H), 1.12 – 1.01 (m, 
21H). 13C NMR (101 MHz, CDCl3) δ 170.8, 169.0, 166.9, 157.0, 130.0, 122.5, 114.8, 109.9, 76.1, 
68.5, 67.1, 66.1, 63.1, 61.4, 59.8, 55.5, 26.4, 24.8, 21.0, 20.6, 18.2, 12.6. FTIR (thin film): 3258, 

















2.9.2.8: General Procedure for TIPS Deprotection, 3-Nor Scaffold: A flask was charged with 
2.124, 2.143, or 2.161 and the material was resuspended in THF (0.075 M) and was cooled to 0 
˚C in an ice bath.  Once cooled, a 2:1 solution of AcOH (4 equiv) and TBAF (2 equiv, 1.0 M 
solution in THF) was added dropwise via addition funnel. The reaction stirred at 0 ˚C for 5 minutes 
and was then heated to 30 ˚C for 48 hours or until complete (reaction monitored by UPLC).  Once 
complete, the reaction was concentrated, resuspended in EtOAc,  transferred to a separatory funnel, 
diluted with brine, and shaken.  The layers were then separated and the aqueous layer was extracted 
3× with EtOAc. The organic layers were then combined, washed with brine, dried over sodium 
sulfate, filtered, and concentrated.  The crude material was then purified via column 
























HHX2:1 AcOH:TBAF, 0 ˚C 
to 30 ˚C, 48 h






hydroxypropyl acetate (2.125): 2.124 (8.71 g, 15.8 mmol) was reacted according to the general 
procedure to afford the product as a clear, colorless oil. Recrystallization (Et2O/hexanes) provided 
the compound as a white solid (5.17 g, 13.1 mmol, 83% total yield, 1.25 g recovered after 
recrystallization). Rf = 0.4 (50% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.28 
(complex, 5H), 4.90 (d, J = 11.7 Hz, 1H), 4.65 (d, J = 11.7 Hz, 1H), 4.61 (d, J = 5.4 Hz, 1H), 4.47 
– 4.29 (complex, 3H), 4.21 (X part of AMX system, JAX = 4.2, JMX = 4.2 Hz, 1H), 4.04-3.96 (m, 
1H), 3.88 – 3.79 (complex, 3H), 3.66 (M part of AMX system, JAM = 9.2, JMX = 6.3 Hz, 1H), 2.05 
(s, 3H), 1.45 (s, 3H), 1.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.9, 169.2, 136.7, 128.7, 
128.4, 128.0, 110.1, 79.9, 77.3, 73.2, 67.1, 61.8, 61.3, 61.2, 54.9, 26.7, 25.2, 21.0.  FTIR (thin 















phenoxyacetamido)azetidin-1-yl)-3-hydroxypropyl acetate (2.144):  2.143 (2.14 g, 3.61 mmol) 
was reacted according to the general procedure to afford 2.144 as a clear, colorless oil (1.15 g, 
2.63 mmol, 73%). Rf = 0.4 (75% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 
8.9 Hz, 1H), 7.33 – 7.28 (m, 2H), 7.03 (app. t, J = 7.4 Hz, 1H), 6.91 (app. d, J = 7.8 Hz, 2H), 5.32 
(dd, J = 8.9, 5.2 Hz, 1H), 4.49 (s, 2H), 4.36 – 4.27 (m, 2H), 4.20 – 4.11 (m, 1H), 4.11 – 4.03 (m, 
1H), 3.92 – 3.72 (complex, 4H), 3.58 (dd, J = 8.9, 5.9 Hz, 1H), 2.06 (s, 3H), 1.43 (s, 3H), 1.29 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 170.8, 169.1, 168.2, 157.1, 130.0, 122.5, 114.8, 110.3, 76.8, 






















phenoxyacetamido)azetidin-1-yl)-3-hydroxypropyl acetate (2.176): 2.175 (1.42 g, 2.40 mmol) 
was reacted according to the general procedure to provide 2.176 as a clear, colorless oil (790 mg, 
1.81 mmol, 76% yield). Rf = 0.4 (75% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.48 (d, 
J = 9.3 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.04 (app. t, J = 7.4 Hz, 1H), 6.90 (d, J = 7.8 Hz, 2H), 5.42 
(dd, J = 9.3, 5.3 Hz, 1H), 4.61 – 4.47 (m, 2H), 4.34 – 4.24 (m, 2H), 4.15 – 4.05 (m, 1H), 4.04 – 
3.91 (m, 4H), 3.86 (dd, J = 9.1, 4.9 Hz, 1H), 3.81 – 3.72 (m, 1H), 2.08 (s, 3H), 1.45 (s, 3H), 1.25 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.7, 168.9, 167.6, 157.1, 129.9, 122.4, 110.4, 74.6, 67.1, 



















2.9.2.9: General Procedure for TIPS Deprotection, 3-Me Scaffold:  A flask was charged with 
2.175 or 2.189 and the material was resuspended in THF (0.10 M) and to this was added TEA 
trihydrofluoride (8 equiv) and the solution was heated to 45 ˚C for 48-72 hours or until complete 
(reaction monitored by UPLC).  The reaction was then quenched with the addition of saturated 
aqueous sodium bicarbonate followed by solid sodium bicarbonate until the solution had a pH of 
~7-8.  The solution was then transferred to a separatory funnel, diluted with water and EtOAc, and 
shaken. The layers were then separated and the aqueous layer was extracted 3× EtOAc. The 
organic layers were then combined, washed with brine, dried over sodium sulfate, filtered, and 
concentrated. The crude material was then purified via column chromatography (0-100% EtOAc 


















THF, 45 ˚C, 48 h










phenoxyacetamido)azetidin-1-yl)-3-hydroxybutyl acetate (2.162): 2.161 (1.93 g, 3.16 mmol) 
was reacted according to the general procedure to afford the product as a clear, colorless oil (1.01 
g, 2.23 mmol, 70%). Rf = 0.5 (75% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J 
= 8.5 Hz, 1H), 7.33 (app. t, J = 7.6 Hz, 2H), 7.05 (t, J = 7.4 Hz, 1H), 6.94 (d, J = 7.8 Hz, 2H), 5.29 
(dd, J = 8.5, 5.3 Hz, 1H), 4.53 (s, 2H), 4.41 (dd, J = 11.8, 4.7 Hz, 1H), 4.32 (dd, J = 11.8, 8.9 Hz, 
1H), 4.15 (tt, J = 10.4, 6.7 Hz, 1H), 3.98 (p, J = 6.2 Hz, 1H), 3.91 – 3.81 (complex, 3H), 3.63 (dd, 
J = 9.0, 5.9 Hz, 1H), 2.06 (s, 3H), 1.44 (s, 3H), 1.32 – 1.27 (complex, 6H). 13C NMR (101 MHz, 
CDCl3) δ 170.6, 169.1, 168.9, 157.0, 129.8, 122.4, 114.8, 110.2, 75.8, 67.0, 66.2, 61.7, 60.9, 59.2, 



















phenoxyacetamido)azetidin-1-yl)-3-hydroxybutyl acetate (2.190): 2.189 (3.28 g, 5.40 mmol) 
was reacted according to the general procedure to afford 2.190 as a clear, colorless oil (1.65 g, 
3.65 mmol, 68%). Rf = 0.4 (75% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 
(m, 2H), 7.06 (app. t, J = 7.4 Hz, 1H), 6.92 (app. d, J = 7.8 Hz, 2H), 5.29 (dd, J = 8.4, 5.2 Hz, 1H), 
4.54 (s, 2H), 4.40 (dd, J = 11.7, 4.6 Hz, 1H), 4.25 (dd, J = 11.7, 7.4 Hz, 1H), 4.14 – 4.02 (m, 2H), 
3.95 (dd, J = 7.4, 5.2 Hz, 1H), 3.88 (dd, J = 8.9, 6.8 Hz, 1H), 3.74 – 3.64 (m, 2H), 2.09 (s, 3H), 
1.46 – 1.39 (m, 3H), 1.32 (d, J = 6.1 Hz, 3H), 1.27 (t, J = 1.2 Hz, 3H) (1H missing, signal hidden 
under CDCl3 solvent signal). 13C NMR (101 MHz, CDCl3) δ 170.7, 169.1, 167.2, 157.0, 130.0, 
122.6, 114.7, 110.2, 76.0, 67.1, 66.2, 65.9, 63.7, 61.6, 61.1, 55.0, 26.6, 25.0, 21.0, 20.8. FTIR (thin 

















2.9.2.10: Alcohol to Azide Conversion, 7-Benzoxy Scaffold: (S)-3-Azido-2-((2S,3R)-3-
(benzyloxy)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-oxoazetidin-1-yl)propyl acetate (2.126): 
A flame-dried flask was charged with 2.125 (3.57 g, 9.07 mmol) and was put under argon.  To this 
was then added anhydrous DCM (121 mL, 0.075 M) and the solution was cooled to -78 ˚C in a 
dry-ice/acetone bath.  Once cooled, Tf2O (2.3 mL, 2.48 g, 13.6 mmol, 1.5 equiv) was added 
dropwise followed by the addition of anhydrous 2,6-lutidene (1.6 mL, 1.46 g, 13.6 mmol, 1.5 
equiv) and the solution stirred at -78 ˚C for 30 minutes.  After this time, TBAA (7.74 g, 27.2 mmol, 
3.0 equiv) was added and the solution stirred overnight coming to rt.  The following day, the 
reaction was quenched with the addition of saturated aqueous sodium bicarbonate and the solution 
was transferred to a separatory funnel and shaken. The layers were then separated and the aqueous 
layer was extracted 3× with DCM. The organic layers were then combined, washed with brine, 
dried over sodium sulfate, filtered, and purified via column chromatography (0-40% EtOAc in 
hexanes) to afford the product as a clear, colorless oil (2.52 g, 6.02 mmol, 66%). Rf = 0.5 (30% 
EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.28 (complex, 5H), 4.91 (d, J = 11.8 
Hz, 1H), 4.67 – 4.61 (complex, 2H), 4.37 – 4.25 (complex, 3H), 4.18 (dd, J = 8.9, 6.7 Hz, 1H), 
4.06 – 3.95 (m, 1H), 3.81 – 3.71 (m, 2H), 3.63 (dd, J = 8.9, 6.0 Hz, 1H), 3.46 (dd, J = 12.4, 5.8 
















1)Tf2O, 2,6-lutidene, DCM, 
-78 ˚C, 30 min
2)TBAA, -78 ˚C to rt, 18h.
2.126 (66%)
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136.8, 128.7, 128.3, 128.0, 109.9, 80.0, 76.7, 73.1, 66.9, 61.4, 61.2, 52.4, 50.3, 26.9, 25.2, 20.9. 




2.9.2.11: General Procedure for Alcohol to Azide Conversion, 3-Nor and 3-Me scaffold: A 
flame-dried flask was charged with 2.144, 2.162, or 2.176 and was put under argon.  To this was 
then added anhydrous DCM (0.15 M) and the solution was cooled to 0 ˚C in an ice bath. Once 
cooled, TEA (1.5 equiv) was added followed by slow addition of MsCl (2 equiv) and the reaction 
stirred at 0 ˚C for 30 minutes or until complete (reaction monitored by UPLC).  Once complete, 
the reaction was transferred to a separatory funnel, diluted with water, and shaken.  The layers 
were then separated and the organic layer was washed once more with water. The aqueous layers 
were then combined and extracted 3× with DCM. The organic layers were then combined, washed 
with brine, dried over sodium sulfate, filtered, and concentrated to afford the crude mesylated 
alcohol.  This material was then transferred to a microwave vial and was resuspended in DMF 
(0.10 – 0.23 M) and to this was added NaN3 (3.5 equiv) and 15-crown-5 (6 equiv) and the reaction 
was heated in the microwave at 100 ˚C for 1–4 hours (reaction monitored by UPLC).  Once 
complete, the solution was concentrated under a stream of nitrogen and the crude material was 



















i) MsCl, TEA, DCM,
   0 ˚C, 30 min
ii) NaN3, 15-crown-5,
    DMF, µW, 1-4 h
R = H or Me
2.144, 2.162, or 2.176
2.145, 2.163, or 2.177
(61-74%)
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The aqueous layer was then extracted 3x with EtOAc and the organic layers were combined, 
washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude material was 





phenoxyacetamido)azetidin-1-yl)propyl acetate (2.145): 2.144 (1.15 g, 2.64 mmol) was reacted 
according to the general procedure to afford 2.145 as a clear, colorless oil (904 mg, 1.96 mmol, 
74%). Rf = 0.4 (50% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.29 (complex, 
3H), 7.04 (app. t, J = 7.4 Hz, 1H), 6.93 (app. d, J = 7.8 Hz, 1H), 5.31 (dd, J = 8.5, 5.2 Hz, 1H), 
4.52 (s, 2H), 4.42 (dd, J = 11.6, 5.1 Hz, 1H), 4.26 (dd, J = 11.6, 7.2 Hz, 1H), 4.13 – 4.03 (m, 1H), 
4.02 – 3.91 (m, 1H), 3.89 – 3.77 (m, 3H), 3.63 (dd, J = 9.0, 5.8 Hz, 1H), 3.48 (dd, J = 12.4, 5.5 
Hz, 1H), 2.08 (s, 3H), 1.47 – 1.40 (m, 3H), 1.33 – 1.22 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.8, 168.9, 166.6, 157.0, 130.0, 122.6, 114.8, 110.2, 75.7, 67.1, 66.3, 61.5, 61.4, 55.9, 53.4, 50.3, 



















phenoxyacetamido)azetidin-1-yl)butyl acetate (2.163): 2.162 (1.28 g, 2.84 mmol) was reacted 
according to the general procedure to afford 2.163 as a clear, colorless oil (823 mg, 1.73 mmol, 
61%). Rf = 0.4 (50% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.27 (m, 3H), 7.05 
(app. t, J = 7.4 Hz, 1H), 6.93 (app. d, J = 7.8 Hz, 2H), 5.22 (dd, J = 8.5, 5.2 Hz, 1H), 4.65 (dd, J = 
11.8, 4.1 Hz, 1H), 4.53 (s, 2H), 4.31 (dd, J = 11.8, 8.0 Hz, 1H), 4.14 – 4.06 (m, 1H), 3.98 – 3.87 
(m, 1H), 3.88 – 3.81 (m, 2H), 3.73 – 3.61 (m, 2H), 2.07 (s, 3H), 1.46 – 1.38 (complex, 6H), 1.32 
– 1.27 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 170.9, 169.0, 166.7, 157.0, 130.0, 122.7, 114.8, 
110.1, 75.6, 67.1, 66.3, 61.5, 61.3, 57.9, 56.6, 55.8, 26.7, 25.0, 21.0, 16.6. FTIR (thin film): 3287, 





















phenoxyacetamido)azetidin-1-yl)propyl acetate (2.177): 2.176 (760 mg, 1.74 mmol) was 
reacted according to the general procedure to afford 2.177 as a clear, colorless oil (556 mg, 1.21 
mmol, 69%). Rf = 0.4 (50% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.6 
Hz, 1H), 7.36 – 7.28 (m, 2H), 7.04 (app. t, J = 7.4 Hz, 1H), 6.91 (app. d, J = 7.8 Hz, 2H), 5.27 (dd, 
J = 8.6, 5.2 Hz, 1H), 4.51 (s, 2H), 4.33 – 4.22 (m, 2H), 4.12 – 4.03 (m, 1H), 4.03 – 3.92 (m, 1H), 
3.89 – 3.79 (complex, 3H), 3.69 – 3.58 (m, 2H), 2.09 (s, 3H), 1.43 (s, 3H), 1.28 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.8, 168.9, 166.5, 157.0, 130.0, 122.6, 110.2, 75.8, 67.1, 66.3, 62.2, 61.0, 



















2.9.2.12: General Procedure for Acetonide Deprotection: A microwave vial was charged with 
2.126, 2.145, 2.163, or 2.177 and the material was resuspended in MeCN (0.10 M) and to this was 
added La(NO3)3 • 7H2O (3 equiv) and the reaction vial was capped and heated to 100 ˚C for 1.5-3 
hours or until complete (reaction monitored by UPLC). Once complete, the reaction was 
concentrated and resuspended in EtOAc and transferred to a separatory funnel, diluted with water, 
and shaken.  The layers were then separated and the organic layer was washed 4× with H2O. The 
aq. layers were then combined and extracted 3× with EtOAc. The organic layers were then 
combined, washed with brine, dried over sodium sulfate, filtered, and concentrated to afford crude 
diol that was purified via column chromatography (0-100% EtOAc in hexanes) unless otherwise 












2.126, 2.145, 2.163, or 2.177
























acetate (2.127): 2.126 (2.51 g, 6.00 mmol) was reacted according to the general procedure to 
afford 2.127 as a yellow oil that was used without further purification (2.15 g, 5.67 mmol, 95%). 
Rf = 0.6 (75% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.27 (complex, 5H), 4.93 
(d, J = 11.7 Hz, 1H), 4.74 – 4.65 (complex, 2H), 4.48 – 4.38 (m, 1H), 4.38 – 4.28 (m, 1H), 4.03 – 
3.93 (m, 1H), 3.93 – 3.78 (complex, 3H), 3.61 (dd, J = 11.3, 5.7 Hz, 1H), 3.51-3.45 (m, 2H), 2.07 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.8, 168.4, 136.6, 128.7, 128.4, 128.2, 80.0, 73.3, 71.3, 


























procedure to afford 2.146 as a clear, colorless oil (573 mg, 1.26 mmol, 70%). Rf = 0.2 (80% EtOAc 
in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 9.9 Hz, 1H), 7.32 (dd, J = 8.7, 7.4 Hz, 2H), 
7.03 (app t, J = 7.4 Hz, 1H), 6.94 (app. d, J = 7.9 Hz, 3H), 5.50 (dd, J = 9.8, 5.5 Hz, 1H), 4.58 – 
4.49 (complex, 3H), 4.31 (dd, J = 11.7, 6.2 Hz, 1H), 3.99 (dd, J = 5.5, 2.7 Hz, 1H), 3.93 (dd, J = 
12.4, 9.5 Hz, 1H), 3.81 – 3.69 (m, 1H), 3.67 – 3.48 (complex, 3H), 3.15 (d, J = 7.9 Hz, 1H), 2.10 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 171.3, 169.3, 167.8, 157.1, 129.9, 122.4, 114.8, 69.7, 67.1, 





phenoxyacetamido)azetidin-1-yl)butyl acetate (2.164): 2.163 (816 mg, 1.72 mmol) was reacted 
according to the general procedure to afford 2.164 as a clear, colorless oil (653 mg, 1.50 mmol, 
87%). Rf = 0.4 (80% EtOAc in hexanes).  1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 9.8 Hz, 1H), 
7.34 – 7.27 (m, 2H), 7.02 (app. t, J = 7.4 Hz, 1H), 6.92 (app. d, J = 7.8 Hz, 2H), 5.44 (dd, J = 9.8, 
5.4 Hz, 1H), 4.67 (dd, J = 11.7, 4.3 Hz, 1H), 4.53 (ABq, J = 11.99 Hz, 2H), 4.40 (dd, J = 11.7, 7.3 
Hz, 1H), 4.07 – 3.92 (complex, 2H), 3.75 – 3.65 (m, 1H), 3.65 – 3.52 (complex, 3H), 2.09 (s, 3H), 













114.8, 69.7, 67.2, 64.5, 61.9, 61.0, 59.1, 56.7, 55.5, 21.1, 16.4. FTIR (thin film): 3366, 2096, 1737, 




yl)propyl acetate (2.178): 2.177 (532 mg, 1.15 mmol) was reacted according to the general 
procedure to afford 2.178 as a clear, colorless oil (408 mg, 0.968 mmol, 84%). Rf = 0.3 (50% 
EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 9.9 Hz, 1H), 7.34 – 7.27 (m, 2H), 
7.02 (app. t, J = 7.4 Hz, 1H), 6.93 (app. d, J = 7.8 Hz, 2H), 5.45 (dd, J = 9.9, 5.4 Hz, 1H), 4.54 
(ABq, J = 15.19 Hz, 2H), 4.32 – 4.22 (m, 2H), 4.15 (dd, J = 12.2, 10.0 Hz, 1H), 3.98 (dd, J = 5.4, 
2.2 Hz, 1H), 3.91 – 3.80 (m, 1H), 3.71 (dd, J = 10.9, 3.3 Hz, 1H), 3.68 – 3.45 (m, 3H), 2.08 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 170.9, 169.2, 167.8, 157.1, 129.9, 122.4, 114.8, 76.8, 69.7, 


















2.9.2.13: General Procedure for Diol Cleavage:  A flask containing 2.127, 2.146, 2.164,  2.178, 
or 2.192 was charged with DCM (0.05 M) and silica-supported NaIO4 (10 equiv) and the slurry 
stirred at rt overnight. The following day, the reaction was filtered and concentrated to afford the 




(S)-3-Azido-2-((2R,3R)-3-(benzyloxy)-2-formyl-4-oxoazetidin-1-yl)propyl acetate (2.128): 
2.127 (2.12 g, 5.60 mmol) was reacted according to the general procedure to afford 2.128 as an 
opaque, white amorphous solid (1.74 g, 5.02 mmol, 90%). Rf = 0.5 (50% EtOAc in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 9.57 (d, J = 2.8 Hz, 1H), 7.41 – 7.28 (complex, 5H), 4.92 (d, J = 5.3 
Hz, 1H), 4.77 (d, J = 11.7 Hz, 1H), 4.64 (d, J = 11.7 Hz, 1H), 4.31 (dd, J = 5.3, 2.9 Hz, 1H), 4.27 









R = H or Me
2.127, or 2.164,
NaIO4 on silica gel,

























Hz, 1H), 4.08-4.03 (app. pentet, M part of ABMXY, 1H), 3.73 (X part of ABMXY, JXY= 12.7, 
JXM=5.26 Hz, 1H), 3.62 (Y part of ABMXY, JXY = 12.7, JYM= 6.74 Hz, 1H), 2.06 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 198.2, 170.5, 166.8, 135.9, 128.8, 128.6, 128.4, 83.5, 73.6, 64.5, 61.5, 51.5, 





acetate (2.165): 2.164 (491 mg, 1.13 mmol) was reacted according to the general procedure to 
afford 2.165 as a white, opaque oil (368 mg, 0.912 mmol, 91%). Rf = 0.2 (50% EtOAc in hexanes). 
1H NMR (400 MHz, CDCl3) δ 9.67 (d, J = 1.6 Hz, 1H), 7.37 – 7.23 (m, 3H), 7.04 (t, J = 7.4 Hz, 
1H), 6.87 (d, J = 7.8 Hz, 2H), 5.04 (dd, J = 7.1, 5.9 Hz, 1H), 4.60 (dd, J = 5.9, 1.6 Hz, 1H), 4.47 
(d, J = 4.0 Hz, 2H), 4.37 (dd, J = 12.0, 7.4 Hz, 1H), 4.28 (dd, J = 12.0, 3.3 Hz, 1H), 3.97 – 3.86 
(m, 2H), 2.06 (s, 3H), 1.51 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 196.5, 170.6, 169.6, 
165.8, 156.9, 130.0, 122.6, 67.1, 64.2, 60.2, 59.4, 57.5, 55.7, 20.9, 16.4. FTIR (thin film): 3341, 


















2.9.2.14 General Procedure for Reductive Ring-Closing and N-Acylation: A flame-dried flask 
was charge with 2.128, 2.147, 2.165, 2.179, or 2.193 and Pd/C (0.4 equiv, 10 wt. %)  and was put 
under argon.  To this was then added anhydrous THF (0.10 M) and the reaction was put under 
argon.  H2 was then sparged continuously for 30 min to 2 h and was then left to stir under an 
atmosphere of H2 until SM was consumed (reaction monitored by UPLC).  Once the starting 
material has been consumed, the reaction was sparged with argon for 30 minutes and was then 
filtered over Celite and concentrated to afford the cyclized amine as a light amber oil that turned 
into an off-white, amorphous  solid when applied to high-vacuum (~0.7 torr).  This material then 
resuspended in DCM (0.15 M) and to this was added pyridine and Ac2O sequentially and the 
reaction stirred at rt for 2 h.  The reaction was then quenched with a saturated aqueous sodium 
bicarbonate solution and was transferred to a separatory funnel and shaken.  The layers were then 
separated and the aq. layer was extracted 3× with DCM. The organic layers were combined, 
washed with 2N HCl, washed with brine, dried over sodium sulfate, filtered, concentrated and 
purified on either preparative TLC (40% [4% MeOH in EtOAc] in hexanes) or via column 

























1) Pd/C, H2, THF,
    rt, overnight
2) Ac2O, pyridine,







(2.130): 2.128 (100 mg, 0.288 mmol) was reacted according to the general procedure to afford 
2.130 as a set of rotamers as a clear, colorless oil (30.4 mg, 0.087 mmol, 31%). Rf = 0.23 (70% 
EtOAc in hexanes). 1H NMR, (400 MHz, CDCl3)2 δ 7.45 – 7.29 (m, 8H; major+minor), 4.91 (d, J 
= 11.8 Hz, 1H; major), 4.80 – 4.60 (m, 4H; major+minor), 4.59 – 4.44 (m, 3H; major+minor), 4.20 
– 4.06 (m, 3.5 H; major+minor), 3.98 (dd, J = 9.6, 6.0 Hz, 0.75 H; minor), 3.86 (dd, J = 9.9, 4.3 
Hz, 1H; major), 3.79 (d, J = 14.2 Hz, 0.75 H; minor), 3.70 – 3.60 (m, 0.75 H; minor), 3.61 – 3.51 
(m, 1H; major), 3.31 (dd, J = 14.1, 4.2 Hz, 0.75 H; minor), 3.27 – 3.12 (m, 2H; major+minor), 
2.85 – 2.74 (m, 2H; major+minor), 2.07 (app. d, J = 2.6 Hz, 4.5 H; major+minor), 2.04 (s, 3H; 
major), 1.97 (s, 3H; minor).13C NMR (101 MHz, CDCl3)3 δ 170.5, 170.2, 169.7, 169.6, 167.8, 
167.6, 136.5, 136.3, 128.8, 128.7, 128.7, 128.6, 128.4, 128.2, 82.2, 82.1, 74.2, 73.5, 61.0, 61.0, 
50.2, 49.8, 47.4, 46.3, 46.3, 46.2, 41.5, 41.3, 21.4, 21.3, 20.8, 20.7. FTIR (thin film): 3390, 2927, 
1745, 1622 cm-1.  
 
                                                        
2 Peaks in 1H-NMR spectrum split in a 3:2 ratio due to N-acyl rotamers.  Both rotamers are 
described. 












yl)methyl acetate (2.167): 2.165 (93.4 mg, 0.232 mmol) was reacted according to the general 
procedure to afford 2.167 as a clear, colorless oil (32.5 mg, 0.081 mmol, 35%). Rf = 0.3 (4% 
MeOH in DCM). 1H NMR (400 MHz, CDCl3)4 δ 7.93 (br. s, 1H), 7.33 – 7.27 (m, 2H), 7.04-6.88 
(m, 3H), 5.48 (br. s, 1H), 4.55 (s, 2H), 4.35 – 3.90 (m, 4H), 3.38 (br. s, 2H), 2.08 (s, 7H), 1.42 – 
1.09 (m, 4H). 13C NMR (101 MHz, CDCl3)5 δ 170.6, 169.3, 157.3, 129.9, 122.3, 114.8, 67.1, 62.2, 





                                                        
4 Peaks in 1H-NMR are broad and unresolved due to presence of N-acyl rotamers; no ratio of 
rotamers can be obtained.  
5 Peaks in 13C-NMR are split due to presence of N-acyl rotamers.  Both rotamers are described. 














2.9.2.15: General Procedure for Reductive Ring-Closing and N-Methylation: A flame-dried 
flask was charge with 2.128, 2.147, 2.165, 2.179, or 2.193 and Pd/C (0.4 equiv, 10 wt. %)  and 
was put under argon.  To this was then added anhydrous THF (0.10 M) and the reaction was put 
under argon.  H2 was then sparged continuously for 30 min to 2 h and was then left to stir under 
an atmosphere of H2 until SM was consumed (reaction monitored by UPLC).  Once the starting 
material has been consumed, the reaction was sparged with argon for 30 minutes and was then 
filtered over Celite and concentrated to afford the cyclized amine as a light amber oil that turned 
into an off-white, amorphous  solid when applied to high-vacuum (~0.7 torr). This material was 
then resuspended in MeOH (0.05 M) and to this was then added acetic acid (2 equiv), 
formaldehyde (1.2 equiv, 37% solution), and NaCNBH4 (3 equiv) and the reaction stirred at rt for 
80 minutes or until complete.  The reaction was then quenched with the addition of a saturated 
aqueous ammonium chloride solution and the resulting solution was then basified with the addition 
of 2N NaOH to ~pH 10.  The reaction was then transferred to a separatory funnel and the aqueous 
layer was then extracted 3× DCM. The organic layers were combined and were purified on either 
preparative TLC (70% [4% MeOH in EtOAc] in hexanes) or via column chromatography (0-8% 























1) Pd/C, H2, THF, rt,
    overnight
2) formaldehyde,
    AcOH, NaCNBH4,







(2.131): 2.128 (157 mg, 0.453 mmol) was reacted according to the general procedure to afford 
2.131 as a clear, colorless oil (59.4 mg, 0.187 mmol, 41%). Rf =  0.6 (4% MeOH in DCM). 1H 
NMR (400 MHz, CDCl3) δ 7.39 – 7.29 (complex, 5H), 4.80 (d, J = 11.7 Hz, 1H), 4.69 (d, J = 4.4 
Hz, 1H), 4.56 (d, J = 11.8 Hz, 1H), 4.36 – 4.26 (m, 1H), 4.09 – 4.00 (m, 2H), 3.73 – 3.64 (m, 1H), 
2.67 – 2.55 (complex, 2H), 2.25 (s, 3H), 2.18 – 2.09 (m, 2H), 2.04 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.8, 168.4, 136.9, 128.7, 128.4, 82.3, 73.6, 62.2, 54.6, 54.3, 50.4, 47.4, 46.8, 21.0. 





yl)methyl acetate (2.168): 2.165 (88.6 mg, 0.220 mmol) was reacted according to the general 

















MeOH in DCM). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.28 (m, 2H), 7.13 (d, J = 6.8 Hz, 1H), 
7.04 (app. t, J = 7.4 Hz, 1H), 6.92 (app. d, J = 7.8 Hz, 2H), 5.17 (dd, J = 6.9, 4.6 Hz, 1H), 4.53 (s, 
2H), 4.33 (t, J = 10.8 Hz, 1H), 4.19 (dd, J = 11.5, 4.0 Hz, 1H), 3.98 – 3.82 (m, 2H), 2.85 (dd, J = 
11.6, 4.7 Hz, 1H), 2.28-2.12 (complex, 3H), 2.06 (s, 3H), 1.96 – 1.52 (m, 2H), 1.11 (d, J = 6.8 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 171.0, 168.8, 165.9, 157.0, 129.9, 122.5, 114.8, 67.1, 59.7, 





2.10.2.16: Reductive Ring Closing and N-Boc Functionalization, 7-Benzoxy Scaffold: Tert-
butyl (2S,6S,7R)-2-(acetoxymethyl)-7-(benzyloxy)-8-oxo-1,4-diazabicyclo[4.2.0]octane-4-
carboxylate (2.132):  A flame-dried flask was charged with 2.128 (105 mg, 0.304 mmol) and Pd/C 
(0.4 equiv, 10 wt. %)  and was put under argon.  To this was then added anhydrous THF (0.10 M) 
and the reaction was put under argon.  H2 was then sparged continuously for 30 min to 2 h and 
was then left to stir under an atmosphere of H2 until SM was consumed (reaction monitored by 
UPLC).  Once the starting material has been consumed, the reaction was sparged with argon for 
30 minutes and was then filtered over Celite and concentrated to afford the cyclized amine as a 
light amber oil that turned into an off-white, amorphous  solid when applied to high-vacuum (~0.7 














1) Pd/C, H2, THF,
    rt, overnight
2) Boc2O, HFIP, 
    rt, 30 min
2.128 2.132 (28%)
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and the reaction stirred at rt for 30 minutes. After this time, the reaction was concentrated and the 
crude material was purified via preparative TLC (30% [4% MeOH in EtOAc] in hexanes) to afford 
2.132 as a clear, colorless oil (34.2 mg, 0.086 mmol, 28%).  Rf = 0.6 (50% EtOAc in hexanes).  1H 
NMR (500 MHz, DMSO-D6)6 δ 7.42 – 7.30 (m, 5H), 4.81 (d, J = 4.3 Hz, 1H), 4.69 (d, J = 11.8 
Hz, 1H), 4.56 (d, J = 11.8 Hz, 1H), 4.09 – 4.01 (m, 1H), 3.98 – 3.91 (m, 2H), 3.86 (d, J = 14.0 Hz, 
2H), 3.68 – 3.60 (m, 1H), 3.05 – 2.99 (m, 1H), 2.92 (dd, J = 13.2, 10.6 Hz, 1H), 2.01 (s, 3H), 1.41 
(s, 9H). 13C NMR (126 MHz, DMSO-D6)7 δ 169.5, 166.6, 153.7, 136.8, 128.0, 127.7, 127.6, 81.9, 




2.9.2.17: General Procedure for Acyl Deprotection:  A flask was charged with the acyl-
containing compound and the material was resuspended in MeOH (0.075 M) and the solution was 
cooled to 0 ˚C.  To this was then added K2CO3 in portions and the reaction stirred at 0 ˚C for 30 
minutes (reaction monitored by TLC).  The reaction was then quenched with the addition of a 
saturated aqueous ammonium chloride solution and the material was transferred to a separatory 
funnel, diluted with water and EtOAc, and shaken. The layers were then separated and the aqueous 
                                                        
6 1H-NMR spectrum taken at 75 ˚C. 












0 ˚C, 30 min
2.133, 2,134R2 = Ac or Me
2.130, 2,131
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layer was extracted 3x with EtOAc and the organic layers were combined, washed with brine, 
dried over sodium sulfate, filtered, and concentrated to afford the crude alcohol. The crude material 





(2.133): 2.130 (24.1 mg, 0.069 mmol) was reacted according to the general procedure to afford 
2.133 as a white crystalline solid (18.4 mg, 0.061 mmol, 87%). Rf = 0.1 (75% EtOAc in hexanes).  
1H NMR (400 MHz, CDCl3)8 δ 7.44 – 7.30 (m, 6.5H; major+minor), 4.92 (d, J = 11.7 Hz, 1H; 
major), 4.80 – 4.48 (m, 4.5H; major+minor) 4.05 – 3.95 (m, 2H; major+minor), 3.69 – 3.47 (m, 
3H; major+minor), 3.36 (dd, J = 12.0, 8.3 Hz, 1H; major), 3.25 (d, J = 7.9 Hz, 2.5H; major+minor), 
2.87 – 2.73 (m, 1.5H; major+minor), 2.14 (s, 1H; minor), 2.00 (s, 3H; major). 13C NMR (101 MHz, 
CDCl3)9 δ 171.1, 170.6, 168.2, 167.8, 136.6, 136.5, 129.0, 128.8, 128.8, 128.7, 128.5, 128.3, 82.3, 
82.2, 77.5, 74.3, 73.6, 59.9, 59.1, 50.8, 50.0, 49.5, 49.1, 47.2, 45.6, 42.2, 41.7, 21.5, 21.4.FTIR 
(thin film): 3390, 2927, 1745, 1622 cm-1. mp = 154-157 ˚C.  
                                                        
8 Peaks in 1H-NMR spectrum split in a 3:2 ratio due to N-acyl rotamers.  Both rotamers are 
described.  












(2.134): 2.131 (35.9 mg, 0.113 mmol) was reacted according to the general procedure to afford 
2.133 as  slightly yellow oil (24.8 mg, 0.090 mmol, 80%). Rf = 0.1 (75% EtOAc in hexanes). 1H 
NMR (400 MHz, CDCl3) δ 7.42 – 7.29 (m, 5H), 4.89 – 4.71 (complex, 2H), 4.55 (d, J = 11.7 Hz, 
1H), 3.95 – 3.83 (m, 3H), 3.77 (dd, J = 10.3, 3.3 Hz, 1H), 2.89 (d, J = 11.6 Hz, 1H), 2.64 (dd, J = 
11.6, 4.9 Hz, 1H), 2.30 (s, 3H), 2.22 (t, J = 11.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 168.4, 
136.8, 128.7, 128.4, 83.0, 73.7, 66.2, 57.0, 54.2, 51.9, 48.5, 46.7. FTIR (thin film): 3335, 2940, 




2.9.2.18: General Procedure for Oxidation of Primary Alcohol to Carboxylic Acid: A flask 
was charged with the alcohol SM and the material was resuspended in acetone (0.05 M) and the 























acetone,0 ˚C, 2 h
O O
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added dropwise and the reaction stirred at 0 ˚C for 2 hours.  The reaction was then quenched with 
the addition of 2 mL isopropanol and the reaction stirred for 15 minutes.  Water was then added to 
the reaction and the solution was basified with 2N NaOH to ~pH 10.   
N-Acyl workup:  For the N-acyl compounds, the basified solution was then transferred to a 
separatory funnel and washed 4x with EtOAc.  The aqueous phase was then acidified with 4N HCl 
to ~pH 1 and was then transferred back to the separatory funnel and extracted 4x with EtOAc.  The 





(2.135):  2.133 (26.6 mg , 0.087 mmol) was reacted according to the general procedure to afford 
2.135 as a 3:2 mixture of rotamers, white solid (20.0 mg, 0.063 mmol, 72%).  Rf = 0.3 (4% MeOH 
in DCM).  1H NMR (400 MHz, Methanol-d4)10  δ 7.52 – 7.26 (m, 8H; major+minor), 4.94 (app. t, 
J = 4.9 Hz, 3H; major+minor), 4.78 (d, J = 11.5 Hz, 1H; major), 4.67 – 4.48 (m, 5H; major+minor), 
4.37 (d, J = 14.2 Hz, 1H; major), 3.94 – 3.84 (m, 0.8H; minor), 3.81 – 3.72 (m, 1H; major), 3.51 
(dd, J = 13.9, 4.8 Hz, 0.8H; minor), 3.43 (dd, J = 14.2, 4.9 Hz, 1H; major), 3.23 (dd, J = 13.9, 10.8 
                                                        
10 Peaks in 1H-NMR are split in a 3:2 ratio due to the presence of N-acyl rotamers. Both rotamers 










Hz, 0.8H; minor), 2.86 – 2.77 (m, 1H; major), 2.15 (s, 3H; major), 2.01 (s, 2H; minor). 13C NMR 
(101 Hz, DMSO-D6)11 δ 170.3, 170.1, 169.0, 168.9, 166.0, 165.9, 137.0, 128.5, 128.4, 128.4, 
128.2, 128.1, 82.6, 82.3, 72.7, 72.6, 50.2, 50.1, 49.7, 49.6, 47.1, 45.7, 42.4, 40.6, 21.3, 21.0. 
  
                                                        
11 Peaks in 13C-NMR are split due to the presence of N-acyl rotamers.  Both rotamers are described. 
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